U.S. patent application number 14/440018 was filed with the patent office on 2015-10-01 for antisense compounds and uses thereof.
This patent application is currently assigned to Cold Spring Harbor Laboratory. The applicant listed for this patent is COLD SPRING HARBOR LABORATORY, ISIS PHARMACEUTICALS, INC.. Invention is credited to C. Bennett, Adrian R. Krainer, Frank Rigo, Zhenxun Wang.
Application Number | 20150275211 14/440018 |
Document ID | / |
Family ID | 50628065 |
Filed Date | 2015-10-01 |
United States Patent
Application |
20150275211 |
Kind Code |
A1 |
Rigo; Frank ; et
al. |
October 1, 2015 |
ANTISENSE COMPOUNDS AND USES THEREOF
Abstract
The present invention provides compounds comprising
oligonucleotides complementary to a pyruvate kinase M transcript.
Certain such compounds are useful for hybridizing to a pyruvate
kinase M transcript, including but not limited to a pyruvate kinase
M transcript in a cell. In certain embodiments, such hybridization
results in modulation of splicing of the pyruvate kinase M
transcript. In certain embodiments, such compounds are used to
treat one or more symptoms associated with cancer.
Inventors: |
Rigo; Frank; (Carlsbad,
CA) ; Bennett; C.; (Carlsbad, CA) ; Krainer;
Adrian R.; (Huntington Station, NY) ; Wang;
Zhenxun; (Singapore, SG) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ISIS PHARMACEUTICALS, INC.
COLD SPRING HARBOR LABORATORY |
Carlsbad
Cold Spring Harbor |
CA
NY |
US
US |
|
|
Assignee: |
Cold Spring Harbor
Laboratory
Cold Spring Harbor
NY
Isis Pharmaceuticals, Inc.
Carlsbad
CA
|
Family ID: |
50628065 |
Appl. No.: |
14/440018 |
Filed: |
October 31, 2013 |
PCT Filed: |
October 31, 2013 |
PCT NO: |
PCT/US2013/067881 |
371 Date: |
April 30, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61720910 |
Oct 31, 2012 |
|
|
|
Current U.S.
Class: |
514/44A ;
435/375; 536/24.5 |
Current CPC
Class: |
C12N 15/113 20130101;
C12N 2310/14 20130101; C12N 15/1137 20130101; C12Y 207/0104
20130101; C12N 2310/11 20130101 |
International
Class: |
C12N 15/113 20060101
C12N015/113 |
Claims
1. A compound comprising a modified oligonucleotide consisting of 8
to 30 linked nucleosides and having a nucleobase sequence
comprising a complementary region, wherein the complementary region
comprises at least 8 contiguous nucleobases and is complementary to
an equal-length portion of a target region of a PK-M
transcript.
2. The compound of claim 1, wherein the target region of the PK-M
transcript comprises at least a portion of exon 10 of the PK-M
transcript.
3. The compound of claim 1 or 2, wherein the complementary region
of the modified oligonucleotide is 100% complementary to the target
region.
4. The compound of any of claims 1 to 3, wherein the complementary
region of the modified oligonucleotide comprises at least 10
contiguous nucleobases.
5. The compound of any of claims 1 to 3, wherein the complementary
region of the modified oligonucleotide comprises at least 15
contiguous nucleobases.
6. The compound of any of claims 1 to 3, wherein the complementary
region of the modified oligonucleotide comprises at least 20
contiguous nucleobases.
7. The compound of any of claims 1-6, wherein the nucleobase
sequence of the oligonucleotide is at least 80% complementary to an
equal-length region of the PK-M transcript, as measured over the
entire length of the oligonucleotide.
8. The compound of any of claims 1-6, wherein the nucleobase
sequence of the oligonucleotide is at least 90% complementary to an
equal-length region of the PK-M transcript, as measured over the
entire length of the oligonucleotide.
9. The compound of any of claims 1-6, wherein the nucleobase
sequence of the oligonucleotide is 100% complementary to an
equal-length region of the PK-M transcript, as measured over the
entire length of the oligonucleotide.
10. The compound of any of claims 1-9, wherein the target region is
within exon 10 of the PK-M transcript.
11. The compound of any of claims 1-10, wherein the target region
is within nucleobase 29153 and nucleobase 29281 of SEQ ID NO.:
1.
12. The compound of any of claims 1-10, wherein the target region
is within nucleobase 29158 and nucleobase 29262 of SEQ ID NO.:
1.
13. The compound of any of claims 1-10, wherein the target region
is within nucleobase 29164 and nucleobase 29188 of SEQ ID NO.:
1.
14. The compound of any of claims 1-10, wherein the target region
is within nucleobase 29261 and nucleobase 29279 of SEQ ID NO.:
1.
15. The compound of any of claims 1-10, wherein the target region
is within nucleobase 29168 and nucleobase 29183 of SEQ ID NO.:
1.
16. The compound of any of claims 1-15, wherein the nucleobase
sequence of the antisense oligonucleotide comprises any one of SEQ
ID NOs: 4 to 36.
17. The compound of any of claims 1-16, wherein the modified
oligonucleotide comprises at least one modified nucleoside.
18. The compound of claim 17, wherein at least one modified
nucleoside comprises a modified sugar moiety.
19. The compound of claim 18, wherein at least one modified sugar
moiety is a 2'-substituted sugar moiety.
20. The compound of claim 19, wherein the 2'-substitutent of at
least one 2'-substituted sugar moiety is selected from among:
2'-OMe, 2'-F, and 2'-MOE.
21. The compound of any of claims 17-20, wherein the 2'-substituent
of at least one 2'-substituted sugar moiety is a 2'-MOE.
22. The compound of any of claims 1-18, wherein at least one
modified sugar moiety is a bicyclic sugar moiety.
23. The compound of claim 22, wherein at least one bicyclic sugar
moiety is LNA or cEt.
24. The compound of any of claims 18-23, wherein at least one sugar
moiety is a sugar surrogate.
25. The compound of claim 24, wherein at least one sugar surrogate
is a morpholino.
26. The compound of claim 24, wherein at least one sugar surrogate
is a modified morpholino.
27. The compound of any of claim 1-26, wherein the modified
oligonucleotide comprises at least 5 modified nucleosides, each
independently comprising a modified sugar moiety.
28. The compound of claim 27, wherein the modified oligonucleotide
comprises at least 10 modified nucleosides, each independently
comprising a modified sugar moiety.
29. The compound of claim 27, wherein the modified oligonucleotide
comprises at least 15 modified nucleosides, each independently
comprising a modified sugar moiety.
30. The compound of claim 27, wherein each nucleoside of the
modified oligonucleotide is a modified nucleoside, each
independently comprising a modified sugar moiety
31. The compound of any of claims 1-30, wherein the modified
oligonucleotide comprises at least two modified nucleosides
comprising modified sugar moieties that are the same as one
another.
32. The compound of any of claims 1-31, wherein the modified
oligonucleotide comprises at least two modified nucleosides
comprising modified sugar moieties that are different from one
another.
33. The compound of any of claims 1-32, wherein the modified
oligonucleotide comprises a modified region of at least 5
contiguous modified nucleosides.
34. The compound of claim 33, wherein the modified oligonucleotide
comprises a modified region of at least 10 contiguous modified
nucleosides.
35. The compound of claim 33, wherein the modified oligonucleotide
comprises a modified region of at least 15 contiguous modified
nucleosides.
36. The compound of claim 33, wherein the modified oligonucleotide
comprises a modified region of at least 20 contiguous modified
nucleosides.
37. The compound of any of claims 32-36, wherein each modified
nucleoside of the modified region has a modified sugar moiety
independently selected from among: 2'-F, 2'-OMe, 2'-MOE, cEt, LNA,
morpholino, and modified morpholino.
38. The compound of any of claims 33-37, wherein the modified
nucleosides of the modified region each comprise the same
modification as one another.
39. The compound of claim 38, wherein the modified nucleosides of
the modified region each comprise the same 2'-substituted sugar
moiety.
40. The compound of claim 38, wherein the 2'-substituted sugar
moiety of the modified nucleosides of the region of modified
nucleosides is selected from 2'-F, 2'-OMe, and 2'-MOE.
41. The compound of claim 39, wherein the 2'-substituted sugar
moiety of the modified nucleosides of the region of modified
nucleosides is 2'-MOE.
42. The compound of claim 38, wherein the modified nucleosides of
the region of modified nucleosides each comprise the same bicyclic
sugar moiety.
43. The compound of claim 42, wherein the bicyclic sugar moiety of
the modified nucleosides of the region of modified nucleosides is
selected from LNA and cEt.
44. The compound of claim 38, wherein the modified nucleosides of
the region of modified nucleosides each comprises a sugar
surrogate.
45. The compound of claim 44, wherein the sugar surrogate of the
modified nucleosides of the region of modified nucleosides is a
morpholino.
46. The compound of claim 44, wherein the sugar surrogate of the
modified nucleosides of the region of modified nucleosides is a
modified morpholino.
47. The compound of any of claims 1-46, wherein the modified
nucleotide comprises no more than 4 contiguous naturally occurring
nucleosides.
48. The compound of any of claims 1-46, wherein each nucleoside of
the modified oligonucleotide is a modified nucleoside.
49. The compound of claim 48 wherein each modified nucleoside
comprises a modified sugar moiety.
50. The compound of claim 49, wherein the modified nucleosides of
the modified oligonucleotide comprise the same modification as one
another.
51. The compound of claim 50, wherein the modified nucleosides of
the modified oligonucleotide each comprise the same 2'-substituted
sugar moiety.
52. The compound of claim 51, wherein the 2'-substituted sugar
moiety of the modified oligonucleotide is selected from 2'-F,
2'-OMe, and 2'-MOE.
53. The compound of claim 52, wherein the 2'-substituted sugar
moiety of the modified oligonucleotide is 2'-MOE.
54. The compound of claim 50, wherein the modified nucleosides of
the modified oligonucleotide each comprise the same bicyclic sugar
moiety.
55. The compound of claim 54, wherein the bicyclic sugar moiety of
the modified oligonucleotide is selected from LNA and cEt.
56. The compound of claim 50, wherein the modified nucleosides of
the modified oligonucleotide each comprises a sugar surrogate.
57. The compound of claim 56, wherein the sugar surrogate of the
modified oligonucleotide is a morpholino.
58. The compound of claim 56, wherein the sugar surrogate of the
modified oligonucleotide is a modified morpholino.
59. The compound of any of claims 1-58, wherein the modified
oligonucleotide comprises at least one modified internucleoside
linkage.
60. The compound of claim 59, wherein each internucleoside linkage
is a modified internucleoside linkage.
61. The compound of claim 59 or 60, comprising at least one
phosphorothioate internucleoside linkage.
62. The compound of claim 60, wherein each internucleoside linkage
is a modified internucleoside linkage and wherein each
internucleoside linkage comprises the same modification.
63. The compound of claim 62, wherein each internucleoside linkage
is a phosphorothioate internucleoside linkage.
64. The compound of any of claims 1-63 comprising at least one
conjugate.
65. The compound of any of claims 1-64 consisting of the modified
oligonucleotide.
66. The compound of any of claims 1-65, wherein the compound
modulates splicing of the PK-M transcript.
67. The compound of any of claims 1-66, having a nucleobase
sequence comprising any of the sequences as set forth in SEQ ID
NOs. 4 to 36.
68. The compound of any of claims 1-66, having a nucleobase
sequence comprising any of the sequences as set forth in SEQ ID
NOs. 4 to 17.
69. The compound of any of claims 1-66, having a nucleobase
sequence comprising any of the sequences as set forth in SEQ ID
NOs. 18 to 28.
70. The compound of any of claims 1-66, having a nucleobase
sequence comprising any of the sequences as set forth in SEQ ID
NOs. 29 to 36.
71. The compound of any of claims 1-66, having a nucleobase
sequence comprising SEQ ID NO. 32.
72. The compound of any of claims 1-66, having a nucleobase
sequence comprising SEQ ID NO. 7.
73. The compound of any of claims 1-66, having a nucleobase
sequence comprising SEQ ID NO. 24.
74. A pharmaceutical composition comprising a compound according to
any of claims 1-73 and a pharmaceutically acceptable carrier or
diluent.
75. The pharmaceutical composition of claim 74, wherein the
pharmaceutically acceptable carrier or diluent is sterile
saline.
76. A method of modulating splicing of a PK-M transcript in a cell
comprising contacting the cell with a compound according to any of
claims 1-75.
77. The method of claim 76, wherein the cell is in vitro.
78. The method of claim 76, wherein the cell is in an animal.
79. The method of any of claims 76-78, wherein inclusion of exon 9
is increased.
80. The method of any of claims 76-79, wherein exclusion of exon 10
is increased.
81. The method of any of claims 76-79, wherein inclusion of exon 10
is decreased.
82. The method of any of claims 76-81, wherein PK-M1 mRNA
expression is increased.
83. The method of any of claims 76-82, wherein PK-M2 mRNA
expression is decreased.
84. A method of modulating the expression of PK-M in a cell,
comprising contacting the cell with a compound according to any of
claims 1-75.
85. The method of claim 84, wherein PK-M1 expression is
increased.
86. The method of claim 84 or 85, wherein PK-M2 expression is
decreased.
87. The method of claim 84, wherein the cell is in vitro.
88. The method of claim 84, wherein the cell is in an animal.
89. A method of inducing apoptosis in a cell, comprising contacting
the cell with a compound according to any of claims 1-75.
90. The method of claim 89, wherein the cell is in vitro.
91. The method of claim 89, wherein the cell is in an animal.
92. A method comprising administering the compound according to any
of claims 1-67 or the pharmaceutical composition of claim 74 or 75
to an animal.
93. The method of claim 92, wherein the administration is
intracerebroventricular.
94. The method of claim 92, wherein the administration is into the
central nervous system.
95. The method of any of claims 92-94, wherein the animal has one
or more symptoms associated with cancer.
96. The method claim 95, wherein the cancer is glioblastoma.
97. The method of claim 96, wherein the administration results in
amelioration of at least one symptom of cancer.
98. The method of any of claims 91-97, wherein the animal is a
mouse.
99. The method of any of claims 91-97, wherein the animal is a
human.
100. A method of preventing or retarding the growth of a cancerous
tumor, comprising administering the compound according to any of
claims 1-73 or the pharmaceutical composition of claim 74 or 75 to
an animal in need thereof.
101. The method of claim 100, wherein the animal is a mouse.
102. The method of claim 100, wherein the animal is a human.
103. The method of claims 100 to 102, wherein the cancerous tumor
comprises glioblastoma.
104. Use of the compound according to any of claims 1-73 or the
pharmaceutical composition of claim 74 or 75 for the preparation of
a medicament for use in the treatment of cancer.
105. Use of the compound according to any of claims 1-73 or the
pharmaceutical composition of claim 74 or 75 for the preparation of
a medicament for use in the amelioration of one or more symptoms
cancer.
106. The use of claim 104 or 105, wherein the cancer is
glioblastoma.
Description
SEQUENCE LISTING
[0001] The present application is being filed along with a Sequence
Listing in electronic format. The Sequence Listing is provided as a
file entitled BIOL0206WOSEQ.txt, created Oct. 30, 2013, which is 88
Kb in size. The information in the electronic format of the
sequence listing is incorporated herein by reference in its
entirety.
BACKGROUND
[0002] The pyruvate kinase M (PK-M) gene has 12 exons. Exon 9 and
exon 10 are alternatively spliced in a mutually exclusive fashion
to give rise to the M1 and M2 isoforms of the PK-M gene. Inclusion
of exon 9 and exclusion of exon 10 yields the PK-M1 isoform.
Exclusion of exon 9 and inclusion of exon 10 yields the PK-M2
isoform. Exons 9 and 10 each encode a 56 amino acid segment that
confers distinctive properties to the respective PK-M1 and PK-M2
isoforms. The PK-M2 isoform is expressed in a broad range of cancer
cells, whereas PK-M1 is predominantly expressed in terminally
differentiated tissues.
[0003] Antisense compounds have been used to modulate target
nucleic acids. Antisense compounds comprising a variety of chemical
modifications and motifs have been reported. In certain instances,
such compounds are useful as research tools, diagnostic reagents,
and as therapeutic agents. In certain instances antisense compounds
have been shown to modulate protein expression by binding to a
target messenger RNA (mRNA) encoding the protein. In certain
instances, such binding of an antisense compound to its target mRNA
results in cleavage of the mRNA. Antisense compounds that modulate
processing of a pre-mRNA have also been reported. Such antisense
compounds alter splicing, interfere with polyadenlyation or prevent
formation of the 5'-cap of a pre-mRNA.
[0004] Certain antisense compounds have been described previously.
See for example U.S. Pat. No. 7,399,845 and published International
Patent Application No. WO 2008/049085, which are hereby
incorporated by reference herein in their entirety.
SUMMARY
[0005] In certain embodiments, the present invention provides
compounds comprising oligonucleotides. In certain embodiments, such
oligonucleotides are complementary to a pyruvate kinase M (PK-M)
transcript. In certain such embodiments, oligonucleotides are
complementary to a target region of the PK-M transcript comprising
exon 10. In certain such embodiments, oligonucleotides are
complementary to a target region of the PK-M transcript comprising
an intron adjacent to exon 10. In certain such embodiments,
oligonucleotides are complementary to a target region of the PK-M
transcript comprising an intron adjacent to exon 10 and downstream
of exon 10. In certain such embodiments, oligonucleotides are
complementary to a target region of the PK-M transcript comprising
an intron adjacent to exon 10 and upstream of exon 10. In certain
embodiments, the PK-M transcript comprises an exonic splice
enhancer for exon 10. In certain embodiments, oligonucleotides
inhibit inclusion of exon 10. In certain embodiments,
oligonucleotides promote skipping of exon 10. In certain
embodiments, oligonucleotides promote selection of exon 9. In
certain embodiments, oligonucleotides promote skipping of exon 10
and promote inclusion of exon 9. In certain such embodiments, PK-M
mRNA with exon 9 mRNA is increased. In certain such embodiments,
PK-M mRNA with exon 10 mRNA is decreased. In certain embodiments,
the PK-M2 isoform of the PK-M protein is decreased. In certain
embodiments, the PK-M1 isoform of the PK-M protein is
decreased.
[0006] In certain embodiments, including, but not limited to any of
the above numbered embodiments, the PK-M transcript is in a human.
In certain embodiments, including, but not limited to any of the
above numbered embodiments, the PK-M transcript is in a mouse.
[0007] The present disclosure provides the following non-limiting
numbered embodiments:
Embodiment 1
[0008] A compound comprising a modified oligonucleotide consisting
of 8 to 30 linked nucleosides and having a nucleobase sequence
comprising a complementary region, wherein the complementary region
comprises at least 8 contiguous nucleobases and is complementary to
an equal-length portion within a target region of a PK-M
transcript.
Embodiment 2
[0009] The compound of embodiment 1, wherein the target region of
the PK-M transcript comprises exon 10 of the PK-M transcript.
Embodiment 3
[0010] The compound of embodiment 1 or 2, wherein the complementary
region of the modified oligonucleotide is 100% complementary to the
target region.
Embodiment 4
[0011] The compound of any of embodiments 1 to 3, wherein the
complementary region of the modified oligonucleotide comprises at
least 10 contiguous nucleobases.
Embodiment 5
[0012] The compound of any of embodiments 1 to 3, wherein the
complementary region of the modified oligonucleotide comprises at
least 15 contiguous nucleobases.
Embodiment 6
[0013] The compound of any of embodiments 1 to 3, wherein the
complementary region of the modified oligonucleotide comprises at
least 20 contiguous nucleobases.
Embodiment 7
[0014] The compound of any of embodiments 1-6, wherein the
nucleobase sequence of the oligonucleotide is at least 80%
complementary to the target region, as measured over the entire
length of the oligonucleotide.
Embodiment 8
[0015] The compound of any of embodiments 1-6, wherein the
nucleobase sequence of the oligonucleotide is at least 90%
complementary to an equal-length region of the PK-M transcript, as
measured over the entire length of the oligonucleotide.
Embodiment 9
[0016] The compound of any of embodiments 1-6, wherein the
nucleobase sequence of the oligonucleotide is 100% complementary to
an equal-length region of the PK-M transcript, as measured over the
entire length of the oligonucleotide.
Embodiment 10
[0017] The compound of any of embodiments 1-9, wherein the target
region is within exon 10 of the PK-M transcript.
Embodiment 11
[0018] The compound of any of embodiments 1-10, wherein the target
region is within nucleobase 29153 and nucleobase 29281 of SEQ ID
NO.: 1.
Embodiment 12
[0019] The compound of any of embodiments 1-10, wherein the target
region is within nucleobase 29158 and nucleobase 29262 of SEQ ID
NO.: 1.
Embodiment 13
[0020] The compound of any of embodiments 1-10, wherein the target
region is within nucleobase 29164 and nucleobase 29188 of SEQ ID
NO.: 1.
Embodiment 14
[0021] The compound of any of embodiments 1-10, wherein the target
region is within nucleobase 29261 and nucleobase 29279 of SEQ ID
NO.: 1.
Embodiment 15
[0022] The compound of any of embodiments 1-10, wherein the target
region is within nucleobase 29168 and nucleobase 29183 of SEQ ID
NO.: 1.
Embodiment 16
[0023] The compound of any of embodiments 1-15, wherein the
antisense oligonucleotide comprises any one of SEQ ID NOs: 4 to
36.
Embodiment 17
[0024] The compound of any of embodiments 1-16, wherein the
modified oligonucleotide comprises at least one modified
nucleoside.
Embodiment 18
[0025] The compound of embodiment 17, wherein at least one modified
nucleoside comprises a modified sugar moiety.
Embodiment 19
[0026] The compound of embodiment 18, wherein at least one modified
sugar moiety is a 2'-substituted sugar moiety.
Embodiment 20
[0027] The compound of embodiment 19, wherein the 2'-substitutent
of at least one 2'-substituted sugar moiety is selected from among:
2'-OMe, 2'-F, and 2'-MOE.
Embodiment 21
[0028] The compound of any of embodiments 17-20, wherein the
2'-substituent of at least one 2'-substituted sugar moiety is a
2'-MOE.
Embodiment 22
[0029] The compound of any of embodiments 1-18, wherein at least
one modified sugar moiety is a bicyclic sugar moiety.
Embodiment 23
[0030] The compound of embodiment 22, wherein at least one bicyclic
sugar moiety is LNA or cEt.
Embodiment 24
[0031] The compound of any of embodiments 18-23, wherein at least
one sugar moiety is a sugar surrogate.
Embodiment 25
[0032] The compound of embodiment 24, wherein at least one sugar
surrogate is a morpholino.
Embodiment 26
[0033] The compound of embodiment 24, wherein at least one sugar
surrogate is a modified morpholino.
Embodiment 27
[0034] The compound of any of embodiment 1-26, wherein the modified
oligonucleotide comprises at least 5 modified nucleosides, each
independently comprising a modified sugar moiety.
Embodiment 28
[0035] The compound of embodiment 27, wherein the modified
oligonucleotide comprises at least 10 modified nucleosides, each
independently comprising a modified sugar moiety.
Embodiment 29
[0036] The compound of embodiment 27, wherein the modified
oligonucleotide comprises at least 15 modified nucleosides, each
independently comprising a modified sugar moiety.
Embodiment 30
[0037] The compound of embodiment 27, wherein each nucleoside of
the modified oligonucleotide is a modified nucleoside, each
independently comprising a modified sugar moiety
Embodiment 31
[0038] The compound of any of embodiments 1-30, wherein the
modified oligonucleotide comprises at least two modified
nucleosides comprising modified sugar moieties that are the same as
one another.
Embodiment 32
[0039] The compound of any of embodiments 1-31, wherein the
modified oligonucleotide comprises at least two modified
nucleosides comprising modified sugar moieties that are different
from one another.
Embodiment 33
[0040] The compound of any of embodiments 1-32, wherein the
modified oligonucleotide comprises a modified region of at least 5
contiguous modified nucleosides.
Embodiment 34
[0041] The compound of embodiment 33, wherein the modified
oligonucleotide comprises a modified region of at least 10
contiguous modified nucleosides.
Embodiment 35
[0042] The compound of embodiment 33, wherein the modified
oligonucleotide comprises a modified region of at least 15
contiguous modified nucleosides.
Embodiment 36
[0043] The compound of embodiment 33, wherein the modified
oligonucleotide comprises a modified region of at least 20
contiguous modified nucleosides.
Embodiment 37
[0044] The compound of any of embodiments 32-36, wherein each
modified nucleoside of the modified region has a modified sugar
moiety independently selected from among: 2'-F, 2'-OMe, 2'-MOE,
cEt, LNA, morpholino, and modified morpholino.
Embodiment 38
[0045] The compound of any of embodiments 33-37, wherein the
modified nucleosides of the modified region each comprise the same
modification as one another.
Embodiment 39
[0046] The compound of embodiment 38, wherein the modified
nucleosides of the modified region each comprise the same
2'-substituted sugar moiety.
Embodiment 40
[0047] The compound of embodiment 38, wherein the 2'-substituted
sugar moiety of the modified nucleosides of the region of modified
nucleosides is selected from 2'-F, 2'-OMe, and 2'-MOE.
Embodiment 41
[0048] The compound of embodiment 39, wherein the 2'-substituted
sugar moiety of the modified nucleosides of the region of modified
nucleosides is 2'-MOE.
Embodiment 42
[0049] The compound of embodiment 38, wherein the modified
nucleosides of the region of modified nucleosides each comprise the
same bicyclic sugar moiety.
Embodiment 43
[0050] The compound of embodiment 42, wherein the bicyclic sugar
moiety of the modified nucleosides of the region of modified
nucleosides is selected from LNA and cEt.
Embodiment 44
[0051] The compound of embodiment 38, wherein the modified
nucleosides of the region of modified nucleosides each comprises a
sugar surrogate.
Embodiment 45
[0052] The compound of embodiment 44, wherein the sugar surrogate
of the modified nucleosides of the region of modified nucleosides
is a morpholino.
Embodiment 46
[0053] The compound of embodiment 44, wherein the sugar surrogate
of the modified nucleosides of the region of modified nucleosides
is a modified morpholino.
Embodiment 47
[0054] The compound of any of embodiments 1-46, wherein the
modified nucleotide comprises no more than 4 contiguous naturally
occurring nucleosides.
Embodiment 48
[0055] The compound of any of embodiments 1-46, wherein each
nucleoside of the modified oligonucleotide is a modified
nucleoside.
Embodiment 49
[0056] The compound of embodiment 48 wherein each modified
nucleoside comprises a modified sugar moiety.
Embodiment 50
[0057] The compound of embodiment 49, wherein the modified
nucleosides of the modified oligonucleotide comprise the same
modification as one another.
Embodiment 51
[0058] The compound of embodiment 50, wherein the modified
nucleosides of the modified oligonucleotide each comprise the same
2'-substituted sugar moiety.
Embodiment 52
[0059] The compound of embodiment 51, wherein the 2'-substituted
sugar moiety of the modified oligonucleotide is selected from 2'-F,
2'-OMe, and 2'-MOE.
Embodiment 53
[0060] The compound of embodiment 52, wherein the 2'-substituted
sugar moiety of the modified oligonucleotide is 2'-MOE.
Embodiment 54
[0061] The compound of embodiment 50, wherein the modified
nucleosides of the modified oligonucleotide each comprise the same
bicyclic sugar moiety.
Embodiment 55
[0062] The compound of embodiment 54, wherein the bicyclic sugar
moiety of the modified oligonucleotide is selected from LNA and
cEt.
Embodiment 56
[0063] The compound of embodiment 50, wherein the modified
nucleosides of the modified oligonucleotide each comprises a sugar
surrogate.
Embodiment 57
[0064] The compound of embodiment 56, wherein the sugar surrogate
of the modified oligonucleotide is a morpholino.
Embodiment 58
[0065] The compound of embodiment 56, wherein the sugar surrogate
of the modified oligonucleotide is a modified morpholino.
Embodiment 59
[0066] The compound of any of embodiments 1-58, wherein the
modified oligonucleotide comprises at least one modified
internucleoside linkage.
Embodiment 60
[0067] The compound of embodiment 59, wherein each internucleoside
linkage is a modified internucleoside linkage.
Embodiment 61
[0068] The compound of embodiment 59 or 60, comprising at least one
phosphorothioate internucleoside linkage.
Embodiment 62
[0069] The compound of embodiment 60, wherein each internucleoside
linkage is a modified internucleoside linkage and wherein each
internucleoside linkage comprises the same modification.
Embodiment 63
[0070] The compound of embodiment 62, wherein each internucleoside
linkage is a phosphorothioate internucleoside linkage.
Embodiment 64
[0071] The compound of any of embodiments 1-63 comprising at least
one conjugate.
Embodiment 65
[0072] The compound of any of embodiments 1-64 consisting of the
modified oligonucleotide.
Embodiment 66
[0073] The compound of any of embodiments 1-65, wherein the
compound modulates splicing of the PK-M transcript.
Embodiment 67
[0074] The compound of any of embodiments 1-66, having a nucleobase
sequence comprising any of the sequences as set forth in SEQ ID
NOs. 4 to 36.
Embodiment 68
[0075] The compound of any of embodiments 1-66, having a nucleobase
sequence comprising any of the sequences as set forth in SEQ ID
NOs. 4 to 17.
Embodiment 69
[0076] The compound of any of embodiments 1-66, having a nucleobase
sequence comprising any of the sequences as set forth in SEQ ID
NOs. 18 to 28.
Embodiment 70
[0077] The compound of any of embodiments 1-66, having a nucleobase
sequence comprising any of the sequences as set forth in SEQ ID
NOs. 29 to 36.
Embodiment 71
[0078] The compound of any of embodiments 1-66, having a nucleobase
sequence comprising SEQ ID NO. 32.
Embodiment 72
[0079] The compound of any of embodiments 1-66, having a nucleobase
sequence comprising SEQ ID NO. 7.
Embodiment 73
[0080] The compound of any of embodiments 1-66, having a nucleobase
sequence comprising SEQ ID NO. 24.
Embodiment 74
[0081] A pharmaceutical composition comprising a compound according
to any of embodiments 1-73 and a pharmaceutically acceptable
carrier or diluent.
Embodiment 75
[0082] The pharmaceutical composition of embodiment 74, wherein the
pharmaceutically acceptable carrier or diluent is sterile
saline.
Embodiment 76
[0083] A method of modulating splicing of a PK-M transcript in a
cell comprising contacting the cell with a compound according to
any of embodiments 1-75.
Embodiment 77
[0084] The method of embodiment 76, wherein the cell is in
vitro.
Embodiment 78
[0085] The method of embodiment 76, wherein the cell is in an
animal.
Embodiment 79
[0086] The method of any of embodiments 76-78, wherein inclusion of
exon 9 is increased.
Embodiment 80
[0087] The method of any of embodiments 76-78, wherein exclusion of
exon 10 is increased.
Embodiment 81
[0088] The method of any of embodiments 76-78, wherein inclusion of
exon 10 is decreased.
Embodiment 82
[0089] The method of any of embodiments 76-78, wherein PK-M1 mRNA
expression is increased.
Embodiment 83
[0090] The method of any of embodiments 76-78, wherein PK-M2 mRNA
expression is decreased.
Embodiment 84
[0091] A method of modulating the expression of PK-M in a cell,
comprising contacting the cell with a compound according to any of
embodiments 1-75.
Embodiment 85
[0092] The method of embodiment 84, wherein PK-M1 expression is
increased.
Embodiment 86
[0093] The method of embodiments 84 or 85, wherein PK-M2 expression
is decreased.
Embodiment 87
[0094] The method of embodiment 84, wherein the cell is in
vitro.
Embodiment 88
[0095] The method of embodiment 84, wherein the cell is in an
animal.
Embodiment 89
[0096] A method of inducing apoptosis in a cell, comprising
contacting the cell with a compound according to any of embodiments
1-75.
Embodiment 90
[0097] The method of embodiment 89, wherein the cell is in
vitro.
Embodiment 91
[0098] The method of embodiment 89, wherein the cell is in an
animal.
Embodiment 92
[0099] A method comprising administering the compound according to
any of embodiments 1-67 or the pharmaceutical composition of
embodiments 74 or 75 to an animal.
Embodiment 93
[0100] The method of embodiment 92, wherein the administration is
intracerebroventricular.
Embodiment 94
[0101] The method of embodiment 92, wherein the administration is
into the central nervous system.
Embodiment 95
[0102] The method of any of embodiments 92-94, wherein the animal
has one or more symptoms associated with cancer.
Embodiment 96
[0103] The method embodiment 95, wherein the cancer is
glioblastoma.
Embodiment 97
[0104] The method of embodiment 96, wherein the administration
results in amelioration of at least one symptom of cancer.
Embodiment 98
[0105] The method of any of embodiments 91-97, wherein the animal
is a mouse.
Embodiment 99
[0106] The method of any of embodiments 91-97, wherein the animal
is a human.
Embodiment 100
[0107] A method of preventing or retarding the growth of a
cancerous tumor, comprising administering the compound according to
any of embodiments 1-73 or the pharmaceutical composition of
embodiments 74 or 75 to an animal in need thereof.
Embodiment 101
[0108] The method of embodiment 100, wherein the animal is a
mouse.
Embodiment 102
[0109] The method of embodiment 100, wherein the animal is a
human.
Embodiment 103
[0110] The method of embodiment 100 to 102, wherein the cancerous
tumor comprises glioblastoma.
Embodiment 104
[0111] Use of the compound according to any of embodiments 1-73 or
the pharmaceutical composition of embodiments 74 or 75 for the
preparation of a medicament for use in the treatment of cancer.
Embodiment 105
[0112] Use of the compound according to any of embodiments 1-73 or
the pharmaceutical composition of embodiments 74 or 75 for the
preparation of a medicament for use in the amelioration of one or
more symptoms cancer.
Embodiment 106
[0113] The use of embodiment 104 or 105, wherein the cancer is
glioblastoma.
BRIEF DESCRIPTION OF THE FIGURES
[0114] FIG. 1a: Diagram of the PK-M genomic region. This region
comprises introns 8, 9, and 10 (represented by the lines) and
portions of exon 8, intact exons 9 and 10, and portions of exon 11
(represented by boxes). Numbers above the boxes show the length in
nucleotides. cDNA amplicons generated after radioactive RT-PCR are
shown below and labeled accordingly. Three spliced species were
observed: the shorter double-skipped species, comprising only exons
8 and 11 (D, 271 nucleotides); M1, including exon 9 (A, 398
nucleotides); and M2, including exon 10 (B, 398 nucleotides).
[0115] FIG. 1b: Initial ASO walks. ASOs were transfected at 30 nM
in HEK-293 cells. Radioactive RT-PCR and restriction digest of
endogenous PK-M transcripts are shown. The transfected ASO is
indicated at the top. cDNA amplicons and fragments are indicated on
the left. Lane numbers are indicated at the bottom.
[0116] FIG. 1c: ASO microwalks. ASOs were transfected at 60 nM in
HEK-293 cells. Radioactive RT-PCR and restriction digest of
endogenous PK-M transcripts are shown. The transfected ASO is
indicated at the top. cDNA amplicons and fragments are indicated on
the left. Lane numbers are indicated at the bottom.
[0117] FIG. 2a: Scheme of method used to duplicate the exon 10 10 W
region into exon 9 in a minigene. Minigene mutant names are
indicated below. The indicated exon 9 nucleotides at the top were
mutated to the corresponding exon 10 sequences on the right. The
ASOs that target 10 W and flanking regions are indicated below.
[0118] FIG. 2b: Mutant minigenes analyzed by transient transfection
into HEK-293 cells, followed by radioactive RT-PCR and restriction
digest, as in FIG. 1. Constructs from FIG. 2a are labeled at the
top. The labeled bands are indicated in lower case on the left and
right: uncut M1 fragment (a, 481 nucleotide); uncut M2 fragment (b,
481 nucleotides); PstI-cleaved M2 5' fragment (b2, 268
nucleotides); PstI-cleaved M2 3' fragment (b3, 213 nucleotides); a
spliced mRNA that skips both exons 9 and 10 (d, 314 nucleotides);
an exon 9-exon 10 doubly-included mRNA expressed from the 10B
minigene (lanes 5 and 6) is indicated on the left (f, 648
nucleotides). This band is sensitive to PstI (fl, 435
nucleotides).
[0119] FIG. 2c: Wild-type minigene transcript level changes as a
result of ASO co-transfection in HEK-293 cells. Labeled bands are
indicated in lower case on the left.
[0120] FIG. 2d: Exon 10 duplication minigene transcript level
changes as a result of ASO co-transfection in HEK-293 cells.
Labeled bands are indicated in lower case on the left.
[0121] FIG. 2e: Alignment of the sequences of ISIS 461456, the
complementary region in exon 10, and a homologous region in intron
9 is shown. Vertical lines show sequence identity. A diagram of the
minigene mutants is shown on the right.
[0122] FIG. 2f: Minigene transcript level changes as a result of
ASO co-transfection in HEK-293 cells. Labeled bands are indicated
on the left: uncut M1 fragment (a, 481 nucleotide); uncut M2
fragment (b, 481 nucleotides); PstI-cleaved M2 5' fragment (b2, 268
nucleotides); PstI-cleaved M2 3' fragment (b3, 213 nucleotides); a
spliced mRNA that skips both exons 9 and 10 (d, 314
nucleotides).
[0123] FIG. 3a: Effect of ISIS 549197, ISIS 461456, and ISIS 555158
on endogenous PK-M mRNAs in A172 and U87-MG glioblastoma cells.
[0124] FIG. 3b: Immunoblot analysis of PK-M protein isoform levels
in A172 and U87-MG glioblastoma cells transfected with ISIS 549197,
ISIS 461456, or ISIS 555158. Antibodies used are indicated on the
left.
[0125] FIG. 3c: Immunofluroescence staining of glioblastoma cells
with antibodies directed against PK-M2. Cell lines were stained
with PK-M2 antibody and the DNA-binding fluorescent stain,
DAPI.
[0126] FIG. 4: Immunoblot analysis of A172 cells transfected with
ISIS 549197 or control ASO. Antibodies used are indicated on the
left.
[0127] FIG. 5a: Flow cytometric analysis of A172 or U87-MG
glioblastoma cells transfected with the indicated ASOs and stained
with Annexin V-APC/7-AAD.
[0128] FIG. 5b: Dose-dependent apoptosis in glioblastoma cells by
ASO treatment. Error bars represent s.d. (n=3).
[0129] FIG. 6a: Immunoblot analysis of A172 cells stably transduced
with rtTA and doxycycline-inducible human T7-tagged PK-M1 cDNA.
Antibodies used are indicated on the left.
[0130] FIG. 6b: Immunoblot analysis of A172 and U87-MG cells stably
transduced with T7-tagged PK-M1 cDNA. Transduced cells and parental
cell lines were transfected with ASOs. Antibodies used are
indicated on the left.
[0131] FIG. 6c: Histogram analysis of cells grown as in FIG. 6a and
transfected with the indicated ASOs. Doxycycline conditions are
shown on the left. Error bars represent s.d. (n=3).
[0132] FIG. 6d: Histogram analysis of cells grown as in FIG. 6b and
transfected with the indicated ASOs. Error bars represent s.d.
(n=3).
[0133] FIG. 7: Immunoblot analysis of A172 cells independently
transfected with four different PK-M2 siRNAs. Antibodies used are
indicated on the left.
DETAILED DESCRIPTION
[0134] Unless specific definitions are provided, the nomenclature
used in connection with, and the procedures and techniques of,
analytical chemistry, synthetic organic chemistry, and medicinal
and pharmaceutical chemistry described herein are those well known
and commonly used in the art. Standard techniques may be used for
chemical synthesis, and chemical analysis. Certain such techniques
and procedures may be found for example in "Carbohydrate
Modifications in Antisense Research" Edited by Sangvi and Cook,
American Chemical Society, Washington D.C., 1994; "Remington's
Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa.,
21.sup.st edition, 2005; and "Antisense Drug Technology,
Principles, Strategies, and Applications" Edited by Stanley T.
Crooke, CRC Press, Boca Raton, Fla.; and Sambrook et al.,
"Molecular Cloning, A laboratory Manual," 2.sup.nd Edition, Cold
Spring Harbor Laboratory Press, 1989, which are hereby incorporated
by reference for any purpose. Where permitted, all patents,
applications, published applications and other publications and
other data referred to throughout in the disclosure are
incorporated by reference herein in their entirety.
[0135] Unless otherwise indicated, the following terms have the
following meanings:
[0136] As used herein, "nucleoside" means a compound comprising a
nucleobase moiety and a sugar moiety. Nucleosides include, but are
not limited to, naturally occurring nucleosides (as found in DNA
and RNA) and modified nucleosides. Nucleosides may be linked to a
phosphate moiety.
[0137] As used herein, "chemical modification" means a chemical
difference in a compound when compared to a naturally occurring
counterpart. In reference to an oligonucleotide, chemical
modification does not include differences only in nucleobase
sequence. Chemical modifications of oligonucleotides include
nucleoside modifications (including sugar moiety modifications and
nucleobase modifications) and internucleoside linkage
modifications.
[0138] As used herein, "furanosyl" means a structure comprising a
5-membered ring comprising four carbon atoms and one oxygen
atom.
[0139] As used herein, "naturally occurring sugar moiety" means a
ribofuranosyl as found in naturally occurring RNA or a
deoxyribofuranosyl as found in naturally occurring DNA.
[0140] As used herein, "sugar moiety" means a naturally occurring
sugar moiety or a modified sugar moiety of a nucleoside.
[0141] As used herein, "modified sugar moiety" means a substituted
sugar moiety, a bicyclic or tricyclic sugar moiety, or a sugar
surrogate.
[0142] As used herein, "substituted sugar moiety" means a furanosyl
comprising at least one substituent group that differs from that of
a naturally occurring sugar moiety. Substituted sugar moieties
include, but are not limited to furanosyls comprising substituents
at the 2'-position, the 3'-position, the 5'-position and/or the
4'-position.
[0143] As used herein, "2'-substituted sugar moiety" means a
furanosyl comprising a substituent at the 2'-position other than H
or OH. Unless otherwise indicated, a 2'-substituted sugar moiety is
not a bicyclic sugar moiety (i.e., the 2'-substituent of a
2'-substituted sugar moiety does not form a bridge to another atom
of the furanosyl ring.
[0144] As used herein, "MOE" means
--OCH.sub.2CH.sub.2OCH.sub.3.
[0145] As used herein, "bicyclic sugar moiety" means a modified
sugar moiety comprising a 4 to 7 membered ring (including but not
limited to a furanosyl) comprising a bridge connecting two atoms of
the 4 to 7 membered ring to form a second ring, resulting in a
bicyclic structure. In certain embodiments, the 4 to 7 membered
ring is a sugar ring. In certain embodiments the 4 to 7 membered
ring is a furanosyl. In certain such embodiments, the bridge
connects the 2'-carbon and the 4'-carbon of the furanosyl.
[0146] As used herein the term "sugar surrogate" means a structure
that does not comprise a furanosyl and that is capable of replacing
the naturally occurring sugar moiety of a nucleoside, such that the
resulting nucleoside is capable of (1) incorporation into an
oligonucleotide and (2) hybridization to a complementary
nucleoside. Such structures include rings comprising a different
number of atoms than furanosyl (e.g., 4, 6, or 7-membered rings);
replacement of the oxygen of a furanosyl with a non-oxygen atom
(e.g., carbon, sulfur, or nitrogen); or both a change in the number
of atoms and a replacement of the oxygen. Such structures may also
comprise substitutions corresponding to those described for
substituted sugar moieties (e.g., 6-membered carbocyclic bicyclic
sugar surrogates optionally comprising additional substituents).
Sugar surrogates also include more complex sugar replacements
(e.g., the non-ring systems of peptide nucleic acid). Sugar
surrogates include without limitation morpholino, modified
morpholinos, cyclohexenyls and cyclohexitols.
[0147] As used herein, "nucleotide" means a nucleoside further
comprising a phosphate linking group. As used herein, "linked
nucleosides" may or may not be linked by phosphate linkages and
thus includes, but is not limited to "linked nucleotides." As used
herein, "linked nucleosides" are nucleosides that are connected in
a continuous sequence (i.e. no additional nucleosides are present
between those that are linked).
[0148] As used herein, "nucleobase" means a group of atoms that can
be linked to a sugar moiety to create a nucleoside that is capable
of incorporation into an oligonucleotide, and wherein the group of
atoms is capable of bonding with a complementary naturally
occurring nucleobase of another oligonucleotide or nucleic acid.
Nucleobases may be naturally occurring or may be modified.
[0149] As used herein, "heterocyclic base" or "heterocyclic
nucleobase" means a nucleobase comprising a heterocyclic
structure.
[0150] As used herein the terms, "unmodified nucleobase" or
"naturally occurring nucleobase" means the naturally occurring
heterocyclic nucleobases of RNA or DNA: the purine bases adenine
(A) and guanine (G), and the pyrimidine bases thymine (T), cytosine
(C) (including 5-methyl C), and uracil (U).
[0151] As used herein, "modified nucleobase" means any nucleobase
that is not a naturally occurring nucleobase.
[0152] As used herein, "modified nucleoside" means a nucleoside
comprising at least one chemical modification compared to naturally
occurring RNA or DNA nucleosides. Modified nucleosides comprise a
modified sugar moiety and/or a modified nucleobase.
[0153] As used herein, "bicyclic nucleoside" or "BNA" means a
nucleoside comprising a bicyclic sugar moiety.
[0154] As used herein, "constrained ethyl nucleoside" or "cEt"
means a nucleoside comprising a bicyclic sugar moiety comprising a
4'-CH(CH.sub.3)--O-2'bridge.
[0155] As used herein, "locked nucleic acid nucleoside" or "LNA"
means a nucleoside comprising a bicyclic sugar moiety comprising a
4'-CH.sub.2--O-2'bridge.
[0156] As used herein, "2'-substituted nucleoside" means a
nucleoside comprising a substituent at the 2'-position other than H
or OH. Unless otherwise indicated, a 2'-substituted nucleoside is
not a bicyclic nucleoside.
[0157] As used herein, "2'-deoxynucleoside" means a nucleoside
comprising 2'-H furanosyl sugar moiety, as found in naturally
occurring deoxyribonucleosides (DNA). In certain embodiments, a
2'-deoxynucleoside may comprise a modified nucleobase or may
comprise an RNA nucleobase (e.g., uracil).
[0158] As used herein, "oligonucleotide" means a compound
comprising a plurality of linked nucleosides. In certain
embodiments, an oligonucleotide comprises one or more unmodified
ribonucleosides (RNA) and/or unmodified deoxyribonucleosides (DNA)
and/or one or more modified nucleosides.
[0159] As used herein "oligonucleoside" means an oligonucleotide in
which none of the internucleoside linkages contains a phosphorus
atom. As used herein, oligonucleotides include
oligonucleosides.
[0160] As used herein, "modified oligonucleotide" means an
oligonucleotide comprising at least one modified nucleoside and/or
at least one modified internucleoside linkage.
[0161] As used herein "internucleoside linkage" means a covalent
linkage between adjacent nucleosides in an oligonucleotide.
[0162] As used herein "naturally occurring internucleoside linkage"
means a 3' to 5' phosphodiester linkage.
[0163] As used herein, "modified internucleoside linkage" means any
internucleoside linkage other than a naturally occurring
internucleoside linkage.
[0164] As used herein, "oligomeric compound" means a polymeric
structure comprising two or more sub-structures. In certain
embodiments, an oligomeric compound comprises an oligonucleotide.
In certain embodiments, an oligomeric compound comprises one or
more conjugate groups and/or terminal groups. In certain
embodiments, an oligomeric compound consists of an
oligonucleotide.
[0165] As used herein, "terminal group" means one or more atom
attached to either, or both, the 3' end or the 5' end of an
oligonucleotide. In certain embodiments a terminal group is a
conjugate group. In certain embodiments, a terminal group comprises
one or more terminal group nucleosides.
[0166] As used herein, "conjugate" means an atom or group of atoms
bound to an oligonucleotide or oligomeric compound. In general,
conjugate groups modify one or more properties of the compound to
which they are attached, including, but not limited to
pharmacodynamic, pharmacokinetic, binding, absorption, cellular
distribution, cellular uptake, charge and/or clearance
properties.
[0167] As used herein, "conjugate linking group" means any atom or
group of atoms used to attach a conjugate to an oligonucleotide or
oligomeric compound.
[0168] As used herein, "antisense compound" means a compound
comprising or consisting of an oligonucleotide at least a portion
of which is complementary to a target nucleic acid to which it is
capable of hybridizing, resulting in at least one antisense
activity.
[0169] As used herein, "antisense activity" means any detectable
and/or measurable change attributable to the hybridization of an
antisense compound to its target nucleic acid.
[0170] As used herein, "detecting" or "measuring" means that a test
or assay for detecting or measuring is performed. Such detection
and/or measuring may result in a value of zero. Thus, if a test for
detection or measuring results in a finding of no activity
(activity of zero), the step of detecting or measuring the activity
has nevertheless been performed.
[0171] As used herein, "detectable and/or measurable activity"
means a statistically significant activity that is not zero.
[0172] As used herein, "essentially unchanged" means little or no
change in a particular parameter, particularly relative to another
parameter which changes much more. In certain embodiments, a
parameter is essentially unchanged when it changes less than 5%. In
certain embodiments, a parameter is essentially unchanged if it
changes less than two-fold while another parameter changes at least
ten-fold. For example, in certain embodiments, an antisense
activity is a change in the amount of a target nucleic acid. In
certain such embodiments, the amount of a non-target nucleic acid
is essentially unchanged if it changes much less than the target
nucleic acid does, but the change need not be zero.
[0173] As used herein, "expression" means the process by which a
gene ultimately results in a protein. Expression includes, but is
not limited to, transcription, post-transcriptional modification
(e.g., splicing, polyadenlyation, addition of 5'-cap), and
translation.
[0174] As used herein, "target nucleic acid" means a nucleic acid
molecule to which an antisense compound hybridizes.
[0175] As used herein, "mRNA" means an RNA molecule that encodes a
protein.
[0176] As used herein, "pre-mRNA" means an RNA transcript that has
not been fully processed into mRNA. Pre-RNA includes one or more
intron.
[0177] As used herein, "transcript" means an RNA molecule
transcribed from DNA. Transcripts include, but are not limited to
mRNA, pre-mRNA, and partially processed RNA.
[0178] As used herein, "PK-M transcript" means a transcript
transcribed from a PK-M gene. In certain embodiments, a PK-M
transcript comprises SEQ ID NO: 1: the complement of GENBANK
Accession No. NT.sub.--010194.16 truncated from nucleotides
43281289 to 43314403.
[0179] As used herein, "PK-M gene" means a gene that encodes a
pyruvate kinase M protein and any pyruvate kinase M protein
isoforms. In certain embodiments, pyruvate kinase M protein
isoforms include pyruvate kinase M1 and pyruvate kinase M2. In
certain embodiments, a pyruvate kinase M gene is represented by
GENBANK Accession No. NT.sub.--010194.16 truncated from nucleotides
43281289 to 43314403, or a variant thereof. In certain embodiments,
a pyruvate kinase M gene is at least 95% identical to GENBANK
Accession No. NT.sub.--010194.16 truncated from nucleotides
43281289 to 43314403. In certain embodiments, a pyruvate kinase M
gene is at least 90% identical to GENBANK Accession No.
NT.sub.--010194.16 truncated from nucleotides 43281289 to
43314403.
[0180] As used herein, "PK-M1" means a pyruvate kinase M transcript
that includes exon 9 but does not include exon 10.
[0181] As used herein, "PK-M1 isoform" means a pyruvate kinase M
protein isoform that includes amino acids encoded from exon 9 but
does not include amino acids encoded from exon 10.
[0182] As used herein, "PK-M2" means a pyruvate kinase M transcript
that includes exon 10 but does not include exon 9.
[0183] As used herein, "PK-M2 isoform" means a pyruvate kinase M
protein isoform that includes amino acids encoded from exon 10 but
does not include amino acids encoded from exon 9.
[0184] As used herein, "targeting" or "targeted to" means the
association of an antisense compound to a particular target nucleic
acid molecule or a particular region of a target nucleic acid
molecule. An antisense compound targets a target nucleic acid if it
is sufficiently complementary to the target nucleic acid to allow
hybridization under physiological conditions.
[0185] As used herein, "nucleobase complementarity" or
"complementarity" when in reference to nucleobases means a
nucleobase that is capable of base pairing with another nucleobase.
For example, in DNA, adenine (A) is complementary to thymine (T).
For example, in RNA, adenine (A) is complementary to uracil (U). In
certain embodiments, complementary nucleobase means a nucleobase of
an antisense compound that is capable of base pairing with a
nucleobase of its target nucleic acid. For example, if a nucleobase
at a certain position of an antisense compound is capable of
hydrogen bonding with a nucleobase at a certain position of a
target nucleic acid, then the position of hydrogen bonding between
the oligonucleotide and the target nucleic acid is considered to be
complementary at that nucleobase pair. Nucleobases comprising
certain modifications may maintain the ability to pair with a
counterpart nucleobase and thus, are still capable of nucleobase
complementarity.
[0186] As used herein, "non-complementary" in reference to
nucleobases means a pair of nucleobases that do not form hydrogen
bonds with one another.
[0187] As used herein, "complementary" in reference to oligomeric
compounds (e.g., linked nucleosides, oligonucleotides, or nucleic
acids) means the capacity of such oligomeric compounds or regions
thereof to hybridize to another oligomeric compound or region
thereof through nucleobase complementarity under stringent
conditions. Complementary oligomeric compounds need not have
nucleobase complementarity at each nucleoside. Rather, some
mismatches are tolerated. In certain embodiments, complementary
oligomeric compounds or regions are complementary at 70% of the
nucleobases (70% complementary). In certain embodiments,
complementary oligomeric compounds or regions are 80%
complementary. In certain embodiments, complementary oligomeric
compounds or regions are 90% complementary. In certain embodiments,
complementary oligomeric compounds or regions are 95%
complementary. In certain embodiments, complementary oligomeric
compounds or regions are 100% complementary.
[0188] As used herein, "hybridization" means the pairing of
complementary oligomeric compounds (e.g., an antisense compound and
its target nucleic acid). While not limited to a particular
mechanism, the most common mechanism of pairing involves hydrogen
bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen
hydrogen bonding, between complementary nucleobases.
[0189] As used herein, "specifically hybridizes" means the ability
of an oligomeric compound to hybridize to one nucleic acid site
with greater affinity than it hybridizes to another nucleic acid
site. In certain embodiments, an antisense oligonucleotide
specifically hybridizes to more than one target site.
[0190] As used herein, "percent complementarity" means the
percentage of nucleobases of an oligomeric compound that are
complementary to an equal-length portion of a target nucleic acid.
Percent complementarity is calculated by dividing the number of
nucleobases of the oligomeric compound that are complementary to
nucleobases at corresponding positions in the target nucleic acid
by the total length of the oligomeric compound.
[0191] As used herein, "percent identity" means the number of
nucleobases in a first nucleic acid that are the same type
(independent of chemical modification) as nucleobases at
corresponding positions in a second nucleic acid, divided by the
total number of nucleobases in the first nucleic acid.
[0192] As used herein, "modulation" means a change of amount or
quality of a molecule, function, or activity when compared to the
amount or quality of a molecule, function, or activity prior to
modulation. For example, modulation includes the change, either an
increase (stimulation or induction) or a decrease (inhibition or
reduction) in gene expression. As a further example, modulation of
expression can include a change in splice site selection of
pre-mRNA processing, resulting in a change in the absolute or
relative amount of a particular splice-variant compared to the
amount in the absence of modulation.
[0193] As used herein, "motif" means a pattern of chemical
modifications in an oligomeric compound or a region thereof. Motifs
may be defined by modifications at certain nucleosides and/or at
certain linking groups of an oligomeric compound.
[0194] As used herein, "nucleoside motif" means a pattern of
nucleoside modifications in an oligomeric compound or a region
thereof. The linkages of such an oligomeric compound may be
modified or unmodified. Unless otherwise indicated, motifs herein
describing only nucleosides are intended to be nucleoside motifs.
Thus, in such instances, the linkages are not limited.
[0195] As used herein, "sugar motif" means a pattern of sugar
modifications in an oligomeric compound or a region thereof.
[0196] As used herein, "linkage motif" means a pattern of linkage
modifications in an oligomeric compound or region thereof. The
nucleosides of such an oligomeric compound may be modified or
unmodified. Unless otherwise indicated, motifs herein describing
only linkages are intended to be linkage motifs. Thus, in such
instances, the nucleosides are not limited.
[0197] As used herein, "nucleobase modification motif" means a
pattern of modifications to nucleobases along an oligonucleotide.
Unless otherwise indicated, a nucleobase modification motif is
independent of the nucleobase sequence.
[0198] As used herein, "sequence motif" means a pattern of
nucleobases arranged along an oligonucleotide or portion thereof.
Unless otherwise indicated, a sequence motif is independent of
chemical modifications and thus may have any combination of
chemical modifications, including no chemical modifications.
[0199] As used herein, "type of modification" in reference to a
nucleoside or a nucleoside of a "type" means the chemical
modification of a nucleoside and includes modified and unmodified
nucleosides. Accordingly, unless otherwise indicated, a "nucleoside
having a modification of a first type" may be an unmodified
nucleoside.
[0200] As used herein, "differently modified" mean chemical
modifications or chemical substituents that are different from one
another, including absence of modifications. Thus, for example, a
MOE nucleoside and an unmodified DNA nucleoside are "differently
modified," even though the DNA nucleoside is unmodified. Likewise,
DNA and RNA are "differently modified," even though both are
naturally-occurring unmodified nucleosides. Nucleosides that are
the same but for comprising different nucleobases are not
differently modified. For example, a nucleoside comprising a 2'-OMe
modified sugar and an unmodified adenine nucleobase and a
nucleoside comprising a 2'-OMe modified sugar and an unmodified
thymine nucleobase are not differently modified.
[0201] As used herein, "the same type of modifications" refers to
modifications that are the same as one another, including absence
of modifications. Thus, for example, two unmodified DNA nucleoside
have "the same type of modification," even though the DNA
nucleoside is unmodified. Such nucleosides having the same type
modification may comprise different nucleobases.
[0202] As used herein, "pharmaceutically acceptable carrier or
diluent" means any substance suitable for use in administering to
an animal. In certain embodiments, a pharmaceutically acceptable
carrier or diluent is sterile saline. In certain embodiments, such
sterile saline is pharmaceutical grade saline.
[0203] As used herein, "substituent" and "substituent group," means
an atom or group that replaces the atom or group of a named parent
compound. For example a substituent of a modified nucleoside is any
atom or group that differs from the atom or group found in a
naturally occurring nucleoside (e.g., a modified 2'-substituent is
any atom or group at the 2'-position of a nucleoside other than H
or OH). Substituent groups can be protected or unprotected. In
certain embodiments, compounds of the present invention have
substituents at one or at more than one position of the parent
compound. Substituents may also be further substituted with other
substituent groups and may be attached directly or via a linking
group such as an alkyl or hydrocarbyl group to a parent
compound.
[0204] Likewise, as used herein, "substituent" in reference to a
chemical functional group means an atom or group of atoms differs
from the atom or a group of atoms normally present in the named
functional group. In certain embodiments, a substituent replaces a
hydrogen atom of the functional group (e.g., in certain
embodiments, the substituent of a substituted methyl group is an
atom or group other than hydrogen which replaces one of the
hydrogen atoms of an unsubstituted methyl group). Unless otherwise
indicated, groups amenable for use as substituents include without
limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl
(--C(O)R.sub.aa), carboxyl (--C(O)O--R.sub.aa), aliphatic groups,
alicyclic groups, alkoxy, substituted oxy (--O--R.sub.aa), aryl,
aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, amino
(--N(R.sub.bb)(R.sub.cc)), imino(.dbd.NR.sub.bb), amido
(--C(O)N(R.sub.bb)(R.sub.cc) or --N(R.sub.bb)C(O)R.sub.aa), azido
(--N.sub.3), nitro (--NO.sub.2), cyano (--CN), carbamido
(--OC(O)N(R.sub.bb)(R.sub.cc) or --N(R.sub.bb)C(O)OR.sub.aa),
ureido (--N(R.sub.bb)C(O)N(R.sub.bb)(R.sub.cc)), thioureido
(--N(R.sub.bb)C(S)N(R.sub.bb)--(R.sub.cc)), guanidinyl
(--N(R.sub.bb)C(.dbd.NR.sub.bb)N(R.sub.bb)(R.sub.cc)), amidinyl
(--C(.dbd.NR.sub.bb)N(R.sub.bb)(R.sub.cc) or
--N(R.sub.bb)C(.dbd.NR.sub.bb)(R.sub.aa)), thiol (--SR.sub.bb),
sulfinyl (--S(O)R.sub.bb), sulfonyl (--S(O).sub.2R.sub.bb) and
sulfonamidyl (--S(O).sub.2N(R.sub.bb)(R.sub.cc) or
--N(R.sub.bb)S--(O).sub.2R.sub.bb). Wherein each R.sub.aa, R.sub.bb
and R.sub.cc is, independently, H, an optionally linked chemical
functional group or a further substituent group with a preferred
list including without limitation, alkyl, alkenyl, alkynyl,
aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic,
heterocyclic and heteroarylalkyl. Selected substituents within the
compounds described herein are present to a recursive degree.
[0205] As used herein, "alkyl," as used herein, means a saturated
straight or branched hydrocarbon radical containing up to twenty
four carbon atoms. Examples of alkyl groups include without
limitation, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl,
octyl, decyl, dodecyl and the like. Alkyl groups typically include
from 1 to about 24 carbon atoms, more typically from 1 to about 12
carbon atoms (C.sub.1-C.sub.12 alkyl) with from 1 to about 6 carbon
atoms being more preferred.
[0206] As used herein, "alkenyl," means a straight or branched
hydrocarbon chain radical containing up to twenty four carbon atoms
and having at least one carbon-carbon double bond. Examples of
alkenyl groups include without limitation, ethenyl, propenyl,
butenyl, 1-methyl-2-buten-1-yl, dienes such as 1,3-butadiene and
the like. Alkenyl groups typically include from 2 to about 24
carbon atoms, more typically from 2 to about 12 carbon atoms with
from 2 to about 6 carbon atoms being more preferred. Alkenyl groups
as used herein may optionally include one or more further
substituent groups.
[0207] As used herein, "alkynyl," means a straight or branched
hydrocarbon radical containing up to twenty four carbon atoms and
having at least one carbon-carbon triple bond. Examples of alkynyl
groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl,
and the like. Alkynyl groups typically include from 2 to about 24
carbon atoms, more typically from 2 to about 12 carbon atoms with
from 2 to about 6 carbon atoms being more preferred. Alkynyl groups
as used herein may optionally include one or more further
substituent groups.
[0208] As used herein, "acyl," means a radical formed by removal of
a hydroxyl group from an organic acid and has the general Formula
--C(O)--X where X is typically aliphatic, alicyclic or aromatic.
Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic
sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic
phosphates, aliphatic phosphates and the like. Acyl groups as used
herein may optionally include further substituent groups.
[0209] As used herein, "alicyclic" means a cyclic ring system
wherein the ring is aliphatic. The ring system can comprise one or
more rings wherein at least one ring is aliphatic. Preferred
alicyclics include rings having from about 5 to about 9 carbon
atoms in the ring. Alicyclic as used herein may optionally include
further substituent groups.
[0210] As used herein, "aliphatic" means a straight or branched
hydrocarbon radical containing up to twenty four carbon atoms
wherein the saturation between any two carbon atoms is a single,
double or triple bond.
[0211] An aliphatic group preferably contains from 1 to about 24
carbon atoms, more typically from 1 to about 12 carbon atoms with
from 1 to about 6 carbon atoms being more preferred. The straight
or branched chain of an aliphatic group may be interrupted with one
or more heteroatoms that include nitrogen, oxygen, sulfur and
phosphorus. Such aliphatic groups interrupted by heteroatoms
include without limitation, polyalkoxys, such as polyalkylene
glycols, polyamines, and polyimines Aliphatic groups as used herein
may optionally include further substituent groups.
[0212] As used herein, "alkoxy" means a radical formed between an
alkyl group and an oxygen atom wherein the oxygen atom is used to
attach the alkoxy group to a parent molecule. Examples of alkoxy
groups include without limitation, methoxy, ethoxy, propoxy,
isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy,
neopentoxy, n-hexoxy and the like. Alkoxy groups as used herein may
optionally include further substituent groups.
[0213] As used herein, "aminoalkyl" means an amino substituted
C.sub.1-C.sub.12 alkyl radical. The alkyl portion of the radical
forms a covalent bond with a parent molecule. The amino group can
be located at any position and the aminoalkyl group can be
substituted with a further substituent group at the alkyl and/or
amino portions.
[0214] As used herein, "aralkyl" and "arylalkyl" mean an aromatic
group that is covalently linked to a C.sub.1-C.sub.12 alkyl
radical. The alkyl radical portion of the resulting aralkyl (or
arylalkyl) group forms a covalent bond with a parent molecule.
Examples include without limitation, benzyl, phenethyl and the
like. Aralkyl groups as used herein may optionally include further
substituent groups attached to the alkyl, the aryl or both groups
that form the radical group.
[0215] As used herein, "aryl" and "aromatic" mean a mono- or
polycyclic carbocyclic ring system radicals having one or more
aromatic rings. Examples of aryl groups include without limitation,
phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like.
Preferred aryl ring systems have from about 5 to about 20 carbon
atoms in one or more rings. Aryl groups as used herein may
optionally include further substituent groups.
[0216] As used herein, "halo" and "halogen," mean an atom selected
from fluorine, chlorine, bromine and iodine.
[0217] As used herein, "heteroaryl," and "heteroaromatic," mean a
radical comprising a mono- or polycyclic aromatic ring, ring system
or fused ring system wherein at least one of the rings is aromatic
and includes one or more heteroatoms. Heteroaryl is also meant to
include fused ring systems including systems where one or more of
the fused rings contain no heteroatoms. Heteroaryl groups typically
include one ring atom selected from sulfur, nitrogen or oxygen.
Examples of heteroaryl groups include without limitation,
pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl,
thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl,
thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl,
benzooxazolyl, quinoxalinyl and the like. Heteroaryl radicals can
be attached to a parent molecule directly or through a linking
moiety such as an aliphatic group or hetero atom. Heteroaryl groups
as used herein may optionally include further substituent
groups.
Oligomeric Compounds
[0218] In certain embodiments, the present invention provides
oligomeric compounds. In certain embodiments, such oligomeric
compounds comprise oligonucleotides optionally comprising one or
more conjugate and/or terminal groups. In certain embodiments, an
oligomeric compound consists of an oligonucleotide. In certain
embodiments, oligonucleotides comprise one or more chemical
modifications. Such chemical modifications include modifications
one or more nucleoside (including modifications to the sugar moiety
and/or the nucleobase) and/or modifications to one or more
internucleoside linkage.
[0219] Certain Sugar Moieties
[0220] In certain embodiments, oligomeric compounds of the
invention comprise one or more modified nucleosides comprising a
modified sugar moiety. Such oligomeric compounds comprising one or
more sugar-modified nucleosides may have desirable properties, such
as enhanced nuclease stability or increased binding affinity with a
target nucleic acid relative to oligomeric compounds comprising
only nucleosides comprising naturally occurring sugar moieties. In
certain embodiments, modified sugar moieties are substituted sugar
moieties. In certain embodiments, modified sugar moieties are
bicyclic or tricyclic sugar moieties. In certain embodiments,
modified sugar moieties are sugar surrogates. Such sugar surrogates
may comprise one or more substitutions corresponding to those of
substituted sugar moieties.
[0221] In certain embodiments, modified sugar moieties are
substituted sugar moieties comprising one or more substituent,
including but not limited to substituents at the 2' and/or 5'
positions. Examples of sugar substituents suitable for the
2'-position, include, but are not limited to: 2'-F, 2'-OCH.sub.3
("OMe" or "O-methyl"), and 2'-O(CH.sub.2).sub.2OCH.sub.3 ("MOE").
In certain embodiments, sugar substituents at the 2' position is
selected from allyl, amino, azido, thio, O-allyl,
O--C.sub.1-C.sub.10 alkyl, O--C.sub.1-C.sub.10 substituted alkyl;
O--C.sub.1-C.sub.10 alkoxy; O--C.sub.1-C.sub.10 substituted alkoxy,
OCF.sub.3, O(CH.sub.2).sub.2SCH.sub.3,
O(CH.sub.2).sub.2--O--N(Rm)(Rn), and
O--CH.sub.2--C(.dbd.O)--N(Rm)(Rn), where each Rm and Rn is,
independently, H or substituted or unsubstituted C.sub.1-C.sub.10
alkyl. Examples of sugar substituents at the 5'-position, include,
but are not limited to: 5'-methyl (R or S); 5'-vinyl, and
5'-methoxy. In certain embodiments, substituted sugars comprise
more than one non-bridging sugar substituent, for example,
2'-F-5'-methyl sugar moieties (see, e.g., PCT International
Application WO 2008/101157, for additional 5',2'-bis substituted
sugar moieties and nucleosides).
[0222] Nucleosides comprising 2'-substituted sugar moieties are
referred to as 2'-substituted nucleosides. In certain embodiments,
a 2'-substituted nucleoside comprises a 2'-substituent group
selected from halo, allyl, amino, azido, O--C.sub.1-C.sub.10
alkoxy; O--C.sub.1-C.sub.10 substituted alkoxy, SH, CN, OCN,
CF.sub.3, OCF.sub.3, O-alkyl, S-alkyl, N(R.sub.m)-alkyl; O-alkenyl,
S-alkenyl, or N(R.sub.m)-alkenyl; O-alkynyl, S-alkynyl,
N(R.sub.m)-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl,
O-alkaryl, O-aralkyl, O(CH.sub.2).sub.2SCH.sub.3,
O--(CH.sub.2).sub.2--O--N(R.sub.m)(R.sub.n) or
O--CH.sub.2--C(.dbd.O)--N(R.sub.m)(R.sub.n), where each R.sub.m and
R.sub.n is, independently, H, an amino protecting group or
substituted or unsubstituted C.sub.1-C.sub.10 alkyl. These
2'-substituent groups can be further substituted with one or more
substituent groups independently selected from hydroxyl, amino,
alkoxy, carboxy, benzyl, phenyl, nitro (NO.sub.2), thiol,
thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and
alkynyl.
[0223] In certain embodiments, a 2'-substituted nucleoside
comprises a 2'-substituent group selected from F, NH.sub.2,
N.sub.3, OCF.sub.3, O--CH.sub.3, O(CH.sub.2).sub.3NH.sub.2,
CH.sub.2--CH.dbd.CH.sub.2, O--CH.sub.2--CH.dbd.CH.sub.2,
OCH.sub.2CH.sub.2OCH.sub.3, O(CH.sub.2).sub.2SCH.sub.3,
O--(CH.sub.2).sub.2--O--N(R.sub.m)(R.sub.n),
O(CH.sub.2).sub.2O(CH.sub.2).sub.2N(CH.sub.3).sub.2, and
N-substituted acetamide
(O--CH.sub.2--C(.dbd.O)--N(R.sub.m)(R.sub.n) where each R.sub.m and
R.sub.n is, independently, H, an amino protecting group or
substituted or unsubstituted C.sub.1-C.sub.10 alkyl.
[0224] In certain embodiments, a 2'-substituted nucleoside
comprises a sugar moiety comprising a 2'-substituent group selected
from F, OCF.sub.3, O--CH.sub.3, OCH.sub.2CH.sub.2OCH.sub.3,
O(CH.sub.2).sub.2SCH.sub.3,
O--(CH.sub.2).sub.2--O--N(CH.sub.3).sub.2,
--O(CH.sub.2).sub.2O(CH.sub.2).sub.2N(CH.sub.3).sub.2, and
O--CH.sub.2--C(.dbd.O)--N(H)CH.sub.3.
[0225] In certain embodiments, a 2'-substituted nucleoside
comprises a sugar moiety comprising a 2'-substituent group selected
from F, O--CH.sub.3, and OCH.sub.2CH.sub.2OCH.sub.3.
[0226] Certain modified sugar moieties comprise a bridging sugar
substituent that forms a second ring resulting in a bicyclic sugar
moiety. In certain such embodiments, the bicyclic sugar moiety
comprises a bridge between the 4' and the 2' furanose ring atoms.
Examples of such 4' to 2' sugar substituents, include, but are not
limited to: --[C(R.sub.a)(R.sub.b)].sub.n--,
--[C(R.sub.a)(R.sub.b)].sub.n--O--, --C(R.sub.aR.sub.b)--N(R)--O--
or, --C(R.sub.aR.sub.b)--O--N(R)--; 4'-CH.sub.2-2',
4'-(CH.sub.2).sub.2-2', 4'-(CH.sub.2).sub.3-2', 4'-(CH.sub.2)--O-2'
(LNA); 4'-(CH.sub.2)--S-2; 4'-(CH.sub.2).sub.2--O-2' (ENA);
4'-CH(CH.sub.3)--O-2' (cEt) and 4'-CH(CH.sub.2OCH.sub.3)--O-2', and
analogs thereof (see, e.g., U.S. Pat. No. 7,399,845, issued on Jul.
15, 2008); 4'-C(CH.sub.3)(CH.sub.3)--O-2' and analogs thereof,
(see, e.g., WO2009/006478, published Jan. 8, 2009);
4'-CH.sub.2--N(OCH.sub.3)-2' and analogs thereof (see, e.g.,
WO2008/150729, published Dec. 11, 2008);
4'-CH.sub.2--O--N(CH.sub.3)-2' (see, e.g., US2004/0171570,
published Sep. 2, 2004); 4'-CH.sub.2--O--N(R)-2', and
4'-CH.sub.2--N(R)--O-2'-, wherein each R is, independently, H, a
protecting group, or C.sub.1-C.sub.12 alkyl;
4'-CH.sub.2--N(R)--O-2', wherein R is H, C.sub.1-C.sub.12 alkyl, or
a protecting group (see, U.S. Pat. No. 7,427,672, issued on Sep.
23, 2008); 4'-CH.sub.2--C(H)(CH.sub.3)-2' (see, e.g.,
Chattopadhyaya, et al., J. Org. Chem., 2009, 74, 118-134); and
4'-CH.sub.2--C(.dbd.CH.sub.2)-2' and analogs thereof (see,
published PCT International Application WO 2008/154401, published
on Dec. 8, 2008).
[0227] In certain embodiments, such 4' to 2' bridges independently
comprise from 1 to 4 linked groups independently selected from
--[C(R.sub.a)(R.sub.b)].sub.n--, --C(R.sub.a).dbd.C(R.sub.b)--,
--C(R.sub.a).dbd.N--, --C(.dbd.NR.sub.a)--, --C(.dbd.O)--,
--C(.dbd.S)--, --O--, --Si(R.sub.a).sub.2--, --S(.dbd.O).sub.x--,
and --N(R.sub.a)--;
[0228] wherein:
[0229] x is 0, 1, or 2;
[0230] n is 1, 2, 3, or 4;
[0231] each R.sub.a and R.sub.b is, independently, H, a protecting
group, hydroxyl, C.sub.1-C.sub.12 alkyl, substituted
C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, substituted
C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, substituted
C.sub.2-C.sub.12 alkynyl, C.sub.5-C.sub.20 aryl, substituted
C.sub.5-C.sub.20 aryl, heterocycle radical, substituted heterocycle
radical, heteroaryl, substituted heteroaryl, C.sub.5-C.sub.7
alicyclic radical, substituted C.sub.5-C.sub.7 alicyclic radical,
halogen, OJ.sub.1, NJ.sub.1J.sub.2, SJ.sub.1, N.sub.3, COOJ.sub.1,
acyl (C(.dbd.O)--H), substituted acyl, CN, sulfonyl
(S(.dbd.O).sub.2-J.sub.1), or sulfoxyl (S(.dbd.O)-J.sub.1); and
[0232] each J.sub.1 and J.sub.2 is, independently, H,
C.sub.1-C.sub.12 alkyl, substituted C.sub.1-C.sub.12 alkyl,
C.sub.2-C.sub.12 alkenyl, substituted C.sub.2-C.sub.12 alkenyl,
C.sub.2-C.sub.12 alkynyl, substituted C.sub.2-C.sub.12 alkynyl,
C.sub.5-C.sub.20 aryl, substituted C.sub.5-C.sub.20 aryl, acyl
(C(.dbd.O)--H), substituted acyl, a heterocycle radical, a
substituted heterocycle radical, C.sub.1-C.sub.12 aminoalkyl,
substituted C.sub.1-C.sub.12 aminoalkyl, or a protecting group.
[0233] Nucleosides comprising bicyclic sugar moieties are referred
to as bicyclic nucleosides or BNAs. Bicyclic nucleosides include,
but are not limited to, (A) .alpha.-L-Methyleneoxy
(4'-CH.sub.2--O-2') BNA, (B) .beta.-D-Methyleneoxy
(4'-CH.sub.2--O-2') BNA (also referred to as locked nucleic acid or
LNA), (C) Ethyleneoxy (4'-(CH.sub.2).sub.2--O-2') BNA, (D) Aminooxy
(4'-CH.sub.2--O--N(R)-2') BNA, (E) Oxyamino
(4'-CH.sub.2--N(R)--O-2') BNA, (F) Methyl(methyleneoxy)
(4'-CH(CH.sub.3)--O-2') BNA (also referred to as constrained ethyl
or cEt), (G) methylene-thio(4'-CH.sub.2--S-2') BNA, (H)
methylene-amino (4'-CH.sub.2--N(R)-2') BNA, (I) methyl carbocyclic
(4'-CH.sub.2--CH(CH.sub.3)-2') BNA, and (J) propylene carbocyclic
(4'-(CH.sub.2).sub.3-2') BNA as depicted below.
##STR00001## ##STR00002##
wherein Bx is a nucleobase moiety and R is, independently, H, a
protecting group, or C.sub.1-C.sub.12 alkyl.
[0234] Additional bicyclic sugar moieties are known in the art, for
example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et
al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc.
Natl. Acad. Sci. U.S.A., 2000, 97, 5633-5638; Kumar et al., Bioorg.
Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem.,
1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc.,
129(26) 8362-8379 (Jul. 4, 2007); Elayadi et al., Curr. Opinion
Invens. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001,
8, 1-7; Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243;
U.S. Pat. Nos. 7,053,207, 6,268,490, 6,770,748, 6,794,499,
7,034,133, 6,525,191, 6,670,461, and 7,399,845; WO 2004/106356, WO
1994/14226, WO 2005/021570, and WO 2007/134181; U.S. Patent
Publication Nos. US2004/0171570, US2007/0287831, and
US2008/0039618; U.S. patent Ser. Nos. 12/129,154, 60/989,574,
61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and
61/099,844; and PCT International Applications Nos.
PCT/US2008/064591, PCT/US2008/066154, and PCT/US2008/068922.
[0235] In certain embodiments, bicyclic sugar moieties and
nucleosides incorporating such bicyclic sugar moieties are further
defined by isomeric configuration. For example, a nucleoside
comprising a 4'-2' methylene-oxy bridge, may be in the .alpha.-L
configuration or in the .beta.-D configuration. Previously,
.alpha.-L-methyleneoxy (4'-CH.sub.2--O-2') bicyclic nucleosides
have been incorporated into antisense oligonucleotides that showed
antisense activity (Frieden et al., Nucleic Acids Research, 2003,
21, 6365-6372).
[0236] In certain embodiments, substituted sugar moieties comprise
one or more non-bridging sugar substituent and one or more bridging
sugar substituent (e.g., 5'-substituted and 4'-2' bridged sugars).
(see, PCT International Application WO 2007/134181, published on
Nov. 22, 2007, wherein LNA is substituted with, for example, a
5'-methyl or a 5'-vinyl group).
[0237] In certain embodiments, modified sugar moieties are sugar
surrogates. In certain such embodiments, the oxygen atom of the
naturally occurring sugar is substituted, e.g., with a sulfur,
carbon or nitrogen atom. In certain such embodiments, such modified
sugar moiety also comprises bridging and/or non-bridging
substituents as described above. For example, certain sugar
surrogates comprise a 4'-sulfur atom and a substitution at the
2'-position (see, e.g., published U.S. Patent Application
US2005/0130923, published on Jun. 16, 2005) and/or the 5' position.
By way of additional example, carbocyclic bicyclic nucleosides
having a 4'-2' bridge have been described (see, e.g., Freier et
al., Nucleic Acids Research, 1997, 25(22), 4429-4443 and Albaek et
al., J. Org. Chem., 2006, 71, 7731-7740).
[0238] In certain embodiments, sugar surrogates comprise rings
having other than 5-atoms. For example, in certain embodiments, a
sugar surrogate comprises a six-membered tetrahydropyran. Such
tetrahydropyrans may be further modified or substituted.
Nucleosides comprising such modified tetrahydropyrans include, but
are not limited to, hexitol nucleic acid (HNA), anitol nucleic acid
(ANA), manitol nucleic acid (MNA) (see Leumann, C J. Bioorg. &
Med. Chem. (2002) 10:841-854), fluoro HNA (F-HNA), and those
compounds having Formula VII:
##STR00003##
wherein independently for each of said at least one tetrahydropyran
nucleoside analog of Formula VII:
[0239] Bx is a nucleobase moiety;
[0240] T.sub.3 and T.sub.4 are each, independently, an
internucleoside linking group linking the tetrahydropyran
nucleoside analog to the antisense compound or one of T.sub.3 and
T.sub.4 is an internucleoside linking group linking the
tetrahydropyran nucleoside analog to the antisense compound and the
other of T.sub.3 and T.sub.4 is H, a hydroxyl protecting group, a
linked conjugate group, or a 5' or 3'-terminal group;
q.sub.1, q.sub.2, q.sub.3, q.sub.4, q.sub.5, q.sub.6 and q.sub.7
are each, independently, H, C.sub.1-C.sub.6 alkyl, substituted
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, substituted
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, or substituted
C.sub.2-C.sub.6 alkynyl; and each of R.sub.1 and R.sub.2 is
independently selected from among: hydrogen, halogen, substituted
or unsubstituted alkoxy, NJ.sub.1J.sub.2, SJ.sub.1, N.sub.3,
OC(.dbd.X)J.sub.1, OC(.dbd.X)NJ.sub.1J.sub.2,
NJ.sub.3C(.dbd.X)NJ.sub.1J.sub.2, and CN, wherein X is O, S or
NJ.sub.1, and each J.sub.1, J.sub.2, and J.sub.3 is, independently,
H or C.sub.1-C.sub.6 alkyl.
[0241] In certain embodiments, the modified THP nucleosides of
Formula VII are provided wherein q.sub.1, q.sub.2, q.sub.3,
q.sub.4, q.sub.5, q.sub.6 and q.sub.7 are each H. In certain
embodiments, at least one of q.sub.1, q.sub.2, q.sub.3, q.sub.4,
q.sub.5, q.sub.6 and q.sub.7 is other than H. In certain
embodiments, at least one of q.sub.1, q.sub.2, q.sub.3, q.sub.4,
q.sub.5, q.sub.6 and q.sub.7 is methyl. In certain embodiments, THP
nucleosides of Formula VII are provided wherein one of R.sub.1 and
R.sub.2 is F. In certain embodiments, R.sub.1 is fluoro and R.sub.2
is H, R.sub.1 is methoxy and R.sub.2 is H, and R.sub.1 is
methoxyethoxy and R.sub.2 is H.
[0242] Many other bicyclic and tricyclic sugar and sugar surrogate
ring systems are known in the art that can be used to modify
nucleosides (see, e.g., review article: Leumann, J. C, Bioorganic
& Medicinal Chemistry, 2002, 10, 841-854).
[0243] In certain embodiments, sugar surrogates comprise rings
having more than 5 atoms and more than one heteroatom. For example
nucleosides comprising morpholino sugar moieties and their use in
oligomeric compounds has been reported (see for example: Braasch et
al., Biochemistry, 2002, 41, 4503-4510; and U.S. Pat. No.
5,698,685; 5,166,315; 5,185,444; and 5,034,506). As used here, the
term "morpholino" means a sugar surrogate having the following
structure:
##STR00004##
In certain embodiments, morpholinos may be modified, for example by
adding or altering various substituent groups from the above
morpholino structure. Such sugar surrogates are referred to herein
as "modified morpholinos."
[0244] Combinations of modifications are also provided without
limitation, such as 2'-F-5'-methyl substituted nucleosides (see PCT
International Application WO 2008/101157 Published on Aug. 21, 2008
for other disclosed 5',2'-bis substituted nucleosides) and
replacement of the ribosyl ring oxygen atom with S and further
substitution at the 2'-position (see published U.S. Patent
Application US2005-0130923, published on Jun. 16, 2005) or
alternatively 5'-substitution of a bicyclic nucleic acid (see PCT
International Application WO 2007/134181, published on Nov. 22,
2007 wherein a 4'-CH.sub.2--O-2' bicyclic nucleoside is further
substituted at the 5' position with a 5'-methyl or a 5'-vinyl
group). The synthesis and preparation of carbocyclic bicyclic
nucleosides along with their oligomerization and biochemical
studies have also been described (see, e.g., Srivastava et al., J.
Am. Chem. Soc. 2007, 129(26), 8362-8379).
[0245] Certain Nucleobases
[0246] In certain embodiments, nucleosides of the present invention
comprise one or more unmodified nucleobases. In certain
embodiments, nucleosides of the present invention comprise one or
more modified nucleobases.
[0247] In certain embodiments, modified nucleobases are selected
from: universal bases, hydrophobic bases, promiscuous bases,
size-expanded bases, and fluorinated bases as defined herein.
5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6
substituted purines, including 2-aminopropyladenine,
5-propynyluracil; 5-propynylcytosine; 5-hydroxymethyl cytosine,
xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl
derivatives of adenine and guanine, 2-propyl and other alkyl
derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and
2-thiocytosine, 5-halouracil and cytosine, 5-propynyl
(--C.ident.C--CH.sub.3) uracil and cytosine and other alkynyl
derivatives of pyrimidine bases, 6-azo uracil, cytosine and
thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino,
8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines
and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and
other 5-substituted uracils and cytosines, 7-methylguanine and
7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and
8-azaadenine, 7-deazaguanine and 7-deazaadenine, 3-deazaguanine and
3-deazaadenine, universal bases, hydrophobic bases, promiscuous
bases, size-expanded bases, and fluorinated bases as defined
herein. Further modified nucleobases include tricyclic pyrimidines
such as phenoxazine cytidine([5,4-b][1,4]benzoxazin-2(3H)-one),
phenothiazine cytidine
(1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a
substituted phenoxazine cytidine (e.g.
9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one),
carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole
cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one).
Modified nucleobases may also include those in which the purine or
pyrimidine base is replaced with other heterocycles, for example
7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone.
Further nucleobases include those disclosed in U.S. Pat. No.
3,687,808, those disclosed in The Concise Encyclopedia Of Polymer
Science And Engineering, Kroschwitz, J. I., Ed., John Wiley &
Sons, 1990, 858-859; those disclosed by Englisch et al., Angewandte
Chemie, International Edition, 1991, 30, 613; and those disclosed
by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications,
Crooke, S. T. and Lebleu, B., Eds., CRC Press, 1993, 273-288.
[0248] Representative United States Patents that Teach the
Preparation of Certain of the Above Noted Modified nucleobases as
well as other modified nucleobases include without limitation, U.S.
Pat. Nos. 3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273;
5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177;
5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617;
5,645,985; 5,681,941; 5,750,692; 5,763,588; 5,830,653 and
6,005,096, certain of which are commonly owned with the instant
application, and each of which is herein incorporated by reference
in its entirety.
[0249] Certain Internucleoside Linkages
[0250] In certain embodiments, the present invention provides
oligomeric compounds comprising linked nucleosides. In such
embodiments, nucleosides may be linked together using any
internucleoside linkage. The two main classes of internucleoside
linking groups are defined by the presence or absence of a
phosphorus atom. Representative phosphorus containing
internucleoside linkages include, but are not limited to,
phosphodiesters (P.dbd.O), phosphotriesters, methylphosphonates,
phosphoramidate, and phosphorothioates (P.dbd.S). Representative
non-phosphorus containing internucleoside linking groups include,
but are not limited to, methylenemethylimino
(--CH.sub.2--N(CH.sub.3)--O--CH.sub.2--), thiodiester
(--O--C(O)--S--), thionocarbamate (--O--C(O)(NH)--S--); siloxane
(--O--Si(H).sub.2--O--); and N,N'-dimethylhydrazine
(--CH.sub.2--N(CH.sub.3)--N(CH.sub.3)--). Modified linkages,
compared to natural phosphodiester linkages, can be used to alter,
typically increase, nuclease resistance of the oligomeric compound.
In certain embodiments, internucleoside linkages having a chiral
atom can be prepared as a racemic mixture, or as separate
enantiomers. Representative chiral linkages include, but are not
limited to, alkylphosphonates and phosphorothioates. Methods of
preparation of phosphorous-containing and
non-phosphorous-containing internucleoside linkages are well known
to those skilled in the art.
[0251] The oligonucleotides described herein contain one or more
asymmetric centers and thus give rise to enantiomers,
diastereomers, and other stereoisomeric configurations that may be
defined, in terms of absolute stereochemistry, as (R) or (S), a or
.beta. such as for sugar anomers, or as (D) or (L) such as for
amino acids etc. Included in the antisense compounds provided
herein are all such possible isomers, as well as their racemic and
optically pure forms.
[0252] Neutral internucleoside linkages include without limitation,
phosphotriesters, methylphosphonates, MMI
(3'-CH.sub.2--N(CH.sub.3)--O-5'), amide-3
(3'-CH.sub.2--C(.dbd.O)--N(H)-5'), amide-4
(3'-CH.sub.2--N(H)--C(.dbd.O)-5'), formacetal
(3'-O--CH.sub.2--O-5'), and thioformacetal (3'-S--CH.sub.2--O-5').
Further neutral internucleoside linkages include nonionic linkages
comprising siloxane (dialkylsiloxane), carboxylate ester,
carboxamide, sulfide, sulfonate ester and amides (See for example:
Carbohydrate Modifications in Antisense Research; Y. S. Sanghvi and
P. D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4,
40-65). Further neutral internucleoside linkages include nonionic
linkages comprising mixed N, O, S and CH.sub.2 component parts.
[0253] Certain Motifs
[0254] In certain embodiments, the present invention provides
oligomeric compounds comprising oligonucleotides. In certain
embodiments, such oligonucleotides comprise one or more chemical
modification. In certain embodiments, chemically modified
oligonucleotides comprise one or more modified nucleosides. In
certain embodiments, chemically modified oligonucleotides comprise
one or more modified nucleosides comprising modified sugars. In
certain embodiments, chemically modified oligonucleotides comprise
one or more modified nucleosides comprising one or more modified
nucleobases. In certain embodiments, chemically modified
oligonucleotides comprise one or more modified internucleoside
linkages. In certain embodiments, the chemically modifications
(sugar modifications, nucleobase modifications, and/or linkage
modifications) define a pattern or motif. In certain embodiments,
the patterns of chemical modifications of sugar moieties,
internucleoside linkages, and nucleobases are each independent of
one another. Thus, an oligonucleotide may be described by its sugar
modification motif, internucleoside linkage motif and/or nucleobase
modification motif (as used herein, nucleobase modification motif
describes the chemical modifications to the nucleobases independent
of the sequence of nucleobases).
[0255] Certain Sugar Motifs
[0256] In certain embodiments, oligonucleotides comprise one or
more type of modified sugar moieties and/or naturally occurring
sugar moieties arranged along an oligonucleotide or region thereof
in a defined pattern or sugar modification motif Such motifs may
include any of the sugar modifications discussed herein and/or
other known sugar modifications.
[0257] In certain embodiments, the oligonucleotides comprise or
consist of a region having a gapmer sugar modification motif, which
comprises two external regions or "wings" and an internal region or
"gap." The three regions of a gapmer motif (the 5'-wing, the gap,
and the 3'-wing) form a contiguous sequence of nucleosides wherein
at least some of the sugar moieties of the nucleosides of each of
the wings differ from at least some of the sugar moieties of the
nucleosides of the gap. Specifically, at least the sugar moieties
of the nucleosides of each wing that are closest to the gap (the
3'-most nucleoside of the 5'-wing and the 5'-most nucleoside of the
3'-wing) differ from the sugar moiety of the neighboring gap
nucleosides, thus defining the boundary between the wings and the
gap. In certain embodiments, the sugar moieties within the gap are
the same as one another. In certain embodiments, the gap includes
one or more nucleoside having a sugar moiety that differs from the
sugar moiety of one or more other nucleosides of the gap. In
certain embodiments, the sugar modification motifs of the two wings
are the same as one another (symmetric gapmer). In certain
embodiments, the sugar modification motifs of the 5'-wing differs
from the sugar modification motif of the 3'-wing (asymmetric
gapmer). In certain embodiments, oligonucleotides comprise 2'-MOE
modified nucleosides in the wings and 2'-F modified nucleosides in
the gap.
[0258] In certain embodiments, oligonucleotides are fully modified.
In certain such embodiments, oligonucleotides are uniformly
modified. In certain embodiments, oligonucleotides are uniform
2'-MOE. In certain embodiments, oligonucleotides are uniform 2'-F.
In certain embodiments, oligonucleotides are uniform morpholino. In
certain embodiments, oligonucleotides are uniform BNA. In certain
embodiments, oligonucleotides are uniform LNA. In certain
embodiments, oligonucleotides are uniform cEt.
[0259] In certain embodiments, oligonucleotides comprise a
uniformly modified region and additional nucleosides that are
unmodified or differently modified. In certain embodiments, the
uniformly modified region is at least 5, 10, 15, or 20 nucleosides
in length. In certain embodiments, the uniform region is a 2'-MOE
region. In certain embodiments, the uniform region is a 2'-F
region. In certain embodiments, the uniform region is a morpholino
region. In certain embodiments, the uniform region is a BNA region.
In certain embodiments, the uniform region is a LNA region. In
certain embodiments, the uniform region is a cEt region.
[0260] In certain embodiments, the oligonucleotide does not
comprise more than 4 contiguous unmodified 2'-deoxynucleosides. In
certain circumstances, antisesense oligonucleotides comprising more
than 4 contiguous 2'-deoxynucleosides activate RNase H, resulting
in cleavage of the target RNA. In certain embodiments, such
cleavage is avoided by not having more than 4 contiguous
2'-deoxynucleosides, for example, where alteration of splicing and
not cleavage of a target RNA is desired.
[0261] Certain Internucleoside Linkage Motifs
[0262] In certain embodiments, oligonucleotides comprise modified
internucleoside linkages arranged along the oligonucleotide or
region thereof in a defined pattern or modified internucleoside
linkage motif. In certain embodiments, internucleoside linkages are
arranged in a gapped motif, as described above for sugar
modification motif. In such embodiments, the internucleoside
linkages in each of two wing regions are different from the
internucleoside linkages in the gap region. In certain embodiments
the internucleoside linkages in the wings are phosphodiester and
the internucleoside linkages in the gap are phosphorothioate. The
sugar modification motif is independently selected, so such
oligonucleotides having a gapped internucleoside linkage motif may
or may not have a gapped sugar modification motif and if it does
have a gapped sugar motif, the wing and gap lengths may or may not
be the same.
[0263] In certain embodiments, oligonucleotides comprise a region
having an alternating internucleoside linkage motif. In certain
embodiments, oligonucleotides of the present invention comprise a
region of uniformly modified internucleoside linkages. In certain
such embodiments, the oligonucleotide comprises a region that is
uniformly linked by phosphorothioate internucleoside linkages. In
certain embodiments, the oligonucleotide is uniformly linked by
phosphorothioate. In certain embodiments, each internucleoside
linkage of the oligonucleotide is selected from phosphodiester and
phosphorothioate. In certain embodiments, each internucleoside
linkage of the oligonucleotide is selected from phosphodiester and
phosphorothioate and at least one internucleoside linkage is
phosphorothioate.
[0264] In certain embodiments, the oligonucleotide comprises at
least 6 phosphorothioate internucleoside linkages. In certain
embodiments, the oligonucleotide comprises at least 8
phosphorothioate internucleoside linkages. In certain embodiments,
the oligonucleotide comprises at least 10 phosphorothioate
internucleoside linkages. In certain embodiments, the
oligonucleotide comprises at least one block of at least 6
consecutive phosphorothioate internucleoside linkages. In certain
embodiments, the oligonucleotide comprises at least one block of at
least 8 consecutive phosphorothioate internucleoside linkages. In
certain embodiments, the oligonucleotide comprises at least one
block of at least 10 consecutive phosphorothioate internucleoside
linkages. In certain embodiments, the oligonucleotide comprises at
least block of at least one 12 consecutive phosphorothioate
internucleoside linkages. In certain such embodiments, at least one
such block is located at the 3' end of the oligonucleotide. In
certain such embodiments, at least one such block is located within
3 nucleosides of the 3' end of the oligonucleotide.
[0265] Certain Nucleobase Modification Motifs
[0266] In certain embodiments, oligonucleotides comprise chemical
modifications to nucleobases arranged along the oligonucleotide or
region thereof in a defined pattern or nucleobases modification
motif. In certain such embodiments, nucleobase modifications are
arranged in a gapped motif. In certain embodiments, nucleobase
modifications are arranged in an alternating motif. In certain
embodiments, each nucleobase is modified. In certain embodiments,
none of the nucleobases is chemically modified.
[0267] In certain embodiments, oligonucleotides comprise a block of
modified nucleobases. In certain such embodiments, the block is at
the 3'-end of the oligonucleotide. In certain embodiments the block
is within 3 nucleotides of the 3'-end of the oligonucleotide. In
certain such embodiments, the block is at the 5'-end of the
oligonucleotide. In certain embodiments the block is within 3
nucleotides of the 5'-end of the oligonucleotide.
[0268] In certain embodiments, nucleobase modifications are a
function of the natural base at a particular position of an
oligonucleotide. For example, in certain embodiments each purine or
each pyrimidine in an oligonucleotide is modified. In certain
embodiments, each adenine is modified. In certain embodiments, each
guanine is modified. In certain embodiments, each thymine is
modified. In certain embodiments, each cytosine is modified. In
certain embodiments, each uracil is modified.
[0269] In certain embodiments, some, all, or none of the cytosine
moieties in an oligonucleotide are 5-methyl cytosine moieties.
Herein, 5-methyl cytosine is not a "modified nucleobase."
Accordingly, unless otherwise indicated, unmodified nucleobases
include both cytosine residues having a 5-methyl and those lacking
a 5 methyl. In certain embodiments, the methylation state of all or
some cytosine nucleobases is specified.
[0270] Certain Overall Lengths
[0271] In certain embodiments, the present invention provides
oligomeric compounds including oligonucleotides of any of a variety
of ranges of lengths. In certain embodiments, the invention
provides oligomeric compounds or oligonucleotides consisting of X
to Y linked nucleosides, where X represents the fewest number of
nucleosides in the range and Y represents the largest number of
nucleosides in the range. In certain such embodiments, X and Y are
each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and
50; provided that X.ltoreq.Y. For example, in certain embodiments,
the invention provides oligomeric compounds which comprise
oligonucleotides consisting of 8 to 9, 8 to 10, 8 to 11, 8 to 12, 8
to 13, 8 to 14, 8 to 15, 8 to 16, 8 to 17, 8 to 18, 8 to 19, 8 to
20, 8 to 21, 8 to 22, 8 to 23, 8 to 24, 8 to 25, 8 to 26, 8 to 27,
8 to 28, 8 to 29, 8 to 30, 9 to 10, 9 to 11, 9 to 12, 9 to 13, 9 to
14, 9 to 15, 9 to 16, 9 to 17, 9 to 18, 9 to 19, 9 to 20, 9 to 21,
9 to 22, 9 to 23, 9 to 24, 9 to 25, 9 to 26, 9 to 27, 9 to 28, 9 to
29, 9 to 30, 10 to 11, 10 to 12, 10 to 13, 10 to 14, 10 to 15, 10
to 16, 10 to 17, 10 to 18, 10 to 19, 10 to 20, 10 to 21, 10 to 22,
10 to 23, 10 to 24, 10 to 25, 10 to 26, 10 to 27, 10 to 28, 10 to
29, 10 to 30, 11 to 12, 11 to 13, 11 to 14, 11 to 15, 11 to 16, 11
to 17, 11 to 18, 11 to 19, 11 to 20, 11 to 21, 11 to 22, 11 to 23,
11 to 24, 11 to 25, 11 to 26, 11 to 27, 11 to 28, 11 to 29, 11 to
30, 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to 17, 12 to 18, 12
to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to 24, 12 to 25,
12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to 14, 13 to
15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to 21, 13
to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to 28,
13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to
19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14
to 26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17,
15 to 18, 15 to 19, 15 to 20, 15 to 21, 15 to 22, 15 to 23, 15 to
24, 15 to 25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16
to 17, 16 to 18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23,
16 to 24, 16 to 25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to
30, 17 to 18, 17 to 19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17
to 24, 17 to 25, 17 to 26, 17 to 27, 17 to 28, 17 to 29, 17 to 30,
18 to 19, 18 to 20, 18 to 21, 18 to 22, 18 to 23, 18 to 24, 18 to
25, 18 to 26, 18 to 27, 18 to 28, 18 to 29, 18 to 30, 19 to 20, 19
to 21, 19 to 22, 19 to 23, 19 to 24, 19 to 25, 19 to 26, 19 to 29,
19 to 28, 19 to 29, 19 to 30, 20 to 21, 20 to 22, 20 to 23, 20 to
24, 20 to 25, 20 to 26, 20 to 27, 20 to 28, 20 to 29, 20 to 30, 21
to 22, 21 to 23, 21 to 24, 21 to 25, 21 to 26, 21 to 27, 21 to 28,
21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to 25, 22 to 26, 22 to
27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to 25, 23 to 26, 23
to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to 26, 24 to 27,
24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to 28, 25 to
29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to 28, 27
to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linked
nucleosides. In embodiments where the number of nucleosides of an
oligomeric compound or oligonucleotide is limited, whether to a
range or to a specific number, the oligomeric compound or
oligonucleotide may, nonetheless further comprise additional other
substituents. For example, an oligonucleotide comprising 8-30
nucleosides excludes oligonucleotides having 31 nucleosides, but,
unless otherwise indicated, such an oligonucleotide may further
comprise, for example one or more conjugates, terminal groups, or
other substituents. In certain embodiments, a gapmer
oligonucleotide has any of the above lengths.
[0272] One of skill in the art will appreciate that certain lengths
may not be possible for certain motifs. For example: a gapmer
having a 5'-wing region consisting of four nucleotides, a gap
consisting of at least six nucleotides, and a 3'-wing region
consisting of three nucleotides cannot have an overall length less
than 13 nucleotides. Thus, one would understand that the lower
length limit is 13 and that the limit of 10 in "10-20" has no
effect in that embodiment.
[0273] Further, where an oligonucleotide is described by an overall
length range and by regions having specified lengths, and where the
sum of specified lengths of the regions is less than the upper
limit of the overall length range, the oligonucleotide may have
additional nucleosides, beyond those of the specified regions,
provided that the total number of nucleosides does not exceed the
upper limit of the overall length range. For example, an
oligonucleotide consisting of 20-25 linked nucleosides comprising a
5'-wing consisting of 5 linked nucleosides; a 3'-wing consisting of
5 linked nucleosides and a central gap consisting of 10 linked
nucleosides (5+5+10=20) may have up to 5 nucleosides that are not
part of the 5'-wing, the 3'-wing, or the gap (before reaching the
overall length limitation of 25). Such additional nucleosides may
be 5' of the 5'-wing and/or 3' of the 3' wing.
[0274] Certain Oligonucleotides
[0275] In certain embodiments, oligonucleotides of the present
invention are characterized by their sugar motif, internucleoside
linkage motif, nucleobase modification motif and overall length. In
certain embodiments, such parameters are each independent of one
another. Thus, each internucleoside linkage of an oligonucleotide
having a gapmer sugar motif may be modified or unmodified and may
or may not follow the gapmer modification pattern of the sugar
modifications. Thus, the internucleoside linkages within the wing
regions of a sugar-gapmer may be the same or different from one
another and may be the same or different from the internucleoside
linkages of the gap region. Likewise, such sugar-gapmer
oligonucleotides may comprise one or more modified nucleobase
independent of the gapmer pattern of the sugar modifications.
Herein if a description of an oligonucleotide or oligomeric
compound is silent with respect to one or more parameter, such
parameter is not limited. Thus, an oligomeric compound described
only as having a gapmer sugar motif without further description may
have any length, internucleoside linkage motif, and nucleobase
modification motif. Unless otherwise indicated, all chemical
modifications are independent of nucleobase sequence.
[0276] Certain Conjugate Groups
[0277] In certain embodiments, oligomeric compounds are modified by
attachment of one or more conjugate groups. In general, conjugate
groups modify one or more properties of the attached oligomeric
compound including but not limited to pharmacodynamics,
pharmacokinetics, stability, binding, absorption, cellular
distribution, cellular uptake, charge and clearance. Conjugate
groups are routinely used in the chemical arts and are linked
directly or via an optional conjugate linking moiety or conjugate
linking group to a parent compound such as an oligomeric compound,
such as an oligonucleotide. Conjugate groups includes without
limitation, intercalators, reporter molecules, polyamines,
polyamides, polyethylene glycols, thioethers, polyethers,
cholesterols, thiocholesterols, cholic acid moieties, folate,
lipids, phospholipids, biotin, phenazine, phenanthridine,
anthraquinone, adamantane, acridine, fluoresceins, rhodamines,
coumarins and dyes. Certain conjugate groups have been described
previously, for example: cholesterol moiety (Letsinger et al.,
Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid
(Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a
thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y.
Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med.
Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et
al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain,
e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al.,
EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990,
259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a
phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium
1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.,
Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids
Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol
chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14,
969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron
Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al.,
Biochim Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine
or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J.
Pharmacol. Exp. Ther., 1996, 277, 923-937).
[0278] In certain embodiments, a conjugate group comprises an
active drug substance, for example, aspirin, warfarin,
phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen,
(S)-(+)-pranoprofen, carprofen, dansylsarcosine,
2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a
benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a
barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an
antibacterial or an antibiotic.
[0279] In certain embodiments, conjugate groups are directly
attached to oligonucleotides in oligomeric compounds. In certain
embodiments, conjugate groups are attached to oligonucleotides by a
conjugate linking group. In certain such embodiments, conjugate
linking groups, including, but not limited to, bifunctional linking
moieties such as those known in the art are amenable to the
compounds provided herein. Conjugate linking groups are useful for
attachment of conjugate groups, such as chemical stabilizing
groups, functional groups, reporter groups and other groups to
selective sites in a parent compound such as for example an
oligomeric compound. In general a bifunctional linking moiety
comprises a hydrocarbyl moiety having two functional groups. One of
the functional groups is selected to bind to a parent molecule or
compound of interest and the other is selected to bind essentially
any selected group such as chemical functional group or a conjugate
group. In some embodiments, the conjugate linker comprises a chain
structure or an oligomer of repeating units such as ethylene glycol
or amino acid units. Examples of functional groups that are
routinely used in a bifunctional linking moiety include, but are
not limited to, electrophiles for reacting with nucleophilic groups
and nucleophiles for reacting with electrophilic groups. In some
embodiments, bifunctional linking moieties include amino, hydroxyl,
carboxylic acid, thiol, unsaturations (e.g., double or triple
bonds), and the like.
[0280] Some nonlimiting examples of conjugate linking moieties
include pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO),
succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
and 6-aminohexanoic acid (AHEX or AHA). Other linking groups
include, but are not limited to, substituted C.sub.1-C.sub.10
alkyl, substituted or unsubstituted C.sub.2-C.sub.10 alkenyl or
substituted or unsubstituted C.sub.2-C.sub.10 alkynyl, wherein a
nonlimiting list of preferred substituent groups includes hydroxyl,
amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy,
halogen, alkyl, aryl, alkenyl and alkynyl.
[0281] Conjugate groups may be attached to either or both ends of
an oligonucleotide (terminal conjugate groups) and/or at any
internal position.
[0282] In certain embodiments, conjugate groups are at the 3'-end
of an oligonucleotide of an oligomeric compound. In certain
embodiments, conjugate groups are near the 3'-end. In certain
embodiments, conjugates are attached at the 3'end of an oligomeric
compound, but before one or more terminal group nucleosides. In
certain embodiments, conjugate groups are placed within a terminal
group.
In certain embodiments, the present invention provides oligomeric
compounds. In certain embodiments, oligomeric compounds comprise an
oligonucleotide. In certain embodiments, an oligomeric compound
comprises an oligonucleotide and one or more conjugate and/or
terminal groups. Such conjugate and/or terminal groups may be added
to oligonucleotides having any of the chemical motifs discussed
above. Thus, for example, an oligomeric compound comprising an
oligonucleotide having region of alternating nucleosides may
comprise a terminal group.
Antisense Compounds
[0283] In certain embodiments, oligomeric compounds of the present
invention are antisense compounds. Such antisense compounds are
capable of hybridizing to a target nucleic acid, resulting in at
least one antisense activity. In certain embodiments, antisense
compounds specifically hybridize to one or more target nucleic
acid. In certain embodiments, a specifically hybridizing antisense
compound has a nucleobase sequence comprising a region having
sufficient complementarity to a target nucleic acid to allow
hybridization and result in antisense activity and insufficient
complementarity to any non-target so as to avoid non-specific
hybridization to any non-target nucleic acid sequences under
conditions in which specific hybridization is desired (e.g., under
physiological conditions for in vivo or therapeutic uses, and under
conditions in which assays are performed in the case of in vitro
assays).
[0284] In certain embodiments, the present invention provides
antisense compounds comprising oligonucleotides that are fully
complementary to the target nucleic acid over the entire length of
the oligonucleotide. In certain embodiments, oligonucleotides are
99% complementary to the target nucleic acid. In certain
embodiments, oligonucleotides are 95% complementary to the target
nucleic acid. In certain embodiments, such oligonucleotides are 90%
complementary to the target nucleic acid.
[0285] In certain embodiments, such oligonucleotides are 85%
complementary to the target nucleic acid. In certain embodiments,
such oligonucleotides are 80% complementary to the target nucleic
acid. In certain embodiments, an antisense compound comprises a
region that is fully complementary to a target nucleic acid and is
at least 80% complementary to the target nucleic acid over the
entire length of the oligonucleotide. In certain such embodiments,
the region of full complementarity is from 6 to 14 nucleobases in
length.
[0286] In certain embodiments antisense compounds and antisense
oligonucleotides comprise single-strand compounds. In certain
embodiments antisense compounds and antisense oligonucleotides
comprise double-strand compounds.
[0287] Certain Pathways and Mechanisms Associated with Cancer
[0288] Many cancer cells preferentially use the glycolytic pathway
with lactate generation to produce energy, even under normal oxygen
conditions. This metabolic feature of cancer is termed the Warburg
effect. In certain embodiments, PK-M2 mediates the Warburg effect.
In certain embodiments, expression of PK-M2 is crucial for tumor
cell growth and proliferation.
[0289] In certain embodiments, reducing expression of PK-M2
inhibits cancer growth. In certain embodiments, reducing expression
of PK-M2 induces apoptosis in a cell. In certain embodiments, the
cell is a cancer cell. In certain embodiments, the cell is a tumor
cell. In certain embodiments, the cell is a glioblastoma cell.
[0290] In certain embodiments, increasing inclusion of exon 9 of a
PK-M transcript inhibits cancer growth. In certain embodiments,
increasing exclusion of exon 10 of a PK-M transcript inhibits
cancer growth. In certain embodiments, increasing inclusion of exon
9 of a PK-M transcript induces apoptosis in a cell. In certain
embodiments, increasing exclusion of exon 10 of a PK-M transcript
induces apoptosis in a cell. In certain embodiments, the cell is a
cancer cell. In certain embodiments, the cell is a tumor cell. In
certain embodiments, the cell is a glioblastoma cell. In certain
embodiments, the downregulation of PK-M2 leads to apoptosis in
certain cancer cells. In certain embodiments, the downregulation of
PK-M2 leads to apoptosis in certain glioblastoma cell lines.
[0291] In certain embodiments, PK-M2 also functions as a
co-activator of HIF-1 and/or .beta.-catenin. In certain
embodiments, reducing expression of PK-M2, as opposed to inhibiting
its kinase function, interferes with anti-apoptotic and
pro-proliferative functions associated with cancer or tumor cells.
In certain embodiments, one or more antisense compounds may be used
to target a PK-M2.
[0292] In certain embodiments, the administration of a modified
oligonucleotide causes a switch in the alternative splicing of the
PK-M transcript. In certain embodiments, the administration of a
modified oligonucleotide causes increased inclusion of exon 9 mRNA
of the PK-M transcript. In certain embodiments, the administration
of a modified oligonucleotide causes an increase in the exclusion
of exon 10 mRNA of the PK-M transcript. In certain embodiments, the
administration of a modified oligonucleotide reduces expression of
PK-M2 in a cell. In certain embodiments, the administration of a
modified oligonucleotide reduces expression of PK-M2 in a cell and
inhibits cancer growth. In certain embodiments, the administration
of a modified oligonucleotide reduces expression of PK-M2 and
induces apoptosis in a cell. In certain embodiments, the cell is a
cancer cell. In certain embodiments, the cell is a tumor cell. In
certain embodiments, the cell is a glioblastoma cell.
[0293] Certain Target Nucleic Acids and Mechanisms
[0294] In certain embodiments, antisense compounds comprise or
consist of an oligonucleotide comprising a region that is
complementary to a target nucleic acid. In certain embodiments, the
target nucleic acid is an endogenous RNA molecule. In certain
embodiments, the target nucleic acid is a pre-mRNA. In certain
embodiments, the target nucleic acid is a PK-M transcript. In
certain embodiments, the target RNA is a PK-M pre-mRNA.
[0295] In certain embodiments, an antisense compound is
complementary to a region of PK-M pre-mRNA. In certain embodiments,
an antisense compound is complementary within a region of PK-M
pre-mRNA comprising an exon encoding PK-M2. In certain embodiments,
an antisense compound is complementary to a region of PK-M pre-mRNA
comprising an intron-exon splice junction. In certain embodiments,
an antisense compound is complementary to a region of PK-M pre-mRNA
comprising the intron-exon splice junction adjacent to exon 10. In
certain embodiments, an antisense compound is complementary within
a region of PK-M pre-mRNA consisting of exon 10. In certain
embodiments, an antisense compound is complementary within a region
of PK-M pre-mRNA comprising an exonic splicing silencer within an
exon 10. In certain embodiments, an antisense compound is
complementary within a region of PK-M pre-mRNA comprising an exonic
splicing enhancer within exon 10. In certain embodiments, an
antisense compound is complementary within a region of PK-M
pre-mRNA comprising an exonic splicing silencer within an exon 9.
In certain embodiments, an antisense compound is complementary
within a region of PK-M pre-mRNA comprising an exonic splicing
enhancer within exon 9.
[0296] In certain embodiments, an antisense compound comprises a
modified oligonucleotide consisting of 8 to 30 linked nucleosides
and having a nucleobase sequence comprising a complementary region
comprising at least 8 contiguous nucleobases complementary to a
target region of equal length of a PK-M transcript. In certain
embodiments, the target region is within nucleobase 29153 and
nucleobase 29281 of SEQ ID NO.: 1. In certain embodiments, the
target region is within nucleobase 29158 and nucleobase 29262 of
SEQ ID NO.: 1. In certain embodiments, the target region is within
nucleobase 29164 and nucleobase 29188 of SEQ ID NO.: 1. In certain
embodiments, the target region is within nucleobase 29261 and
nucleobase 29279 of SEQ ID NO.: 1. In certain embodiments, the
target region is within nucleobase 29168 and nucleobase 29183 of
SEQ ID NO.: 1.
[0297] In certain embodiments, an antisense oligonucleotide
modulates splicing of a pre-mRNA. In certain embodiments, an
antisense oligonucleotide modulates splicing a PK-M pre-mRNA. In
certain embodiments, an antisense oligonucleotide increases the
amount of PK-M mRNA. In certain embodiments, an antisense
oligonucleotide increases the inclusion of exon 9 in PK-M mRNA. In
certain embodiments, an antisense oligonucleotide decreases the
inclusion of exon 10 in PK-M mRNA. In certain embodiments, an
antisense oligonucleotide increases the amount of PK-M1 mRNA. In
certain embodiments, an antisense oligonucleotide decreases the
amount of PK-M2 mRNA.
[0298] In certain embodiments it is desirable to alter the splicing
of PK-M pre-mRNA to include exon 9 and exclude exon 10. By altering
the splicing of PK-M pre-mRNA to include exon 9 and exclude exon
10, expression of PK-M1 will increase and expression of PK-M2 will
decrease. In certain embodiments it is desirable to alter the
splicing of PK-M pre-mRNA to decrease expression of PK-M2.
[0299] Certain Pharmaceutical Compositions
[0300] In certain embodiments, the present invention provides
pharmaceutical compositions comprising one or more antisense
compound. In certain embodiments, such pharmaceutical composition
comprises a suitable pharmaceutically acceptable diluent or
carrier. In certain embodiments, a pharmaceutical composition
comprises a sterile saline solution and one or more antisense
compound. In certain embodiments, such pharmaceutical composition
consists of a sterile saline solution and one or more antisense
compound. In certain embodiments, the sterile saline is
pharmaceutical grade saline. In certain embodiments, a
pharmaceutical composition comprises one or more antisense compound
and sterile water. In certain embodiments, a pharmaceutical
composition consists of one or more antisense compound and sterile
water. In certain embodiments, the sterile saline is pharmaceutical
grade water. In certain embodiments, a pharmaceutical composition
comprises one or more antisense compound and phosphate-buffered
saline (PBS). In certain embodiments, a pharmaceutical composition
consists of one or more antisense compound and sterile
phosphate-buffered saline (PBS). In certain embodiments, the
sterile saline is pharmaceutical grade PBS.
[0301] In certain embodiments, antisense compounds may be admixed
with pharmaceutically acceptable active and/or inert substances for
the preparation of pharmaceutical compositions or formulations.
Compositions and methods for the formulation of pharmaceutical
compositions depend on a number of criteria, including, but not
limited to, route of administration, extent of disease, or dose to
be administered.
[0302] Pharmaceutical compositions comprising antisense compounds
encompass any pharmaceutically acceptable salts, esters, or salts
of such esters. In certain embodiments, pharmaceutical compositions
comprising antisense compounds comprise one or more oligonucleotide
which, upon administration to an animal, including a human, is
capable of providing (directly or indirectly) the biologically
active metabolite or residue thereof. Accordingly, for example, the
disclosure is also drawn to pharmaceutically acceptable salts of
antisense compounds, prodrugs, pharmaceutically acceptable salts of
such prodrugs, and other bioequivalents. Suitable pharmaceutically
acceptable salts include, but are not limited to, sodium and
potassium salts.
[0303] A prodrug can include the incorporation of additional
nucleosides at one or both ends of an oligomeric compound which are
cleaved by endogenous nucleases within the body, to form the active
antisense oligomeric compound.
[0304] Lipid moieties have been used in nucleic acid therapies in a
variety of methods. In certain such methods, the nucleic acid is
introduced into preformed liposomes or lipoplexes made of mixtures
of cationic lipids and neutral lipids. In certain methods, DNA
complexes with mono- or poly-cationic lipids are formed without the
presence of a neutral lipid. In certain embodiments, a lipid moiety
is selected to increase distribution of a pharmaceutical agent to a
particular cell or tissue. In certain embodiments, a lipid moiety
is selected to increase distribution of a pharmaceutical agent to
fat tissue. In certain embodiments, a lipid moiety is selected to
increase distribution of a pharmaceutical agent to muscle
tissue.
[0305] In certain embodiments, pharmaceutical compositions provided
herein comprise one or more modified oligonucleotides and one or
more excipients. In certain such embodiments, excipients are
selected from water, salt solutions, alcohol, polyethylene glycols,
gelatin, lactose, amylase, magnesium stearate, talc, silicic acid,
viscous paraffin, hydroxymethylcellulose and
polyvinylpyrrolidone.
[0306] In certain embodiments, a pharmaceutical composition
provided herein comprises a delivery system. Examples of delivery
systems include, but are not limited to, liposomes and emulsions.
Certain delivery systems are useful for preparing certain
pharmaceutical compositions including those comprising hydrophobic
compounds. In certain embodiments, certain organic solvents such as
dimethylsulfoxide are used.
[0307] In certain embodiments, a pharmaceutical composition
provided herein comprises one or more tissue-specific delivery
molecules designed to deliver the one or more pharmaceutical agents
of the present invention to specific tissues or cell types. For
example, in certain embodiments, pharmaceutical compositions
include liposomes coated with a tissue-specific antibody.
[0308] In certain embodiments, a pharmaceutical composition
provided herein comprises a co-solvent system. Certain of such
co-solvent systems comprise, for example, benzyl alcohol, a
nonpolar surfactant, a water-miscible organic polymer, and an
aqueous phase. In certain embodiments, such co-solvent systems are
used for hydrophobic compounds. A non-limiting example of such a
co-solvent system is the VPD co-solvent system, which is a solution
of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the
nonpolar surfactant Polysorbate 80.TM. and 65% w/v polyethylene
glycol 300. The proportions of such co-solvent systems may be
varied considerably without significantly altering their solubility
and toxicity characteristics. Furthermore, the identity of
co-solvent components may be varied: for example, other surfactants
may be used instead of Polysorbate 80.TM.; the fraction size of
polyethylene glycol may be varied; other biocompatible polymers may
replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other
sugars or polysaccharides may substitute for dextrose.
[0309] In certain embodiments, a pharmaceutical composition
provided herein is prepared for oral administration. In certain
embodiments, pharmaceutical compositions are prepared for buccal
administration.
[0310] In certain embodiments, a pharmaceutical composition is
prepared for administration by injection (e.g., intravenous,
subcutaneous, intramuscular, etc.). In certain of such embodiments,
a pharmaceutical composition comprises a carrier and is formulated
in aqueous solution, such as water or physiologically compatible
buffers such as Hanks's solution, Ringer's solution, or
physiological saline buffer. In certain embodiments, other
ingredients are included (e.g., ingredients that aid in solubility
or serve as preservatives). In certain embodiments, injectable
suspensions are prepared using appropriate liquid carriers,
suspending agents and the like. Certain pharmaceutical compositions
for injection are presented in unit dosage form, e.g., in ampoules
or in multi-dose containers. Certain pharmaceutical compositions
for injection are suspensions, solutions or emulsions in oily or
aqueous vehicles, and may contain formulatory agents such as
suspending, stabilizing and/or dispersing agents. Certain solvents
suitable for use in pharmaceutical compositions for injection
include, but are not limited to, lipophilic solvents and fatty
oils, such as sesame oil, synthetic fatty acid esters, such as
ethyl oleate or triglycerides, and liposomes. Aqueous injection
suspensions may contain substances that increase the viscosity of
the suspension, such as sodium carboxymethyl cellulose, sorbitol,
or dextran. Optionally, such suspensions may also contain suitable
stabilizers or agents that increase the solubility of the
pharmaceutical agents to allow for the preparation of highly
concentrated solutions.
[0311] In certain embodiments, a pharmaceutical composition is
prepared for transmucosal administration. In certain of such
embodiments penetrants appropriate to the barrier to be permeated
are used in the formulation. Such penetrants are generally known in
the art.
[0312] In certain embodiments, a pharmaceutical composition
provided herein comprises an oligonucleotide in a therapeutically
effective amount. In certain embodiments, the therapeutically
effective amount is sufficient to prevent, alleviate or ameliorate
symptoms of a disease or to prolong the survival of the subject
being treated. Determination of a therapeutically effective amount
is well within the capability of those skilled in the art.
[0313] In certain embodiments, one or more modified oligonucleotide
provided herein is formulated as a prodrug. In certain embodiments,
upon in vivo administration, a prodrug is chemically converted to
the biologically, pharmaceutically or therapeutically more active
form of an oligonucleotide. In certain embodiments, prodrugs are
useful because they are easier to administer than the corresponding
active form. For example, in certain instances, a prodrug may be
more bioavailable (e.g., through oral administration) than is the
corresponding active form. In certain instances, a prodrug may have
improved solubility compared to the corresponding active form. In
certain embodiments, prodrugs are less water soluble than the
corresponding active form. In certain instances, such prodrugs
possess superior transmittal across cell membranes, where water
solubility is detrimental to mobility. In certain embodiments, a
prodrug is an ester.
[0314] In certain such embodiments, the ester is metabolically
hydrolyzed to carboxylic acid upon administration. In certain
instances the carboxylic acid containing compound is the
corresponding active form. In certain embodiments, a prodrug
comprises a short peptide (polyaminoacid) bound to an acid group.
In certain of such embodiments, the peptide is cleaved upon
administration to form the corresponding active form.
[0315] In certain embodiments, the present invention provides
compositions and methods for reducing the amount or activity of a
target nucleic acid in a cell. In certain embodiments, the cell is
in an animal. In certain embodiments, the animal is a mammal. In
certain embodiments, the animal is a rodent. In certain
embodiments, the animal is a primate. In certain embodiments, the
animal is a non-human primate. In certain embodiments, the animal
is a human.
[0316] In certain embodiments, the present invention provides
methods of administering a pharmaceutical composition comprising an
oligomeric compound of the present invention to an animal. Suitable
administration routes include, but are not limited to, oral,
rectal, transmucosal, intestinal, enteral, topical, suppository,
through inhalation, intrathecal, intracerebroventricular,
intraperitoneal, intranasal, intraocular, intratumoral, and
parenteral (e.g., intravenous, intramuscular, intramedullary, and
subcutaneous). In certain embodiments, pharmaceutical intrathecals
are administered to achieve local rather than systemic exposures.
For example, pharmaceutical compositions may be injected directly
in the area of desired effect (e.g., into the eyes, ears).
[0317] In certain embodiments, a pharmaceutical composition is
administered to an animal having at least one cancer cell. In
certain embodiments, such administration results in apoptosis of at
least cancer cell. In certain embodiments, a pharmaceutical
composition is administered to an animal having at least one
symptom associated with cancer. In certain embodiments, such
administration results in amelioration of at least one symptom. In
certain embodiments, administration of a pharmaceutical composition
to an animal results in a decrease of PK-M2 mRNA in a cell of the
animal. In certain embodiments, such administration results in an
increase in PK-M1 mRNA. In certain embodiments, such administration
results in a decrease in PK-M2 protein and an increase PK-M1
protein. In certain embodiments, a PK-M1 protein is preferred over
a PK-M2 protein. In certain embodiments, the administration of
certain antisense oligonucleotides delays the onset of cancer. In
certain embodiments, the administration of certain antisense
oligonucleotides slows the proliferation of cancer cells. In
certain embodiments, the administration of certain antisense
oligonucleotides slows the proliferation of tumor cells. In certain
embodiments, the administration of certain antisense
oligonucleotides prevents the growth of cancer. In certain
embodiments, the administration of certain antisense
oligonucleotides prevents the formation of tumors. In certain
embodiments, the administration of certain antisense
oligonucleotides causes tumor mass to decrease. In certain
embodiments, the administration of certain antisense
oligonucleotides rescues cellular phenotype.
NONLIMITING DISCLOSURE AND INCORPORATION BY REFERENCE
[0318] While certain compounds, compositions and methods described
herein have been described with specificity in accordance with
certain embodiments, the following examples serve only to
illustrate the compounds described herein and are not intended to
limit the same. Each of the references, GenBank accession numbers,
and the like recited in the present application is incorporated
herein by reference in its entirety.
[0319] Although the sequence listing accompanying this filing
identifies each sequence as either "RNA" or "DNA" as required, in
reality, those sequences may be modified with any combination of
chemical modifications. One of skill in the art will readily
appreciate that such designation as "RNA" or "DNA" to describe
modified oligonucleotides is, in certain instances, arbitrary. For
example, an oligonucleotide comprising a nucleoside comprising a
2'-OH sugar moiety and a thymine base could be described as a DNA
having a modified sugar (2'-OH for the natural 2'-H of DNA) or as
an RNA having a modified base (thymine (methylated uracil) for
natural uracil of RNA).
[0320] Accordingly, nucleic acid sequences provided herein,
including, but not limited to those in the sequence listing, are
intended to encompass nucleic acids containing any combination of
natural or modified RNA and/or DNA, including, but not limited to
such nucleic acids having modified nucleobases. By way of further
example and without limitation, an oligomeric compound having the
nucleobase sequence "ATCGATCG" encompasses any oligomeric compounds
having such nucleobase sequence, whether modified or unmodified,
including, but not limited to, such compounds comprising RNA bases,
such as those having sequence "AUCGAUCG" and those having some DNA
bases and some RNA bases such as "AUCGATCG" and oligomeric
compounds having other modified or naturally occurring bases, such
as "AT.sup.meCGAUCG," wherein .sup.meC indicates a cytosine base
comprising a methyl group at the 5-position.
EXAMPLES
[0321] The following examples illustrate certain embodiments of the
present invention and are not limiting. Moreover, where specific
embodiments are provided, the inventors have contemplated generic
application of those specific embodiments. For example, disclosure
of an oligonucleotide having a particular motif provides reasonable
support for additional oligonucleotides having the same or similar
motif And, for example, where a particular high-affinity
modification appears at a particular position, other high-affinity
modifications at the same position are considered suitable, unless
otherwise indicated.
Example 1
Screening in HEK-293 Cells to Identify Antisense Oligonucleotides
that Promote the Expression of the Pyruvate Kinase M1 Isoform Via
Alternative Splicing
[0322] Alternative splicing of the Pyruvate kinase M (PK-M) gene
involves a choice between mutually exclusive exons 9 and 10. An
antisense oligonucleotide (ASO) screen was carried out to identify
potent ASOs that switch the splicing of endogenous PK-M transcripts
to include exon 9, thereby promoting PK-M1 isoform expression and
down-regulating PK-M2 isoform expression. A diagram of the PK-M
genomic region is presented in FIG. 1a.
[0323] The ASOs were designed as uniform oligonucleotides, 15
nucleotides in length, with 2'-O-methoxyethyl ribose sugar residues
and a phosphorothioate backbone. All the cytosine nucleobases are
5-methylcytosines. The ASOs target exon 10 of the complement of
GENBANK Accession No. NT.sub.--010194.16 truncated from nucleotides
43281289 to 43314403 (designated herein as SEQ ID NO: 1), and cover
the 167-nucleotide region of exon 10 in 5-nucleotide steps, as
presented in Table 1.
[0324] To examine the effects of antisense oligonucleotide
treatment of the cells on endogenous PK-M transcripts, HEK-293
cells were transfected with each ASO at a final concentration of 30
nM. HEK-293 cells were obtained from ATCC and grown at a density of
2.times.10.sup.6 cells in 6-cm dishes in DMEM supplemented with 10%
(v/v) FBS, penicillin, and streptomycin, at 37.degree. C. and 5%
CO.sub.2. Transfections were performed using an ASO:
LipofectAMINE2000.RTM. ratio of 20 pmoles: 1 .mu.L.
[0325] Splicing of the PK-M transcripts by radioactive RT-PCR was
analyzed 48 hrs after transfection. Two micrograms of total RNA was
extracted from the cells using Trizol reagent (Life Technologies,
Carlsbad, Calif.). Contaminating DNA was removed with DNase I
(Promega). Reverse transcription was carried out using ImPromp-II
reverse transcriptase (Promega). Semiquantitative PCR using
Amplitaq polymerase (Applied Biosystems) was performed by including
[.alpha.-.sup.32P]-dCTP in the reactions. The human-specific primer
sets used to amplify endogenous transcripts anneal to PK-M exons 8
and 11, and their sequences are: hPKMF: 5'-AGAAACAGCCAAAGGGGACT-3'
(designated herein as SEQ ID NO: 2) and hPKMR:
5'-CATTCATGGCAAAGTTCACC-3' (designated herein as SEQ ID NO: 3). The
primers are represented by arrows at the top portion of FIG. 1a.
After 27 amplification cycles for endogenous transcripts, the
reactions were divided into two aliquots for digestion with PstI
(New England Biolabs) or no digestion. Pst1 digestion was carried
out to distinguish between M1 and M2; only M2 has a PstI site,
resulting in two cleavage products, B1 (213 nucleotides) and B2
(185 nucleotides) which are the 3' and 5' ends of M2 respectively,
as shown at the bottom portion of FIG. 1a.
[0326] The products were analyzed on a 5% native polyacrylamide
gel, visualized by autoradiography, and quantified on a Typhoon
9410 phosphorimager (GE Healthcare) using Multi Gauge software
Version 2.3. The results are presented in FIG. 1b, and Table 1. The
% M1 mRNA in endogenous transcripts was calculated using the
GC-content-normalized intensities of the top undigested band (M1;
depicted as A in the figure), the bottom two digested bands (M2;
depicted as B1 and B2 in the figure) in the Pst1-digest lanes, and
the double-skipped species (D), if detectable. Each product was
quantified as a percentage of the total of M1, M2, and
double-skipped species. % M1 and % M2 are presented in the Table.
The first row of Table 1 denotes the numbers from the untreated
control set of cells.
[0327] Some of the ASOs strongly increased the proportion of PK-M1
mRNA, with a concurrent increase in the amount of double-skipped
mRNA, and a decrease in PK-M2 mRNA. The results indicate that these
ASOs target functional enhancer splice elements (ESEs) in exon
10.
[0328] The two most potent ASOs were ISIS 461456 and ISIS 461472.
ISIS 461472 targets the previously characterized exon 10 SRSF3
motif (Wang, Z. et al., J. Mol. Cell Biol. 4: 79-87, 2012), whereas
ISIS 461456 targets a non-overlapping 15-nucleotide region in the
middle of exon 10.
TABLE-US-00001 TABLE 1 RT-PCR screening of ASOs targeting exon 10
in HEK-293 cells Target Target SEQ Start Stop ID Isis No Site Site
Sequence % M1 % M2 NO n/a n/a n/a n/a 2 98 n/a 461453 29153 29167
AATAATTGCAAGTGG 29 69 4 461454 29158 29172 CCTCAAATAATTGCA 26 73 5
461455 29163 29177 GAGTTCCTCAAATAA 27 70 6 461456 29168 29182
CGGCGGAGTTCCTCA 33 64 7 461457 29173 29187 CCAGGCGGCGGAGTT 25 69 8
461458 29178 29192 GGGCGCCAGGCGGCG 21 72 9 461459 29183 29197
GTAATGGGCGCCAGG 17 81 10 461460 29188 29202 CGCTGGTAATGGGCG 23 70
11 461469 29248 29262 CCCCACTGCAGCACT 13 82 12 461470 29253 29267
TATGGCCCCACTGCA 9 90 13 461471 29258 29272 ACGATTATGGCCCCA 6 94 14
461472 29263 29277 TGAGGACGATTATGG 23 74 15 461473 29268 29282
CTTGGTGAGGACGAT 4 95 16 461474 29273 29287 CCAGACTTGGTGAGG 12 88
17
Example 2
ASO Microwalk Centered on the 10 W ESE Region
[0329] An ASO microwalk was performed to find the most potent ASOs
that target the exon 10 regions defined by ISIS 461456 and ISIS
461472.
[0330] Overlapping 15-nucleotide ASOs were designed in 1-nucleotide
steps. The ASOs were designed as uniform oligonucleotides, 15
nucleotides in length, with 2'-O-methoxyethyl ribose sugar residues
and a phosphorothioate backbone. All the cytosine nucleobases are
5-methylcytosines. The ASOs target exon 10 of SEQ ID NO: 1.
[0331] To examine the effects of antisense oligonucleotide
treatment of the cells on endogenous PK-M transcripts, HEK-293
cells were transfected with each ASO at a final concentration of 60
nM. Cell culture, transfection and RNA analysis was conducted in a
similar manner to that described in Example 1. The results of the
microwalks are presented in FIG. 1c and Tables 2 and 3. The % M1
mRNA in endogenous transcripts was calculated using the
GC-content-normalized intensities of the top undigested band (M1;
depicted as A in the figure), the bottom two digested bands (M2;
depicted as B1 and B2 in the figure) in the Pst1-digest lanes, and
the double-skipped species (D), if detectable. Each product was
quantified as a percentage of the total of M1, M2, and
double-skipped species. % M1 and % M2 are presented in the Tables
below. All standard deviations are .ltoreq.4% (n=3).
[0332] The results indicate that ISIS 549197 was the most potent in
increasing endogenous PK-M1 mRNA and decreasing PK-M2 mRNA levels.
The results also indicate that ISIS 555158 optimally abrogated the
SRSF3-dependent ESE in exon 10.
TABLE-US-00002 TABLE 2 ASO microwalk around ISIS 461456 in HEK-293
cells Target Target SEQ Start Stop ID ISIS No Site Site Sequence %
M1 % M2 NO n/a n/a n/a n/a 2 98 n/a 549191 29161 29175
GTTCCTCAAATAATT 11 89 18 549192 29162 29176 AGTTCCTCAAATAAT 17 83
19 549193 29164 29178 GGAGTTCCTCAAATA 28 69 20 549194 29165 29179
CGGAGTTCCTCAAAT 29 69 21 549195 29166 29180 GCGGAGTTCCTCAAA 4 95 22
549196 29167 29181 GGCGGAGTTCCTCAA 39 57 23 549197 29169 29183
GCGGCGGAGTTCCTC 41 39 24 549198 29170 29184 GGCGGCGGAGTTCCT 38 51
25 549199 29171 29185 AGGCGGCGGAGTTCC 38 53 26 549200 29172 29186
CAGGCGGCGGAGTTC 25 69 27 549201 29174 29188 GCCAGGCGGCGGAGT 25 67
28
TABLE-US-00003 TABLE 3 ASO microwalk around ISIS 461472 in HEK-293
cells Target Target SEQ Start Stop ID ISIS No Site Site Sequence %
M1 % M2 NO 555155 29259 29273 GACGATTATGGCCCC 13 88 29 555156 29260
29274 GGACGATTATGGCCC 16 84 30 555157 29261 29275 AGGACGATTATGGCC
26 61 31 555158 29262 29276 GAGGACGATTATGGC 29 60 32 555159 29264
29278 GTGAGGACGATTATG 25 70 33 555160 29265 29279 GGTGAGGACGATTAT
26 68 34 555161 29266 29280 TGGTGAGGACGATTA 18 79 35 555162 29267
29281 TTGGTGAGGACGATT 14 83 36
Example 3
Characterization of the Activation Region of PK-M Exon 10
[0333] The target region of ISIS 461456 and ISIS 549197, the most
potent ASOs, was characterized in detail.
[0334] To map the enhancer elements present in the target region of
ISIS 461456, the high sequence identity between exons 9 and 10 was
taken advantage of The PK-M2 minigene was constructed by amplifying
a 6.4 kb PK-M exon 8-11 fragment from human genomic DNA (Promega),
using Phusion High-Fidelity DNA polymerase and primers PKMinigeneF
(5'-GGGGAAGATATCAATTCCCCATTCTGTCTTCCCATGT-3'; designated SEQ ID NO:
37) and PKMinigeneR (5'-GGGGAACTCGAGCTAGACATTCATGGCAAAGTTCACC-3';
designated SEQ ID NO: 38). The product was then digested and cloned
between the BamHI and XhoI sites of pcDNA3.1+(Invitrogen). For
exon-duplication and intron-deletion constructs, the upstream KpnI
site 1552 nt downstream of exon 8 was removed by a 1-nt deletion,
and an EcoRV restriction site was generated 90 nt upstream of exon
9 by a 2-nt insertion to create a modified wild-type minigene. To
generate the 10 W, 10B7 and 10F7 constructs, modified exon 9
fragments were generated by annealing the following
oligonucleotides: 10 W F
(5'-CCCTAAACCTTACAGATAGCTCGTGAGGCTGAGGCAGCCATGTTCCACCGCAAGCTGTTTGAGG
AACTCCGCCGAGCCTCAAGTCACTCCACAGACCTCATGGAAGCCAT-3'; designated SEQ
ID NO: 39), 10F7F
(5'-CCCTAAACCTTACAGATAGCTCGTGAGGCTGAGGCAGCCATGTTCCACCGCAAGCTGTTTGAGG
AACTTGTGCGAGCCTCAAGTCACTCCACAGACCTCATGGAAGCCAT-3'; designated SEQ
ID NO: 40), 10B7F
(5'-CCCTAAACCTTACAGATAGCTCGTGAGGCTGAGGCAGCCATGTTCCACCGCAAGCTGTTTGAAG
AACTCCGCCGAGCCTCAAGTCACTCCACAGACCTCATGGAAGCCAT-3'; designated SEQ
ID NO: 41) with Exon 9Rev oligo
(5'-CCCTTAGGGCCCTACCTGCCAGACTCCGTCAGAACTATCAAAGCTGCTGCTAAACACTTATAAG
AAGCCTCCACGCTGCCCATGGCCATGGCTTCCATGAGGTCTG-3'; designated SEQ ID
NO: 42) and amplifying using Ex10ADupF
(5'-TTCCCCATTCTGTCTTCCCATGTGTTGTGTCTCGTTTTTTTCCTCCTCCTTCCCTCTTCCTTGCCCC
CTCTTCCCCTAAACCTTACAG-3'; designated SEQ ID NO: 43) and Ex10ADupR
(5'-AGTGTTACCTGCCCTTAGGGCCCTAC-3'; designated SEQ ID NO: 44). The
106-nt oligonucleotide carries mutations that duplicate specific
stretches of exon 10 over the corresponding region of exon 9.
Another fragment was amplified from the wild-type minigene using
the following primer pairs: Ex10BF: 5'-GTAGGGCCCTAAGGGCAGGTAACAC-3'
(designated SEQ ID NO: 45) and RKpnI:
5'-GGGGAAGGTACCACTGAGCAGGGCATT-3' (designated SEQ ID NO: 46). Both
fragments were then gel-purified, subjected to a second
overlap-extension (OE) PCR using the end primers FEcoRV
(5'-GGGGAAGATATCAATTCCCCATTCTGTCTTCCCATGT-3'; designated SEQ ID NO:
47) and RKpnI (5'-GGGGAGGTACCACTGAGCAGGGCATT-3'; designated SEQ ID
NO: 48).
[0335] As shown in FIG. 2a, the minigene comprises the same genomic
region as indicated in FIG. 1a. The 10 W minigene duplicates the
entire exon 10 10 W region into exon 9; the 1 OF minigene
duplicates the first eight nucleotides of ISIS 549197; and the 10B
minigene duplicates the last seven nucleotides of ISIS 549197. Due
to the low baseline PK-M1 inclusion from the wild-type minigene,
any strong ESEs comprised by the candidate regions was expected to
lead to an increase in PK-M1 mRNAs expressed from the
mini-gene.
[0336] The results are presented in FIG. 2b and Table 4. Standard
deviations are 0.2%, 0.3%, and 2.6% for 10G, 10F, and 10B,
respectively (n=3). The data indicate that duplication of the B7
region (10B), but not the F7 (10F) and 10 W region, lead to
increased exon 9 inclusion. This result suggests that the
8-nucleotide B7 motif is a bona fide exon 10 ESE.
TABLE-US-00004 TABLE 4 Analysis of minigenes 10W, 10F and 10B
Minigene % M1 10W 2 10F <1 10B 29
Example 4
Characterization of the Mechanism of Action of the ASOs
[0337] To characterize the mechanism of action of ISIS 461456 and
ISIS 549197 on the inclusion of exon 9 and skipping of exon 10,
these ASOs were co-transfected with the PK-M wild-type or
duplicated exon 10 minigenes. The wild-type minigene comprises the
flanking exons 8 and 11, and the complete genomic region between
both exons, whereas the duplication construct has exon 10 replaced
completely with exon 9.
[0338] HEK-293 cells were cultured, as described above. Five .mu.g
of minigene plasmid per 10-cm dish or one .mu.g per 6-cm dish was
transiently transfected using LipofectAMINE2000.RTM. (Life
Technologies, Carlsbad, Calif.). ASOs were transfected, as
described above, at a final concentration of 60 nM. A control ASO
(5'-TCATTTGCTTCATACAGG-3', designated as SEQ ID NO: 49) was also
used. The results are presented in FIGS. 2c and d, as well as in
Table 5. Standard deviations for FIG. 2c are 0.6%, 4.2% and 2.9%
for control, ISIS 461456 and ISIS 549197, respectively (n=3).
Standard deviations for FIG. 2d are 0.8%, 0.9%, and 2.6% for
control, ISIS 461456 and ISIS 549197, respectively (n=3).
[0339] As expected, both ISIS 461456 and ISIS 549197 switched the
splicing of the minigene transcript by simultaneously increasing
the amount of the M1 mRNA and decreasing the amount of the M2 mRNA
expressed from the wild-type minigene (FIG. 2c and Table 5).
However, ISIS 461456 increased exon 9 inclusion to a greater extent
than ISIS 549197, although the latter decreased exon 10 inclusion
to a greater extent, resulting in higher levels of double-skipped
(Skp) transcripts.
[0340] Co-transfection of ISIS 461456 or ISIS 549197 with the exon
10 duplication minigene interfered with the inclusion of exon 10,
leading to a large increase in double skipped species (FIG. 2d and
Table 5). ISIS 461456 was especially potent, nearly converting all
the mRNA to the Skp isoform.
[0341] These results suggest that both ISIS 461456 and ISIS 549197
interfere with the activation of exon 10.
TABLE-US-00005 TABLE 5 Minigene transcript level as a result of ASO
co-transfection in HEK-293 cells ASO Minigene treatment % M1 % Skp
% M2 Wild-type Control 1 6 93 ISIS 461456 26 63 11 ISIS 5491597 8
85 7 Exon 10 Control n/a 1 99 duplication ISIS 461456 n/a 60 40
ISIS 5491597 n/a 82 18
[0342] Alignment of the 10 W region with the PK-M exons 8-11
genomic region revealed a highly homologous region in intron 9
(FIG. 2e). To weigh the relative contributions of the exon 10 and
intron 9 complementary regions for the effect of ISIS 461456 and
ISIS 549197 on PK-M splicing, minigene mutation were made that
eliminated the presumptive target sites in exon 10, intron 9, or
both. The effect of the ASOs on splicing of the mutant minigene
transcripts was then determined
[0343] Three mutants were generated (FIG. 2e). The exon 10 10 W
region was mutated by duplicating the corresponding exon 9 region
and termed the d10 W construct. To generate the d10 W minigene
construct, a modified exon 10 fragment was constructed by annealing
d10 W F
(5'-ATGTTGCTCCCCTAGATTGCCCGTGAGGCAGAGGCTGCCATCTACCACTTGCAATTATTTGAAGA
ACTTGTGCGCCTGGCGCCCATTACCAGCGACCCCACAGAAGCCAC-3'; designated SEQ ID
NO: 50) with Exon 10 Rev
(5'-CGCTGCCGCCTCCTACCTGCCAGACTTGGTGAGGACGATTATGGCCCCACTGCAGCACTTGAAG
GAGGCCTCCACGGCACCCACGGCGGTGGCTTCTGTGGGGTCGCT-3'; designated SEQ ID
NO: 51) and amplifying using Ex9ADupF
(5'-TGGACGGATGTTGCTCCCCTAG-3'; designated SEQ ID NO: 52) and
Ex9ADupR (5'-GGTACCACTGAGCAGGGCATTCCAGGGAGCCGCTGCCGCCTCCTAC-3';
designated SEQ ID NO: 53). The 108-nt oligonucleotide carries
mutations that duplicate specific stretches of exon 9 over the
corresponding region in exon 10. Another fragment was amplified
from the wild-type minigene using the following primer pairs:
FEcoRV and Ex9BR (5'-GTAGGGCCCTAAGGGCAGGTAACAC-3'; designated SEQ
ID NO: 54). Both fragments were then gel-purified and subjected to
a second OE PCR reaction using the FEcoRV and RKpnI primers.
[0344] A 15-nucleotide deletion was introduced in intron 9 that
removed the homologous target region and this was termed the dInt9
construct. To generate the dInt9 mutant, two fragments were
generated from the wild-type minigene construct, using the
following primer pairs: FEcoRV and PKMdelB12R (5'
TGCCCTGCCATGACCTCCCAGACGAGAAGAGGCTCTGTGCCCAG-3'; designated SEQ ID
NO: 55) and PKMdelB125
(5'-ACAGAGCCTCTTCTCGTCTGGGAGGTCATGGCAGGGCAG-3'; designated SEQ ID
NO: 56).
[0345] To generate the dM double mutant, the same two fragments
were generated from the d10 W minigene. Both fragments were then
gel-purified and subjected to a second OE PCR using FEcoRV and
RKpnI. All generated fragments were then cloned between the EcoRV
and KpnI sites of the modified wild-type minigene plasmid.
[0346] There was a slight decrease in baseline minigene PK-M2 mRNA
expressed from the d10 W minigenes (FIG. 2f and Table 6),
suggesting that the duplicated exon 9 region contains weak
repressor elements. This was not the case for the dInt9 construct,
suggesting that this region alone does not have a major effect in
dictating M1/M2 ratios.
[0347] The loss of the 10 W binding site largely abrogated the exon
9 inclusion and exon 10 skipping promoted by ISIS 461456 and ISIS
549197 (FIG. 2f and Table 6). In contrast, removal of the intron 9
homologous region did not block the effect of ISIS 461456 and ISIS
549197 on splicing. However, when both binding sites were removed,
the effect of ISIS 461456 and ISIS 549197 was completely abrogated.
The results indicate that ISIS 461456 and ISIS 549197 largely
mediate exon 9 inclusion through the 10 W complementary region in
exon 10.
TABLE-US-00006 TABLE 6 Mutant minigene transcript level as a result
of ASO co-transfection in HEK-293 cells ASO Minigene treatment % M1
% Skp % M2 D10W Control 5 9 86 ISIS 461456 11 20 68 ISIS 5491597 10
34 56 dInt9 Control 1 7 92 ISIS 461456 19 74 7 ISIS 5491597 12 80 9
dM Control 2 5 93 ISIS 461456 1 6 93 ISIS 5491597 1 5 94
Example 5
Antisense Inhibition of PK-M in Glioblastoma Cells
[0348] A characteristic splicing switch from PK-M1 to PK-M2 occurs
during gliomagenesis (Clower, C. V. et al., Proc. Natl. Acad. Sci.
USA 107: 1894-1899, 2010; Bluemlein, K. et al., Oncotarget. 2:
393-400, 2011). Glioblastoma cells also have a higher basal level
of PK-M1 mRNA, which is expected to facilitate the ASO-mediated
PK-M splicing switch (Clower, C. V. et al., Proc. Natl. Acad. Sci.
USA 107: 1894-1899, 2010).
[0349] To compare the effect of ASOs targeting the 10 W region
versus those targeting the SRSF3 region, side-by-side ASO
transfections at final concentrations of 30 nM, 60 nM, and 90 nM in
the glioblastoma cell lines A172 and U87-MG were conducted. ISIS
555158 was the ASO targeting the SRSF3 region that was chosen and
was transfected at final concentrations of 60 or 90 nM. The control
oligonucleotide was transfected at a final concentration of 90 nM.
The experiment was run in triplicates.
[0350] U87-MG and A172 cells were obtained from ATCC and grown in
DMEM supplemented with 10% (v/v) FBS, penicillin, and streptomycin,
at 37.degree. C. and 5% CO.sub.2. ASO transfections were conducted
as described above. Radioactive RT-PCR and restriction digest of
endogenous PK-M transcripts were performed 36 hrs after
transfection. The results are presented in FIG. 3a, as well as in
Tables 7 and 8. All standard deviations are .ltoreq.4% (n=3)
[0351] As expected, there was a dose-dependent increase in exon 9
inclusion and exon 10 skipping in these cell lines, with ISIS
461456 and ISIS 549197 performing better than ISIS 555158.
Consistent with the minigene experiments, treatment with ISIS
461456 resulted in greater increase in PK-M1 mRNA levels than
treatment with other ASOs, whereas treatment with ISIS 549197
resulted in more double-skipped mRNA and a larger decrease in PK-M2
mRNA levels than treatment with other ASOs.
TABLE-US-00007 TABLE 7 Effect of ASO treatment on PK-M mRNA levels
in A172 glioblastoma cells Treatment Dose (nM) % M1 % Skp % M2
Control 90 15 -- 85 ISIS 30 52 -- 48 461456 60 63 -- 37 90 73 -- 27
ISIS 30 49 8 42 549197 60 49 12 38 90 56 23 21 ISIS 60 39 10 51
555158 90 44 15 41
TABLE-US-00008 TABLE 8 Effect of ASO treatment on PK-M mRNA levels
in U87-MG glioblastoma cells Treatment Dose (nM) % M1 % Skp % M2
Control 90 4 -- 96 ISIS 30 43 2 55 461456 60 50 3 46 90 54 5 41
ISIS 30 36 12 52 549197 60 38 17 44 90 45 22 33 ISIS 60 24 11 65
555158 90 29 14 57
[0352] To estimate the amount of PK-M1 and PK-M2 proteins in the
cell lysates, isoform-specific antibodies were used. Cells were
lysed in SDS, and total protein concentration was measured by the
Bradford assay. Total protein of 5-30 .mu.g was separated by
SDS-PAGE and transferred onto nitrocellulose. This was followed by
blocking with 5% (w/v) milk in Tris-buffered saline with Tween-20,
probing with antibodies and visualization by enhanced
chemiluminescence (Roche). The primary antibodies used were
.beta.-actin (Genscript mAb, 1:10,000); PK-M2 (Cell Signaling
Technology, rAb, 1:2,000); and PK-M1 (ProteinTech, rAb, 1:1,000).
Secondary antibodies were goat anti-mouse or anti-rabbit HRP
conjugates (Bio-Rad, 1:20,000). The results are presented in FIG.
3b. A representative blot from one of three independent experiments
is shown.
[0353] As expected, PK-M1 and PK-M2 protein isoform levels closely
mirrored their mRNA levels. There was detectable PK-M1 protein
after transfection of each of the three ASOs, but ISIS 549197
resulted in the greatest decrease in PK-M2 levels.
[0354] The data was also confirmed by immunofluorescence technique.
Cells were first transfected with ASOs as described above and then
plated on 4-well culture slides (BD Biosciences) 24-hrs post
transfection. At 36 hrs post-transfection, the cells were washed
with PBS and fixed with 3.7% formaldehyde in PBS for 20 min. Cells
were then permeabilized in 0.1% Triton X-100 in PBS for 10 min
after washing in PBS, and then blocked for 20 min in blocking
buffer (1% goat serum in PBS). The cells were then incubated
overnight with rabbit monoclonal anti-PK-M2 antibody (Cell
Signaling Technology). After washing 3 times with PBS, the cells
were then incubated for 1 hr in blocking buffer containing Alexa
Fluor 594-conjugated goat anti-rabbit secondary antibody (Molecular
Probes/Invitrogen). Cells were analyzed using a Zeiss Axiopian.Z1
upright fluorescent microscope. Downregulation of PK-M2 protein was
also observed when either ISIS 461456 or ISIS 549197, but not the
control ASO, was transfected into A172 or U87-MG cells (FIG.
3c).
Example 6
Effect of Antisense Inhibition of PK-M on Apoptosis in Glioblastoma
Cells
[0355] The effect of treatment with ASOs targeting PK-M on
apoptosis of the glioblastoma cells was studied.
[0356] Treatment with ISIS 549197 resulted in cleaved PARP as early
as 24 hrs post-transfection in A172 cells, indicating that the
cells were undergoing apoptosis. Cells were harvested 24 or 48 hrs
after transfection, whereas the control cells were harvested after
48 hrs. The cells were lysed in SDS and total protein concentration
was measured by the Bradford assay. Total protein (5-30 .mu.g) was
separated by SDS-PAGE and transferred onto nitrocellulose. The
membrane was blocked with 5% (w/v) milk in Tris-buffered saline
with Tween-20 and probed with PARP primary antibody (Cell Signaling
Technology, rAb, 1:1,000). The bands were visualized by enhanced
chemiluminescence (Roche). The results are presented in FIG. 4.
[0357] To confirm this observation, Annexin V staining assays were
performed with A172 and U87-MG cells transfected with ISIS 460456,
ISIS 549197, or ISIS 555158 at a final concentration of 90 nM.
Cells (1.times.10.sup.6 in number) were collected 36 hrs after
transfection, washed twice with PBS and resuspended in 1.times.
Binding Buffer (10 mM HEPES, pH 7.4; 140 mM NaCl; 2.5 mM
CaCl.sub.2). The cells were then stained with 5 .mu.l each of
Annexin V-APC antibody and 7-AAD (Becton Dickinson) in the dark for
15 min, and analyzed for apoptosis for flow cytometry using an
LSRII Cell Analyzer (Becton Dickinson). Both early apoptotic
(7AAD.sup.-/Annexin V.sup.+) and late apoptotic (7AAD.sup.+/Annexin
V.sup.+) cells were included in the quantification. The results are
presented in FIG. 5a and Table 9, and are a representative of 3
biological triplicates each. Table 9 presents the percentage of
Annexin V-positive cells, as indicated in the two right quadrants
in each plot of the flow cytometric analysis.
TABLE-US-00009 TABLE 9 Effect of ASO treatment on apoptosis in A172
glioblastoma cells ASO: Control ISIS 555158 ISIS 461456 ISIS 549197
A172 3 23 34 48 U87-MG 4 18 32 44
[0358] To confirm this finding, cells were transfected with ISIS
461456 or ISIS 549197 at 30 nM, 60 nM, or 90 nM or with ISIS 555158
at 60 nM or 90 nM. The control ASO was transfected at 90 nM. The
data is presented in FIG. 5b and Tables 10 and 11. The proportion
of Annexin V-positive cells increased in an ASO dose-dependent
manner, indicating that ASO-mediated switching of PK-M splicing
induces apoptosis in these cell lines. ISIS 549197 was the most
potent in inducing apoptosis among the three ASOs tested.
TABLE-US-00010 TABLE 10 Effect of ASO multi-dose treatment on
apoptosis in A172 glioblastoma cells Treatment Dose (nM) %
apoptosis Control 90 3 ISIS 30 10 461456 60 20 90 34 ISIS 30 20
549197 60 44 90 48 ISIS 60 16 555158 90 23
TABLE-US-00011 TABLE 11 Effect of ASO multi-dose treatment on
apoptosis in U87-MG glioblastoma cells Treatment Dose (nM) %
apoptosis Control 90 4 ISIS 30 8 461456 60 27 90 32 ISIS 30 13
549197 60 30 90 44 ISIS 60 10 555158 90 18
Example 7
Effect of Antisense Inhibition of PK-M on Apoptosis in PK-M1
Inducible Cells
[0359] To investigate the mechanism of action by which treatment
with ASOs elicits apoptosis in glioblastoma cells, stable cell
lines that express human PK-M1 cDNA in a doxycycline-inducible
manner or PK-M2 cDNA in a constitutive manner were generated.
[0360] To generate cell lines that over-express human PK-M1 isoform
in a doxycycline-dependent manner, A172 cells were first infected
with MSCV-rtTA-hygro virus, and selected in hygromycin for 2 weeks.
Human PK-M1 cDNA was amplified from A172 cells transfected with
ISIS 549197 using the following primer pair: hPKT7cDNAF
(5'-GGGGAACTCGAGATGGCTTCTAGGATGGCATCGATGACAGGTGGCCAACAGATGGGCATGTCG
AAGCCCCATAGTGAAGCCG-3'; designated SEQ ID NO: 57) and hPKT7cDNAR
(5'-GGGGAAGAATTCTCACGGCACAGGAACAACACGCATG-3'; designated SEQ ID NO:
58) with Phusion High-Fidelity DNA Polymerase (Finnzymes). The
resulting amplicon containing the T7 tag was gel-purified and
cloned between the EcoRI and XhoI sites of the retroviral TtiGP
plasmid.A172-rTA cells were then infected with TtiGP-PKM1 virus. To
make cells lines constitutively over-express human PK-M2, PK-M2
cDNA from A172 cells were amplified using the same primers and
cloned between the EcoRI and XhoI sites of the retroviral PIG
plasmid. A172 and U87-MG cells were then infected with the PIG-PKM2
virus. All infected cells were then selected with 100 .mu.g/ml
puromycin for 3 days. All plasmids were sequenced to confirm their
identities.
[0361] FIG. 6a presents the immunoblot analysis of A172 cells
stably transduced with rtTA and doxycycline-inducible human
T7-tagged PK-M1 cDNA. FIG. 6b presents the immunoblot analysis of
A172 and U87 cells stably transduced with T7-tagged human PK-M2
cDNA. Cells were grown in parallel with or without doxycycline, and
harvested after 72 hrs. The cells were lysed and prepared for
western blotting analysis, as described in an earlier Example. The
primary antibodies used were PK-M1 (ProteinTech, rAb, 1:1,000), T7
(mAb, 1:1,000), PK-M2 (Cell Signaling Technology, rAb, 1:2,000) and
.beta.-actin (Genscript mAb, 1:10,000).
[0362] To investigate the role of PK-M1 in ASO-mediated apoptosis,
doxycycline was added to the PK-M1-inducible cells for three days,
after which the cells were treated with ISIS 461456, ISIS 549197,
or control ASO at 60 nM final concentrations. After 36 hrs, the
cells were stained for Annexin V and analyzed by flow cytometry.
The results are presented in FIG. 6c and Table 10. The histograms
of FIG. 6c indicate the fold increase in Annexin V-positive cells,
compared to the control ASO for each condition. The data indicate
that there was a similar increase in the number of Annexin
V-positive cells in the cells that did or did not overexpress
PK-M1, suggesting that PK-M1 induction did not cause apoptosis in
these cells.
[0363] To investigate the role of PK-M2 downregulation in
apoptosis, U87-MG and A172 cells overexpressing PK-M2 were treated
with ISIS 461456, ISIS 549197, ISIS 555158, or control ASO at a
final concentration of 90 nM. The cells were analyzed by
immunoblotting as well as by Annexin V flow cytometry. The results
are presented in FIGS. 6b and 6d, as well as Tables 12 and 13, and
indicate that overexpression of PK-M2 in both cell lines rescued
the cells from the ASO-mediated apoptosis, leading to the decrease
in the number of Annexin V-positive cells to baseline levels. The
histogram shown in FIG. 6d indicates the fold-increase in Annexin
V-positive cells, compared to control ASO for each cell line.
TABLE-US-00012 TABLE 12 Fold change of apoptosis compared to
control ASO in PK-M1-inducible cells Treatment Doxycycline
Fold-change ISIS No 3.0 461456 Yes 3.3 ISIS No 8.4 549197 Yes
7.5
TABLE-US-00013 TABLE 13 Fold change of apoptosis compared to
control ASO in PK-M2-overexpressing cells Cell line Treatment %
apoptosis A172 ISIS 555158 7.3 ISIS 461456 10.8 ISIS 549197 15.0
0.9A172 M2 ISIS 555158 0.9 ISIS 461456 0.9 ISIS 549197 1.0 U87-MG
ISIS 555158 4.6 ISIS 461456 8.2 ISIS 549197 11.3 U87-MG M2 ISIS
555158 1.0 ISIS 461456 1.4 ISIS 549197 1.1
Example 8
siRNA Knockdown of PK-M2 in A172 Cells
[0364] To confirm the effect on apoptosis in glioblastoma cells by
antisense inhibition, siRNA knockdown of PK-M2 in A172 cells was
employed.
[0365] Four siRNAs targeting exon 10 of human PKM2 were obtained
from Sigma Genosys, and have sense-strand sequences
5'-CCAUAAUCGUCCGCACCAA-3' (M2si1; designated SEQ ID NO: 59),
5'-CAUCUACCACUUGCAAUUA-3' (M2si2; designated SEQ ID NO: 60),
5'-CCGUGGAGGCCUCCUUCAA-3' (M2si3; designated SEQ ID NO: 61) and
5'-CUUGCAAUUAUUUGAGGAA-3' (M2si4; designated SEQ ID NO: 62). A172
cells (4.times.10.sup.6) in 6-well plates were transfected with 400
pmol of siRNA duplex using LipofectAMINE2000.RTM.. Cells were
harvested 48 hr later.
[0366] The results are presented in FIG. 7. Knockdown of PK-M2 also
led to the appearance of cleaved PARP after 48 hrs. These
observations confirm that the down-regulation of PK-M2 expression,
but not the induction of PK-M1 expression, leads to apoptosis in
glioblastoma cell lines.
Example 9
Effect of 2'-O-Methoxyethyl Antisense Oligonucleotides on PK-M
Splicing In Vivo
[0367] The ASOs listed in Table 14 below were designed to target
exon 10 of the mouse PK-M transcript comprising GENBANK Accession
No. NT.sub.--039474.8 truncated from nucleotides 5923000 to 5949000
(designated herein as SEQ ID NO: 63). (Note that the human ASOs
described herein target the complement of the human genomic PK-M
sequence NT.sub.--010194.16 truncated from nucleotides 43281289 to
43314403, whereas the mouse ASOs target the mouse genomic sequence
NT.sub.--039474.8 truncated from nucleotides 5923000 to 5949000
because the mouse sequence, SEQ ID: 63, corresponds to the
non-coding strand of the mouse genomic DNA. In each case, the ASOs
are complementary to the RNA transcript.) Each of the ASOs in Table
14 is also complementary to the human PK-M transcript with 0-3
mismatches. Each of the ASOs is 15 nucleotides in length, with
uniform 2'-O-methoxyethyl ribose sugar residues, and uniform
phosphorothioate internucleoside linkages. All the cytosine
nucleobases are 5-methylcytosines.
[0368] To examine the effects of antisense oligonucleotide
treatment on endogenous PK-M transcripts in vivo, C57B1/6 wild-type
(WT) mice were injected subcutaneously once per week for three
weeks with one of the ASOs listed in Table 14 at 100 mg/kg or with
PBS as a control. Each treatment group consisted of 4 animals. Four
days after the administration of the last dose, the mice were
sacrificed and tissues were collected.
[0369] PK-M1 and PK-M2 mRNA levels in each of the mice's livers
were determined using real-time PCR and RIBOGREEN.RTM. RNA
quantification reagent (Molecular Probes, Inc. Eugene, Oreg.)
according to standard protocols. Two mouse-specific primer probe
sets were used to amplify endogenous PK-M1. The first primer set
anneals to PK-M exons 8 and 9 (mPKMF: 5'-TGTCTGGAGAAACAGCCAAGG-3',
designated herein as SEQ ID NO: 64; mPKMR:
5'-CAAGCTCTTCAAACAGCAGACG-3', designated herein as SEQ ID NO:65;
probe sequence: 5'-AGCACCTGATAGCTCGGGAGGC-3', designated herein as
SEQ ID NO: 66). The second PK-M1 primer set anneals to exons 9 and
11 (mPKMF: 5'-AAGATGCCACGGTACAGATGG-3', designated herein as SEQ ID
NO: 67; mPKMR 5'-CAGACCTCATGGAGGCCATG-3', designated herein as SEQ
ID NO: 68; probe sequence: 5'-TGGCAGGAGTGCTCACCAAGT-3', designated
herein as SEQ ID NO: 69). Two mouse-specific primer probe sets were
used to amplify endogenous PK-M2. The first PK-M2 primer set
anneals to PK-M exons 8 and 10 (mPKMF:
5'-GGAGTTCCTCGAATAGCTGCAAG-3', designated herein as SEQ ID NO:70;
and mPKMR: 5'-AGTCCTGGATGGAGCAGACT-3', designated herein as SEQ ID
NO:71; probe sequence: 5'-GCTGTTCGCATGCAGCACCT-3', designated
herein as SEQ ID NO:72). The second PK-M2 primer set anneals to
exons 10 and 11 (mPKMF: 5'-GCGAGCAGTCTGGGGATTTC-3', designated
herein as SEQ ID NO: 73; mPKMR: 5'-ACCCCACAGAAGCTGCC-3', designated
herein as SEQ ID NO:74; probe sequence:
5'-ACCAAGTCTGGCAGGAGTGCTC-3', designated herein as SEQ ID NO:75).
mRNA levels were determined relative to GAPDH prior to
normalization to PBS-treated controls. The results in Table 15 are
presented as the average percent of PK-M1 and PK-M2 mRNA levels for
each treatment group, relative to the PK-M1 and PK-M2 mRNA levels
of the PBS-treated control group, respectively, and are denoted as
"% PBS". The standard error for all PK-M1 results was .ltoreq.34%,
and the standard error for all PK-M2 results was .ltoreq.6%. The
results for each primer probe set are listed. "ND" indicates no
data because the ASO targets a portion of the amplicon, thereby
preventing primer binding and amplification. All of the ASOs were
well tolerated, as assessed by liver weight and ALT and AST
levels.
TABLE-US-00014 TABLE 14 ASOs targeting mouse PK-M exon 10 Mouse
Mouse Target Target SEQ Start Stop ID Isis No. Site Site Sequence
(5' to 3') NO. 606601 20994 21011 GTTCCTCGAATAGCTGCA 76 606602
20995 21012 AGTTCCTCGAATAGCTGC 77 606604 20997 21014
GGAGTTCCTCGAATAGCT 78 606651 21096 21113 TGAGCACGATAATGGCCC 79
606653 21098 21115 GGTGAGCACGATAATGGC 80 606661 21106 21123
CCAGACTTGGTGAGCACG 81
TABLE-US-00015 TABLE 15 Effect of ASOs targeting mouse PK-M exon 10
on PK-M splicing in vivo PK-M1, PK-M1, PK-M2, PK-M2, exons 8, exons
9, exons 8, exons 10, 9 primer 11 primer 10 primer 11 primer Isis
probe set probe set probe set probe set No. (% PBS) (% PBS) (% PBS)
(% PBS) n/a 100 100 100 100 606601 260 250 ND 50 606602 290 270 ND
50 606604 210 200 ND 60 606651 440 400 50 ND 606653 270 270 50 ND
606661 320 200 40 ND
Example 10
Effect of Deoxy, MOE, and cEt Antisense Oligonucleotides on PK-M
Splicing In Vivo
[0370] The ASOs listed in Table 16 below were designed to target
exon 10 of SEQ ID NO: 63. Each of the ASOs in Table 16 is also
complementary to the human PK-M transcript with 0-3 mismatches. The
ASOs are either 16 or 18 nucleotides in length, with deoxy sugar
residues, 2'-MOE modified sugar residues, or cEt modified sugar
residues, and uniform phosphorothioate internucleoside linkages.
The Chemistry column presents the positions of the sugar residues;
`d` signifies a deoxy sugar, `e` signifies 2'-MOE modified sugar
residue, and `k` signifies a cEt modified sugar residue. All the
cytosine nucleobases are 5-methylcytosines.
[0371] To examine the effects of antisense oligonucleotide
treatment on endogenous PK-M transcripts in vivo, C57B1/6 WT mice
were injected subcutaneously once per week for four weeks with one
of the ASOs listed in Table 16 at 100 mg/kg or with PBS as a
control. Each treatment group consisted of 4 animals. Two days
after the administration of the last dose, the mice were sacrificed
and tissues were collected.
[0372] PK-M1 and PK-M2 mRNA levels in each of the mice's livers
were determined using real-time PCR according to standard
protocols. Mouse-specific primer probe sets, described in Example
9, were used to amplify endogenous PK-M1 and PK-M2. mRNA levels
were determined relative to GAPDH prior to normalization to
PBS-treated controls. The results in Table 17 are presented as the
average percent of PK-M1 and PK-M2 mRNA levels for each treatment
group, relative to the PK-M1 and PK-M2 mRNA levels of the
PBS-treated control group, respectively, and are denoted as "%
PBS". "ND" indicates no data because the ASO targets a portion of
the amplicon, thereby preventing primer binding and amplification.
All of the ASOs were well tolerated, as assessed by liver weight
and ALT and AST levels, except for ISIS 607034 which resulted in
elevation in all three or those measures of tolerability.
TABLE-US-00016 TABLE 16 ASOs targeting mouse PK-M exon 10 Mouse
Mouse Target Target SEQ ID Isis No. Start Site Stop Site Chemistry
Sequence (5' to 3') NO 606989 20980 20995 kddkddkddkddkddk
CAAGTGGTAGATGGCA 82 606996 21008 21023 kddkddkddkddkddk
CCAGGCGGCGGAGTTC 83 607001 21044 21059 kddkddkddkddkddk
CGGCGGCAGCTTCTGT 84 607003 21052 21067 kddkddkddkddkddk
GGCACCCACGGCGGCA 85 607016 21104 21119 kddkddkddkddkddk
ACTTGGTGAGCACGAT 86 607034 21000 21017 kkddkddkddkddkddkk
GGCGGAGTTCCTCGAATA 87 607041 21044 21061 kkddkddkddkddkddkk
CACGGCGGCAGCTTCTGT 88 607042 21048 21065 kkddkddkddkddkddkk
CACCCACGGCGGCAGCTT 89 607055 21100 21117 kkddkddkddkddkddkk
TTGGTGAGCACGATAATG 90 607057 21108 21125 kkddkddkddkddkddkk
TGCCAGACTTGGTGAGCA 91 607095 21100 21115 keekeekeekeekeek
GGTGAGCACGATAATG 92 607135 21100 21117 kkeekeekeekeekeeke
TTGGTGAGCACGATAATG 93 607136 21104 21121 kkeekeekeekeekeeke
AGACTTGGTGAGCACGAT 94
TABLE-US-00017 TABLE 17 Effect of ASOs targeting mouse PK-M exon 10
on PK-M splicing in vivo PK-M1, PK-M1, PK-M2, PK-M2, exons 8, exons
9, exons 8, exons 10, 9 primer 11 primer 10 primer 11 primer Isis
probe set probe set probe set probe set No. (% PBS) (% PBS) (% PBS)
(% PBS) n/a 100 100 100 100 606989 421 476 ND 86 606996 326 315 ND
25 607001 398 429 65 ND 607003 365 353 69 ND 607016 435 389 56 ND
607034 525 626 ND 148 607041 335 381 78 ND 607042 240 306 92 ND
607055 987 859 73 ND 607057 327 126 34 ND 607095 428 171 51 ND
607135 475 39 54 ND 607136 389 265 71 ND
Sequence CWU 1
1
94133115DNAHomo sapines 1acgcacaagt ctgcagctct ccccaacttt
ccgttcagct cagtctccga gggtgcgcca 60gagcagacac ccggaggagt ggggagtggc
agggcggggc cgggagaatg ctgccccgga 120acccataaat ctgggccctg
cccaggtagg ccgggacagc tggggtggcc tgggccgaga 180gccaagaaaa
gacaccccat ctggcagccc aacttggcgg caacaggtgg cccggcgccc
240gggggtctgg gaggaaagtc gctccggggg cgggccccgt tgccccgccg
cgtccccatt 300ggtcatcagg tttcttaaaa tgtgactctg aatctgtgtc
cttccgccgc agaatttagt 360cccaccgaaa gggcaacctg cccgcgcgtt
ccgccgccgc cgccgcgctt cctcctgaag 420gtgactgcgc ccgcggggac
gcagggggcg gggcccgggt cgcccggagc cgggattggg 480cagagggcgg
ggcggcggag ggattgcggc ggcccgcagc gggataacct tgaggctgag
540gcagtggctc cttgcacagc agctgcacgc gccgtggctc cggatctctt
cgtctttgca 600gcgtagcccg agtcggtcag cgccggaggt gagcggtgca
ggaggctacg ccatcagtcc 660ccaccaaggg ccagtcgccc ggctagtgcg
gaatcccggc gcgccggccg gccccgggca 720cgcaggcagg gcggcgcagg
atccagggcg tctgggatgc agtggagctc agagagagga 780gaacggctcc
tcacgcctgg ggcctgctct tcagaagtcc ccagcgccgt tccttccaga
840tcaggcgggt ccgccggctc ctttcccgcc ccagccctac cccctcattc
tggtcccatc 900ctcttcctcc tgccccaatc ctcaatgcgc ctccatcctc
gcctgccttc tctcggtccc 960tcgtgattga ttccaccctt gcttcccctt
tctccgcgcc gcctgttccg tgctcgtttt 1020cccctcttcc tccttaagtc
tggtccttcc accccctcct cttcaagctg tgcgtgtccc 1080ctgattctaa
tgctttctgt gtaactcatt gaaactgcgt tctggttccc ctcccgcgtc
1140cattctccat tcatgcgcga ccgcccttcc cgcgccccag ttccctctcg
ccgcccctcc 1200ccctgcttgc tggtcacgtc cgctcccccg catccccttc
ctcgcctggc gtgtccgctc 1260cctccctccc tctctgctct ggtcgcgccc
gcccacttgc tccggtctcc gagcgcggtc 1320ccacccccct tttccatcac
cgcctcccag ctcccagcag gctcgggcgg tgctgaggcc 1380ccgtgtccgg
ggcgggcggg cggagggctg ggctgggtgc cccgcgcggc gggcgggatg
1440cggcggcccg ggggcagctg gagacttacg taacgttggc ctgccccgct
gccgggaggc 1500agggcggttg cccctgcggc gcggtgccgt cccctgtggc
cgggattaga tgggcggcct 1560gcgagggcct gggaatggct cggggcccga
gagctcgacc ggcccttgcc gggtggccgc 1620cagggaccac gctccatctc
gccgcggccg ggctgcacgt agcggccgcg cccagggccc 1680accccgcttc
accgggcgat ggccttgggc ctcgtaacgg gcgggataaa cctctgcagg
1740ctttgctggg gcctcctggc cctcgcccgt tccgcgcctc tccggcacgt
ttctttcttt 1800tcctttcttt tttctttctt tttttttttt ttaattatcc
ggcacatttt ttaacaaatg 1860cgtcctgatt gtggaacgcg gaggccgcgg
ggtggggtgg ggatctggtt acggaggggg 1920caggaaatct gtcgcgttca
ctgaacgcaa acggtgtggg tcaagggctg tttgggggtc 1980agagttagag
accaggatga ctagacgagt catagcccac cgagctcaca atcttaaaat
2040gtatctcctg taatgctggg agtggggtac gagcttcctg ctgtgggagg
gagggggaca 2100ggaagcctcg taaggtctca ccaggtggca agcacactgg
attagaagat gcaggaaagc 2160accttccagt ctgaagatca tttaaagact
cagtcatgta agggcatccc ttggcttctt 2220aatctacgta ctccagaccc
agggcttgga cctttgctgg tacgggttaa agtgaggccg 2280acagtgaagg
tccacgtgga gagagacatt gggaagttgt caaaaaggcg tttagaatca
2340ggtttgactc attaatttcc tgagactctg aaggagttca gcctctacac
ctcagtttcc 2400cctgggaaaa ctgggagtaa cattttcctc atgatggttg
aaaggattca tgcttacgtg 2460gatgtggcac actcagtaag tgtctaatct
ctggcgaaat acccagaaga aaagcctgtg 2520actgaatata ttatttttga
gcacaattac ttagtccaca attgagcata agggccttga 2580tccattgtct
tcctactgtc cccaaacgcc tacagctaat cgtgaggaat caggctctct
2640gaataaccac gtgtctcctg gaaaccagtt ccccaaggga tctggtttaa
tattgacaaa 2700gtaactgata atgtaacttt ccaactctct gcttggagca
gatgcttttt ggtcatctga 2760gattgggacc tgtagacaaa ggcaggcaag
gaggggctga gttaagcctt tggtgttccg 2820ctgtaagtag aatactacct
accagaggaa cattccagcc cttgacttgc tctgcctgct 2880ggtgagatta
ggattggagc cagggtcagt agcccccagt tggccgtctt gagggtgtgg
2940ccactcccta ggtcacagag gagatggagg tcaggactcc cctgctgcag
cgttgttagc 3000aaataatttg ccctttggtg gcctgaggtg ctgtgggggc
aggagtgggc tgtcttgtgg 3060ggaagggaaa tgtaacgtat caccaaatct
gtgggggagt ggggctctgt ggggaagatg 3120actcaacctt tcaattattc
tgcttttgag agaattatct tcgctgggtg agtggggaaa 3180ctacattgtg
gttcttgcag gcttaaaaag tcccttctcc cctttcagtg agtcagataa
3240tgaagcatgc atttccccta attaaaaatg cctcaactac ggagcttgca
gtgagccgag 3300atcgcgccac tgcactccag cctgggcgac agagcgagac
tccttctcaa aaaaaaaaaa 3360aaaaaaagcc acaactaatt aaaaaatgat
tggtccgggt cacctggttc tctgtactgc 3420cttaagagct taagtgtaga
ctggcagagc ccggtgccca gctaatgccg tctgtgcagc 3480ttcattcctg
gcccttttgt agcgggcaca gccgcctctc ctgggacttg attaatgatg
3540acttaaagaa ggttcttgaa ctcatttctc agttactgac ttgagccaaa
atgtatggat 3600gttggtctcc tgtctagcac aactgctttc attttaagca
ttgcattaga aataatgttg 3660tattcatatt ttagcaaaga gcatcattag
ctctttaaga accgtacccc cagtgactta 3720gcaaatttgg tggcggtgac
tctaaacagc tagcacttta tgggagttgc ttctgtgcct 3780tgaatgttgt
gacactgatg tggggtcaca ggaaaaacca ttttatttcc taaagctgtt
3840tatttcttaa tattgaggca atggaagaaa tgaggaaacg gccgtgggca
ggaaggtaga 3900agaaaatgca gcacttacat tacaaactca ctttacttgg
gttttagttt attttgcttc 3960agttttttgt tttttttttt tttttttttt
tttttttttg agatagtttt gctcttgttg 4020cccagtctgg agtgcaatgg
tgtgatctcg gctcactgca acctccacct cctgggttca 4080agcaattctc
ctgcctcagc ctcccgaagt agctggaatt acaggcactt gcaccacgcc
4140cagctaatat ttttgtattt ttagtagaga tggggtttca ccatgttggc
caggctggtc 4200ttgaactcct gacttaggtg atccaccggc ctcggcctcc
caaagtgccg ggattacggg 4260cgtgagccac tgcacctggc ctgcttcagc
ttttatgaag gcaagtcagg atgtgttatc 4320ttggccaaga gctaagactg
agaccggagt agaggaaaat gactcatttg acattaccct 4380tctttctgaa
tcactccaaa agtccacagt caaatctcaa ttagctggta taacacaaga
4440atgcgttgac cctgtgagca gagttttatt gcatcttcaa gggtcttcgt
gagattggtt 4500tatttggtat gaggtcttaa ggattttaag ttgtcccttt
aagcatcagt tctgatacag 4560atgggaatag agctaaacaa ccagatatat
gaagaccatt tttgatacca ccatacttgc 4620ggggagcttg cattttttta
ccaaggggca gactggataa ttgagtaatt taaatacttg 4680ggactttgtt
aaagaagctg ttgggggaag gtgagcctgg gtgagtggtg gagggtgatg
4740tgcagcatct gctgggcctt cctgcctctt ggtatgactg ctcagctcag
gagttgggtg 4800ctttagggcc cctaccatgc agtgcggtga agccccgccc
ctgcagtggt ttgtgcttgt 4860ctgcacgtag gagggaacaa gccggctgca
gtaccttcgg tggcctctga gactcacctc 4920ccccacttct gtccatagac
aaagctcctg gggagcccta agcctctttc ctcatgccag 4980caagcagtct
tggaagcagg ctggggctgc agtgggagag atgccaagac cagttattca
5040agggcagtga ggttgccagt cctagcattt cacactgtgg accagcacag
ctgctggctg 5100aatactgcag tcaagattct ctgaagggag tcctatccct
tccaaacatc ttcagtttac 5160ttgcagataa tgtttcttca ttttttattt
tattttattt tattttattt ttttgagacg 5220gagtctcgca ccatgaccca
ggctggagtg cagtggtgca atctcagctc actgcaagct 5280ccgcctcccg
ggttcatgcc attctcctgc ctcagcctcc tgagtagctg ggactacagg
5340caaccgcaac cacgcctggc tgattttttt tgtatttttt agtagagacg
gggtttcact 5400gtgttagcca ggatggtctc agtctgctga cctcgtgatc
cacctgtctt ggcctcccaa 5460agtgctggga ttacaggcat cagccaccgc
gcctggccat gtttcttcaa ttttaaacaa 5520ctgatatctc ccttggccat
gaacgaaaaa gaactgccca tcagtggagt cagtcagggc 5580acataagaca
cactgtgtcc accatgccat ttcagaggag atttgattga gttaagcagg
5640gaaatagaga tgttgtaaac gttgaaacta tctgggtatc cctctttggt
tattaacatt 5700agatgagcag aaaaacaaat gtcaccgatg ggcaaacatt
taaaaagtct ggcagtacca 5760agtgtggaaa aaggtgtgga aggcagcaac
tcagcgttca ttgatatagc cactttggag 5820agcaattcag ccttatttag
taaaaataga aataaacata ctccatgacc taagacttca 5880atttctggat
atatagaaac tcacacagta cagggagaca tgtactacaa gagtattgat
5940taatagaaga aacttagttt aacggggagg gagagtggcc accagtaaga
cagtccataa 6000ataaaatggt ctgttgtaca gtggactagt gtaacagctt
aaatgaatta gctagatcca 6060tatacccact ggatggatct taaatgtgct
gctgagtgaa aaacaagtta ctcagtgata 6120tatacagtat accacttagg
gcattaagaa aaccacaata ttatagggtt cagtatagac 6180atagatacac
tgtacataga cttcagtgaa ctggaaggat atagagttca tgacagtgat
6240tgggtgtcaa aatgcatgat gtggctggga gcagtggctc acacctgtaa
tcccagcact 6300ttgagaggct gatgcaggag gatcacttga ggccaggagg
tcgagaccag cctgggcaac 6360atcgcaagat tcccatctct atttaaataa
ataaaataga aaaaaaagtt taagatggag 6420gtggaaaggg ttggaggagc
ttggggatgg agaaaaaatg aactgtataa aattaaaatt 6480cttgtttttg
tttttagaaa gtaaagaggg ccgggcacag tggctcatgc ctgtaatccc
6540agcactttgg gaagctgagg tgggcggatc acgaggtcag gagattgaga
ccatcctggc 6600taacacggtg aaaccccgtc tgtactaaaa atacaaaaaa
aaaaaaaaaa aaaaattagc 6660cgggcctggt ggcgggcgcc tgtagtccca
gctactcagg aggctgaggc aggagaatgg 6720cctgaacctg ggaggtggag
cttgcagtga gctgagatcg cgccagtgca ctccagcctg 6780ggcaacagag
cgagactcca tctcaaaaaa aaaaaaaaaa agaaaaaaga aattaaagaa
6840aatacagctc agcctttatt tgtgtttttt tttttttcct ttttttctga
gacagagttt 6900ttcactctgt tgcccgggct ggagggcagt ggtgcgatct
ccgttcactg cagcctccac 6960ttcctggatt caagcaattc tgtgtctcag
ccacccaagt agctgggatt acaggtgcgc 7020gcctggctaa tttttgtatg
tttagtagtg atggtgtttc accatattag ccaggctggt 7080ctcgaactct
tagcctcaag tgatctgccc gcctcagcct ttcaaactgt tgggattaca
7140ggcgtgagcc aacacagcca gccatggctc agtgttaatg gtcagttctg
ggtggtagag 7200aggcagatgt taaaactttt ttttctttaa ttcgtaacat
agaagcaaac ctataaaggc 7260tgccgtagga agaccagtca tagtaactag
ttcagtgctc ttggagagtt ggcactgcct 7320ttcctccttt atccccccga
ctagaatgca gggcagccct tccagtaaat gttgagccag 7380tgcctcactt
tgctgaggcc atcacccacc ttagttgcac ttaagaggac cctaaatcag
7440ggtcccaggt cccttgctga ttttagagtg tggatatcat acccagaaac
accgccctac 7500ttttaatcct agtaaggagg caccatgtcc caggacaact
aatgcttccc ccaaaccacc 7560tccttcaggc tgaaaccagt tctctgcact
gagcagctgg gatggaacca ggaaatcctc 7620ggcatctgag gacattgagg
ggtctctgac ttagggcttc ttcacctgaa gttgagtggt 7680ctttgaggga
agtaggccca tttagcatca gctgctcttc cctattccac actctagttg
7740gaaataggac cttaggttcc tgttgacaag tcatttactt tcagccccga
agaaataaaa 7800gagccaagat tttttttttt tttttaaagc cagggaattt
tactagaacc tacaagtggg 7860ctcattttgt tctgtgtagc ctggtaacac
catactgctt tctgctgtgg ggcctcctgg 7920ggttaaagtg tgggcttaag
acccaggtct cttagctaga agatatctta tcctctgtat 7980cctgcaccca
tatgcaaata cattattgtc attaccctta actatagatg aagatgaaca
8040gtgcctattc cagaccttac taggttctgc tggcccgtca cccattttga
tcatgttgct 8100ggcctagttt gattagggca aatcttagaa actccatttc
cattgttgag gaagagaact 8160agagagcagg ctgacctgaa tgccagcgta
tcatgatgca gactttctaa cggatgcagg 8220tgttcggaag agttgtggat
cgaaacgcct tcatgatggc ttggaggtgt aggtagcaaa 8280ctgacgtcac
aggaaggaac acaatcttgg gtacctactg gcaacgttgg agggagaaag
8340tgagcatcag gtgccatcat tttatagttg atctatgtga tgaggttggt
atcggagcat 8400aattggtaca aaggaaaaat gacttaggca gatgcagact
cacgggccag gctattttat 8460tagggcagaa tgatttggtc ctttgtggaa
gaattggtgg agtgaagcgt gaatctttcc 8520cagcacaacc caacaacagt
cctggcccta agaagtggag catgggagtt gggtgtggtt 8580cgtgcctgta
gtcccagcta cttgggatgc tgaggctgga ggatcgtttg agggtgcagt
8640gagctataat ataatataat cacaccactg cactccagcc tgggtgacag
agtgaaaccc 8700tgtctgaaaa aaaaaaaaaa gaaaaaaaaa aagttggagg
gaggagtgtt gggtattttt 8760tatgattttt gtctcctggt ttctgaagaa
tggccaaaaa attgtgtctg acacaaagga 8820aactaatata aaaagccagg
agctgtctga gatgagaaag gaaagggaga atagggcact 8880tggagctgag
ctgtgattgt gcctgttcca acctgtcact ccagactaag gcctcttaga
8940gatggtgtct cctttctcac agaggagaca tggctctgag gaagatctta
ctgcaggggc 9000tcgggctcaa gaataaggct cctggacctg ggcatggtgt
gtgctgctat cagtggatac 9060gccaggcttc cactgctggc tggaggttgg
ctctgcatgt ctgtgccttc ctaggaggag 9120gatgcaatag tgagtcagac
tggcatgggt ggggccacat gtcctggcag gcactgtcca 9180ggcagctggc
atgagggaga ggagtctttc ccagaagtcc gccctgagaa accaaggctg
9240ggctgctctc ctggagccag gggagtccag tgagtgtttt acatacaact
ctaggtacgt 9300ggttggtggg atgggcagtt tgtgctggga agaggcttgt
ggaggatttt ggagaaggca 9360ggagagctct ggccctccct gcaagggagg
cttcaggtca gagcctgagg aaagacctgg 9420gcatgagata tgaggtctct
ggctgggtag agagcatgaa ggacacatga gatctggagt 9480ctggatgaac
ttgctgacaa gcaagctttt tttgactgct aatgcgtaaa tccactatag
9540aaattttcat ttgtcatttt tgtacttatt ggcaaaaaat tagagcttat
aggcatcaga 9600tttaatttga gatagttgaa atagggtttg tgtttgaggc
caatataatt ttatctgcta 9660atggcatctc gtggacttgg aggcagccct
tctgtaccag aacattgtca aaagctttta 9720ctgtaaagct tgagaacaaa
ctagtttgct ggatttgggc atgtaactaa caggtttgag 9780gcatgggatt
atcctgtgga cttttttttt tttttttttg ctttgaggtt ctgaatgtat
9840taaggttgac cttcttaagc cgttgaaact gttctgcagt acatttgtga
tgtagggcct 9900aagacttgta tcgttttttt tttttaatca caacccagtg
tacagaactt gagacatgcg 9960tcttttctct gccacctttt aaaagcagat
tattcttgaa gtgcatagag cagcaattga 10020ttaatggaat tggtgtcttc
acatttcatt tacttcctcc caacaatttt ataggatgca 10080tataaatatt
tccaaaagag gtacacataa tttcttacta taaaagtatt tttatattta
10140tatcagtaaa tttgttaata aagaggattt ttttttttct gtaatcctac
caccccaatg 10200acgtcctatt aaaatttcag tatatatcct cccaggtctt
ttaggtatgt ttaatttggt 10260gtcccttccc cgctcccaaa aggggaggga
ccaggttctt gtatagaata gtggaatgtt 10320agtaaatcac aggtttaaag
agacataaca gtggaatctc tagagcagct gtcacctgga 10380tacctggtta
ttaaggtaat ttttccatta ccccaaagag ctttagttac actcagcttt
10440ttccttaatc cttgtgcagc tctccagggc acaccgtatt cagctctgag
cggtctttgc 10500tagtgaggcc aaggagccac cctgagccaa aaggggagca
ttatgtcacc ggaagcccaa 10560ccccagagaa ccaaaggtat gacctgatat
tcagtggccc cagccaggtc tttacaggaa 10620gaccctcata tctcaggtct
aagaagagcc agctgatggt ttttaaaaag agtggaatta 10680gttactccaa
cccacttatt cagatcttat tttgttcaca atacagtccc tagattgtag
10740gcccattgga ggccacagca aagcctttgt gttccagttg gcctgatgtg
ccatctctca 10800gtaatgttcc cttaacagcc agacttccct aagcccagct
gggagctctg aaggtatgcg 10860agccctccct caaccatgag tgtagggaaa
gggaccaggg gccccaggct ttcctgtcag 10920taatgcagaa gttcctcaga
tttagggaag ggggagcaga ggcataactt tgattctgac 10980aaagaggcat
tcagagagac tgaaaggtca tttaacaaac actggaatgc ttccacatac
11040taggtgctag gagatacaaa accatatagg tcctggaagg gaggattgat
tttttcattt 11100tggtacgtag tagatattag gggcttagga aatacacatc
gaaatgaaga gtgcatttgc 11160catgttgaac cgttagccgg tatcttattt
ccccatttta aaagttttag aatctgtggt 11220tgaggacttg tggccatcag
ttttccatag ccaacagact gttcactact gccttcagag 11280ctccttggac
ctcagcgggc cttctttgga gatggcagag atggatttag atgtatactc
11340tactcgagcc acccagagag cccacaaagt cagagatgga acagggtaaa
ggagtaaggg 11400tcatatgtgt gagatgcctt gatttggaac tttgagattt
aggatgaggt ggggaagggc 11460taaagaggag cttgttcctg agccttgctt
ggccgaagca tttaggctca agcgttttag 11520aaagagtagc ccttggtctg
agaactcaag gaaacagctt tctgatgaga cgtgtagcaa 11580gcttctggtt
cacatcctta cctgatagtt cttcaaacac tgcctggtct ggttcacatc
11640cttacctgat agttattcaa acactgcctg gaagcttctc ctgagttttt
gtctctaatc 11700agctaactaa caggctgagt gagtttagtt gtaagtcatt
aatgaagaaa gcaaaggttg 11760gggccattgt cagggttgtg acctgggcta
gttaattacc tggaactgat ggtctgtgtt 11820acagagtggt ggtatacttg
tcaggcttag aaaagaaatc aggatgtgta tcaaaaatca 11880tttggggaaa
agatttgacc agcaacttta atttctctat gtttgcaact atcctgttaa
11940tgtagttgtg ataatttcag aattatacca gtgcccttat gttatccttg
ctttgcaaat 12000tgcaaattgc tttgcgtgtc ctgacatcct tctggccaac
agtagatgtg gttttaggtt 12060tagactcctg ggatggaagc ttttgcattc
aggggaatga ctttgggttt gggtgaggat 12120tgtaaagagg caatatgggt
gccccacgac aaagcagcta tttgtagctt tgtgacagct 12180tgacatgcag
agatctaggc ttatcaaggc actaagctag gagtcagttg tttgtatcac
12240tggaagattg gttacaactt ccttcattgg aagctccttc agtgcatgtt
aaatgatgtt 12300atttatagat agggtggtga gaaagctgtc taggtagatg
tcagtcagcc cagtgtaaga 12360gagacctgct tactgtgggt gcttgggact
atgtggagtg ggtgggaggt tttaacttgt 12420tcagtaaggt cctttccatt
gttcacaatc tggtgaaccc tttttctaac atgaggagca 12480cccacataac
cagatcatgt ctggcttccc tgtggcttgt gtacaaagcg tgcttattga
12540gttaatgtgt aagcaggaga cagccttctg tgctaaatgg tatattaacc
acttctcagt 12600cttaccactc tctttcaatt tgtctcgacc caggacctca
gcagccatgt cgaagcccca 12660tagtgaagcc gggactgcct tcattcagac
ccagcagctg cacgcagcca tggctgacac 12720attcctggag cacatgtgcc
gcctggacat tgattcacca cccatcacag cccggaacac 12780tggcatcatc
tgtaccattg gtgagtgggt gtgccccttc ccccaaaaaa gggcttcatg
12840ggcagtgacc tttctctcct gaaaagagta actaaatgtc ctaacaaacc
taggtgctac 12900atgggatact acacagattc ttatgaaagg actcaggtca
taggaagttg cagtaaagaa 12960ttagtatgtg cataggatgg caaatacagt
taataagaga gtattagaca tttcaaaatt 13020gctaagatgg cgaggtatgg
tggctcccag cactttggga ggccaacgtg ggaggattgc 13080ctgagcctcg
aaatttgaga ccagcctgag caacttagac cctgtctctc caaaaagtga
13140aaaaaaaaaa aaaaaaatta gctgggcatg gtggcatgca cctgtagttc
tggctacatg 13200ggaggctgag acaaagatca cttgagtcca ggagattgaa
gttgcagtga gccatgatca 13260caccactgca ctccagtcta ggcaacagag
cgagatcctg tcttaagaaa aaaaaattgt 13320ccgggcgcag tggcacatgc
ctgtaatcca gcacttcggg aggctgaggc aggtggatca 13380cctgaggtca
ggagttcgag accagcctgg ccaacatggt gaaatcccat ctctactaaa
13440aatacaaaaa aattagccgg gggtggtggc gggtacctat aatcccagct
acttgggagg 13500ctgaggcagg agaattgctt gaacctggga ggcggaggtt
gcagtgagct gagatctgac 13560cattgcactc cagccttggc aacaagaacg
aaactctgcc tcaaaaaaaa aaggaagaaa 13620aaagaaaaaa acatcgctaa
gagtaaattt caaatgttct caccacaaaa atgttaagta 13680tttgaagtca
tggatatgtt aactaacctg atttaattat tccacattgt atccaaactg
13740tatgtattgg attacataac tttgtaaccc aaattataaa ttaccagttt
ataataaaaa 13800ataatttgtt gcaaaaagaa tccatatggt ttaggtttta
tgctataggc aaaatttaga 13860agatgttttc cttagcaggt ctttgtagga
gcaacttaaa gacctaggaa agatctttct 13920aacatgttct gtgctaccaa
gattctgtgg ttggacatct ggctgggttt cagtgagggt 13980ggagaaggct
ggccaagtct taacctaggc ttttctgata cagtgggagc ctgcagaact
14040tgaaggaaat ggtcgaagtg tcccagtaga tcaagaaagt aagctggcac
ggtagtagcc 14100ttccatgcac tttttaaaga cttttgagct atttgggaga
ggaaaagttt tcagggaaaa 14160aaattcttta aacttaagca aacttaaatg
tttttccttc tttgaataat taatacttgt 14220ggctttaaaa cttttcctaa
taggcccagc ttcccgatca gtggagacgt tgaaggagat 14280gattaagtct
ggaatgaatg tggctcgtct gaacttctct catggaactc atgaggtgag
14340ctgtggctgg accctatggc cattgtgatg gcctgtagga aacagggagg
gggtgcagtg 14400ttcgtttagc cacagtggac tagacaagga tgagtctgag
tttcacagtc agtgtgaagt 14460ttgtctttac tagcccatcc ctactctcct
tccctcttgt cctgacaaag caactggctg 14520agtctctttt agcaaaaagg
accccctttg ttgctggctg tggttctccc acacacctct 14580cctaccctta
gcttttacaa aggaagatat ggaaaggttc tactggaaaa ccctctaagc
14640cttaggtgtc ctggccacag cgcttgactc tcctgtccca gggtttctgc
ttcaccttgt 14700gttgccatgg taaaccatct agcagattga ttctagctta
gaaccaaaat aactgggcag 14760gtccatgaga acggtttcca ctattctaag
ttttgaggga ctgagcctaa tgcataagca 14820ctatctgggg tgtaataccc
cacttcctca gcactgtatt ctcagcctgt gccttcccag 14880gggttctggt
acattaaaat aacaccagtt agcactcttc cccaggagcc tagtaggact
14940gtatttgtgc tgggctcttt attagctggc tttacctatg gacagaggcc
ttgcccagga 15000gccaggtagc agctgttggg atggctccat tcctgcctcc
attgccagat ttagaattaa 15060cccattctga ggagcttggg gttccctgag
gtaccatgac ttatttattt ttttatttta 15120taaaacaaaa ttttgctctg
tcatccaggc tggactgcag tggtatgatt atggctaact 15180ggatccttga
cctcccaggt tcaagtgatc ctcttgcctc agcctcccga gtagctggga
15240atacaggcat gcaccaccac acctggctaa tttaaaaatt tttttggggg
aaatgaggtc 15300tcactatatt gccttggctg gtctcaaact cctgggctca
agtgattctc tcaaatgttg 15360ggattacagg aatgagctac catgctcagc
ctgggattgt gcctttttaa aaccttcaga 15420cttaaccata ggtttcccat
agatcatggg atttcgtaat ggcattgata agaggaatta 15480cagaagaggc
aaactttgca cctgtcttgg cttctgtatt tcctgttgag agtaaagaaa
15540atgctatcct gtaaggccaa ttgccttaca gaggttgccc tctggcattt
ggaagttggt 15600attaagtttg gactaaaaat aaagcctcag gaaatgcaat
ccaagagtga attcctcctt 15660ttgggaaaca caagactctt catcatagat
tccctaacct gtgttcataa acagcctatg 15720gcctggctag tggctggccc
ttaaatgtca tggggacctg accaagtcca gcagacatac 15780catgtaggtt
aagacatgtc cctgtacctt ttggaaaatt ctgtagtttt ccaaaagcaa
15840ggggtcctta gcaggagtca ccgagaatta cttgttagag aattaagtgt
tagcttagct 15900tagagagagc tgaagacaat gctggaggtc tgttcgctgt
tgatccctgc tgctgtagtc 15960tgccatgggc tcctgcattc aggggaagga
gcagaaatag atttttaaga agttgacctt 16020taagtaggct ttatggttcc
ttcatccagt aaaataacac cacatagctc taacatggca 16080agggcgagtg
atacctgcca cacctgctgg atgagagctg gctccgattt tggtatttta
16140aactttaaga ggcttttgga gattatctct actttcactc ctattcccag
attataatta 16200agatttattt tttatttttt atctatttat tttttaaaga
tgtccctctt gtgtgttcat 16260tttgaagttt tagaccaaga tgaggttgtg
tgtgggctca gcttggaaac tgatctgaaa 16320ttattctaat ttatataatg
taatgtaaac agtttcagcc ttaccatacg tcagggctat 16380cgtttcatgt
gcacctttga ctaggggctg gggcgtactt ttccagtttc tgactatttt
16440aaatgctctt ctgagcagaa cgttgagatt actgtcttcc ctctcactct
gacagaggga 16500catcaaatgt ctgcatctga tcttttaaca gctttttttt
tttgagacag aatcttgctc 16560tgttgcccag gctggagtgc actggcacaa
tctctgctca ccacaacctc tgcctcccag 16620gttcaagcaa ttctcatacc
tcagcctcct gagtagctgg gattacagac ctgtgccacc 16680acgcccagct
aattttttta tatttttagt agagacgggg tttcgccatg ttggccaggc
16740tggtcttgaa cttgtgacct caggtgatcc gactgcctcg gcctcctaaa
ggcgtgagcc 16800accacgccca gccctctttt aacagctttg gcaactagtc
ttcagccctc acttttggca 16860gttcacatgg gcaagatgca ttcttgctga
acatgtggtt ccatatgcca tgttttccag 16920atttatttat ttatttattt
atttatttag agagggagtc tcgctctgtc atccaggctg 16980gagtgcagtg
gcacgatctt ggctcactgc aacctctgcc tcctgggttc aagagattct
17040tctgcctcag cctcctaagt atctgagatt acaggcacct gccaccacac
ccgactaatt 17100tttgtatttt agtagagact tggtttcacc ttgttggcca
ggctgatctc gaattcctga 17160cctcaagtga tccatccgcc ttggcctccc
aaattgctgg gattacaggc gtgagccacc 17220acacctggcc tagaaataat
gacttttaaa caacctaaat gtagagcctt ccacaggaca 17280gcattgatgg
atgctttacc acataacatc ccaataaagc cacagctgaa gtggaagact
17340cagtacacct cccagagatg ctctaagaga ttatgatata tgacatagat
ttgaataata 17400tacctaataa ttggtatgtt tataatatat ggttttacat
ccccaagacc aaaaatgcat 17460gtttgcatga aacactcatg gttacaaaaa
tatattaggc caccaaaaaa acccccacgt 17520ttcataaagt agaaattata
cagacacatt ctctgataaa attttttagt ggaaattaag 17580aacaaagtca
agaaaactga agtgtgctta ctttagaaag caaagatctc aaggtagatg
17640aaataaatat ttaactcaga acactagggg aggaaaaccc taaaaagggt
gaagaaaata 17700attttgtaag attatagctc aatgaaatga aaataaattt
gacagattaa gctaagagct 17760gattctttgt ggggaaaaaa tagtaaaata
gaaagttctg agaagccagg tgaagaatgc 17820gaggatgtgc aaataagagt
atgaatagaa aagagaatat ttcctacaca ttggagattt 17880taaaagtcaa
gaaagactta taacttaatt cctatataga gagatgactc tggctatttt
17940caaagaaaag ataaatatcc aaaagataga aaatatgaat agaccagtgg
ccataagaag 18000ttgaaaaagt gggctgggcg tgcggtggct cacacctgca
atcccagcac tttgggaggc 18060caaggcggag ggatcacttg aggtcaggag
ttcgagacca gcctggccaa catggtgaaa 18120ccctgtctct actaaaaata
caaaaattgg ctgggcatgg tggcacatgc ctgcagtccc 18180agctactcgg
gagcctgagg caggagaatc gcttgaacct gagaggtgga ggctacagtg
18240agccaagatc gcgccactgc actccagcca aaaagttgaa aaagtgatta
agatctggtt 18300cacctcagaa cacttaagtc caaatgattt tagtggctga
attgtctccc cttcaaagtt 18360cagttacatt gttaaactgt tccagagcct
agagaaatat agaaatcttc ccactgtgtt 18420ctttgaaacc aatatacgct
gatactgaga tcaaacaagg acagtaccaa aaccaggcag 18480gtactaacag
ttagtgtgct agaccagtct cacttagatg cagaaaacaa ataaaattta
18540ataatccaaa tccagtagtg attgaaagga atgtcttgat ccatgaccaa
gtagatttta 18600ttctaggaga acaaaattct acatcgggat taagtagagt
taaggttgac attttttttt 18660ttttcttctg agacggagtc tcgctctgtc
acccaggctg gaatgcagtg gcacgatctc 18720ggctcactgc aacctctgcc
ttccgggttc acaccattct cttgcctcag cctcccgagt 18780agctgggact
acaggcgcct gctaccacgc ccggctaatt ttgtttttgt acttttagta
18840gagacggggt ttcaccatgt tagccaggat ggtctcgatc tcctgacctt
gtgatccccc 18900ctcctcggcc tcccaaagtg ctgggattac aggcgtgagc
cactgcgcct ggcctgagtt 18960aaggttgact tttaaacaac ctaaatatag
ctaaatatag agccttccgc aggacagcat 19020tgatgtgtgg aactcttatc
cacgtgataa catcccaaca aagccacagc tgtagtggaa 19080ctcagtacac
ctgagtctta tcattataag atgataatag gtaacattta ttagataatt
19140accatgtact ttgtcctaat acttcatgta ttcttttact cctcacgtca
actctgaagg 19200aaaggcacca cctatcccct taaaagaaaa caactattac
tattcttttt tttttttttc 19260ttttagagac ggaatctcac tctgtctgtc
gcccaggctg gagtgcagtg gcacgatctc 19320ggctcactgc aacttctgcc
tcctaggttc aagtggttct cttgcctcag cctcctgaat 19380agctgggact
acaggtgcac gccaccacgc ccagctaatt tttgtatttt aagttgagac
19440gaggtttcac catgttggcc tggttgttgt caatctcttg atctcatgat
ccacccgcct 19500tggccttcca aagtgtttag atgacaggtg tgagccaccg
cgcccagcct ctattctatt 19560ctattttgtt ctatttctat tacaagccag
taagcaagaa aatatcataa tttataagga 19620accctataaa aaacagacaa
gccaagggtc tgtcattagg aagtatgcct gaataagaag 19680ctgaagattt
ttagacacag gtttcaggca acactgtctt tagaggctag gctctggctc
19740cagctccctc cagcctcctg tgaataacag gcaggcttac ttgcaggtgc
cactttcctg 19800gacagtggtg gttaaaggac aaggcccaga aagtgctgaa
ttaggtgccc ttgttaccgc 19860taatgtctta ttgatgacac tatcttagag
ctcttttgac atcttggctc tgcgtctttt 19920tttttttttt ttcttgagat
agggtgttgc tttgttatcc aggccggagt gcagtggtgt 19980gatcatggct
cactgtagcc ttgacctcct agacataacc cacctcagcc tcacaagtag
20040ctgggacccc aggcacgcac catcatgcac agttaatttt tgtgtttttt
gtagagacga 20100ggtttcgcca tgttgcccag gctcatctca aactcctggc
ccaaactgtc ctcccacctt 20160agcctcccaa agtgtttggt ttataggcat
gagccactgt gcttagcctg agtccctctt 20220ttaaacaaac aaaatggtaa
atggaaagga ggaaaggctt aagaaaaaag attgaagcca 20280ggatttgttg
taagcaagga gtaataaagg gcagttcatt tagagaaagg catatgacca
20340cctttccccc tccaatcaga atctagaaag tgattgaggc cgggcgcagt
ggctcacgcc 20400tgtaatccca gcactttggg aggccgaggt gggcggatca
cgagatcagg agatcgagac 20460catcctggct aacatggtga aaccccgtct
ctactaaaaa tcgaagaagt tagccaggcg 20520tggtggtggg cgcctgcagt
cccagctact cgggaggctg agaggcagga gaatggcgtg 20580aacctgggag
gtggagcttg cagtgagcct agatagtgcc actgcactcc agcctgggcg
20640acagagcaag actctgtctc aaaaaaaaaa aaaacaaagc gattgagaaa
atcaggtctg 20700tgtgacctta gcaatgagtt atttagcttg ggccactgtt
agcttaagtc aataacttca 20760agtttgcgtt gtagttggaa tcaatagagg
aaaagctctc agcattacca catatatcag 20820aatgtgacat tgattgccag
accagcctta tccaaacaca agtcctaggc tttttgccct 20880gtttatgagc
tttatatgct gagggtattt gatgagtctt agggaaaaaa gaacagccct
20940ggggacacag ctgcttttat gatgagacat gtttgcaccc ataccttaat
gggttttggt 21000ggcaatattc tgaaatttgc cacctacatt tcaaagattt
gccctttggg tgaattagtg 21060ctgtagtaga agtgggtgga ggctgaggag
gttggattaa gcaggtagag gatttctcag 21120tgcatggatc gtgctgagga
tggagataga gctctaagac atccacgggc ctttcctgag 21180tgatcagctt
tggctcctgg gcaggggaat tggagctgga ttctagtgtg ggagcacgct
21240tgtcatcttc cttcttttcc cccagtacca tgcggagacc atcaagaatg
tgcgcacagc 21300cacggaaagc tttgcttctg accccatcct ctaccggccc
gttgctgtgg ctctagacac 21360taaaggacct gagatccgaa ctgggctcat
caagggcgtg agtattctgc ggagagcgag 21420gggaaggctc agtaggcaat
atgccccaga gacatgtcct ccaaagcgct gggttgccat 21480gtttcttccc
agtactatga aggactgcag aggagttgag gtctacaaat gaggatttat
21540tcatcactgt aaacaatgtt gatttgatct actttgctag gaaatggtac
cacaaaggaa 21600cctttttttt ttaccctaaa aacctaaact ttaggctttc
taacttggag aaccatctct 21660ttgtatcttt ttccccatca ttaagtagca
taactgaaac atattctttt cttggattat 21720ttccgtgaag tatacagagt
tagagaataa gagcaaaaaa ctgtattact tttagcagtg 21780acttgagcat
tgttcccggg aggaaagagc ttttccattc cttctgaggt gatgctgcta
21840ctggtgtctc cagtttggac tcttgcttac tctcttgtcc ctagagcggc
actgcagagg 21900tggagctgaa gaagggagcc actctcaaaa tcacgctgga
taacgcctac atggaaaagt 21960gtgacgagaa catcctgtgg ctggactaca
agaacatctg caaggtggtg gaagtgggca 22020gcaagatcta cgtggatgat
gggcttattt ctctccaggt gaagcagaaa ggtacgtatg 22080ggagctggag
tccagttgtc taaaacagtc ttttgtctct aaacttcctt gacacaagga
22140agatgggaag gttggttgcc tggcagtgag attgagtctg tgtgttctca
ggaatccctt 22200ttataactca tttatcctca aagataggct ttaatccagc
atagttacat tcttctggtt 22260ctggagaaca caggaacata catacatata
tatatatata tacatatata tatatatata 22320tatatatata tatatatata
tatatatttg tttcgctgtg ttttgttttg ttttcaagac 22380agagtctcgc
tctgttgccc aggctggagt gcagtggcat gatcttggct cactgcaacc
22440tctgcctcca gagttctagc tattctccta cctcagcctc ctgagtagct
gggattacag 22500gcacccgcca ccacacccgg ctaatttttt tgtattttta
gtagagatgg cgttttgcca 22560tgttggccag gctggtctca aactcctgac
ctcaggtgat ctgcctgcct tggcctccca 22620aagtcagaac agtcttaatt
atccttattt atgggtgagg aaagtgaggt acagagaggt 22680taaatggctt
gcccaggatt acacagtgta gtaggttttc aactctggta aaacagctcc
22740agcacccata atgcaccact tcccagctca ctgtccttgc gggaaaggtg
cctgcttcct 22800gttgacctgt gccctcgtgc tctgcctccc ctacttaccc
tttttcatac aggtgccgac 22860ttcctggtga cggaggtgga aaatggtggc
tccttgggca gcaagaaggg tgtgaacctt 22920cctggggctg ctgtggactt
gcctgctgtg tcggagaagg acatccagga tctgaagttt 22980ggggtcgagc
aggatgttga tatggtgttt gcgtcattca tccgcaaggc atctgatgtc
23040catgaagtta ggaaggtcct gggagagaag ggaaagaaca tcaagattat
cagcaaaatc 23100gagaatcatg agggggttcg gaggcaagtc cccgttgtcc
ctgctccagt cccagcgcag 23160ctctccgaag ggcatggtcc atcctgtgaa
tgtctgattc ccagccccta gcccatcaga 23220atgtagactc ccaagccagt
tccaaacctg ctgaatcaga atatcttagg agagtagaag 23280gcattatgtt
tttttgtttt tgtttttttg ttttttttaa aaaaaagctt cccaggtaat
23340tgagatgctg gcagcttgac attgttccct gggcctgggg accaacattt
gagagaacag 23400ggtcactgct cacaggacca ggggccatga tgttctgttc
ctgatcagaa acactaccag 23460tgtttgctgg aatgggggga ccagggggaa
agatgacagc agacacttaa gaaagggctc 23520tttttggccc ttcctgggga
gccatgtgga atttcagggc ctggtgtcca tgttaaagct 23580tatggcctcc
tggtcttcac ttagaatgca gctggctcag tgatcatgct aactctggta
23640tggtccattc cactctcaga ggaagatgtg tggttcttct ccagtttcag
attgccccaa 23700cttagcttac cccctcccca atgctcacaa agtagagccc
agtgggcatg gccaccattt 23760ttggcatcct gctaggaata caactcagca
caactaagat gctagacaca ctcttgtgga 23820ttagaagtgt gtttggggag
ggtgggggag caaccctgtg cacccactgt agtggcctta 23880ctgtctgagc
tttgtgtaga tatcctctgt accaggcaat ttggggtcct cccctttgcc
23940atcctgataa gccataggct agctgaactt ggccctaggc caggcaaagc
cacattccct 24000cttgccttca gcaggttgga gtgggccacc tcaaagggca
gtcctcaagt gtccttgact 24060agatgaggcc atgggtcttt gtggtggaag
cagtcatcag gcctcaggtt ccctgtcttg 24120aagtgctgat tggaaaatgg
aggccctaga gagaccccta acatgcatgg gatttggaga 24180ggagaccttg
ggaatgagcc catttggatt tgccctctcc cctttcttcc gtcaatgaag
24240catccatatt ggtgttgaag cccagcaggc agaattgttg gcccactctg
ggggcctaag 24300gtagctggac tgccttgcca tctgtgtgca cccatgatga
tatcatggat gtctgtcctg 24360gtacaaggac atctaagtta gggaatccca
gggaaacttc ttgtctactg ccatacttgt 24420ggcctctgtt ctatataacc
tctctccccc caactttgtc catcaggttt gatgaaatcc 24480tggaggccag
tgatgggatc atggtggctc gtggtgatct aggcattgag attcctgcag
24540agaaggtctt ccttgctcag aagatgatga ttggacggtg caaccgagct
gggaagcctg 24600tcatctgtgc tactcaggca tgtgcccacc cttccccaca
ttctcatgtg cacactcgca 24660tgtttgtatg ggaaagctct ggaggctgtc
tgatctcttc ccatggaatt gtcgcacgta 24720acacacagat aatccccttc
ccccatgtac ctacacaaag ccatactctg tgtacctact 24780cactatccag
aggatcagct tgctgtcatt tgtctctgaa gacagctcaa gctacatctc
24840actaatgctc tgtcccctcc cagatgctgg agagcatgat caagaagccc
cgccccactc 24900gggctgaagg cagtgatgtg gccaatgcag tcctggatgg
agccgactgc atcatgctgt 24960ctggagaaac agccaaaggg gactatcctc
tggaggctgt gcgcatgcag cacctggtga 25020gttctggggc ctgccccatc
ccccagggct tcggactggg cctgggatgg atgcaagctc 25080tggtgcagag
ctttttaggt ttctccatcc tcttatgcac agcctttcat tatcctccaa
25140gttacagcag caagagggtg ggggtggaag tggaggtggc tttttttttt
ctcctgttct 25200gcattcctgc ccacaccccc acccctccat ttccttctgc
tctggaggca tcctccttca 25260ttggacacca cacagtttat ttcacttctg
acttcaaggt tgtgaattct tcccatggct 25320taagtcctgg gatacttctg
cagtgaaagg aggtcttgta cctcttcctc agagtcagaa 25380gttctgagta
cctttgccct attctgaaaa gggctagggg ctcctgctcc cagctgccct
25440cttcctttgg cttccaattc agttccctct gccccgcatc ctgcagacag
gcgctcccgc 25500agggggccct tgtggacctg cactggagtc tgttgccttc
actgagctgc ctgtgctggc 25560cttgcatggt gcctgtaggg ggatttgctt
tgctgtgcca ttggggtaca gctgctgctc 25620ttactctaga ccaaaaagtc
gggttgagtg actggtggca gggccacaga tagagacagc 25680ggggagggtg
gctgaccctg gcggccctgg actgagcgtc tggaggagtc gtggaggctc
25740tttcccttct ttctcctctg agagctcgtt cttcaggctc ttccagcttg
tcatgtcgag 25800tgcctggcca ctgctcaggg ttggaggctc agtccctttg
ccctgtctgt tccagctctg 25860gagctaactc agggatccct gatcagggtt
acataggttt ggtaaaatga gtgctggaaa 25920ttaactttct cccagtagtc
ttaggtcatg ctcagtgaac ttaaacttta tccagatatg 25980gttttccttc
agcctttcta ttccctttct agccagtgaa agacccgctg ccctttgacc
26040tcagcccctc caagccccca agtttaaaac gccaccccct gccaccagaa
aaaacagaaa 26100aaaaaaaaaa aaaaaaaaac taaaacaccc atctggtctg
ggcatcttcc tttccttttt 26160cactatgtat cctgttactg ggcttaaaca
gctttcagag aagagatgtc atttctatta 26220aatgctcttt cagtagcgaa
ctgagttcac acttgactaa ggatattttc cggactgtct 26280gtcatcagca
tccttagtgg gtttccccat atttaaattg gtagaggcca gggatggtgg
26340ctcacacctg taatctcagt actttgggag gccaaggtag gtggattgct
tgagctcaga 26400agaccagcct gggcaacctg gtgaaaccct gtctctacta
aaaattcaag ttagctagct 26460gggcatggtg atgcacttct gtagtcccag
ctacttggag agggggtgat gctggggcag 26520caggatcgct tgaacccagg
aggttgaggt tgcagtgagc caagatggta ccagcctagg 26580tgacaaagtg
acaccctgtc tcaaaaaaga aaccaaacaa acataaaaaa aaaaacaaaa
26640aaatcggtag agagtgattt ctctcccagg cccacttaat gtagactggg
cctggctgac 26700acctcaccat tcgtgtgatg tgattgctgt tctgatgctt
agatactctt ggcgcagtct 26760cacaattgcc accatggtag gaaggtgtcc
caggagacgg tgcaccttga accagtcacc 26820actaaagtgg ctgcctttct
gggtctctcc acacatcccc tctctctaat ttccctactt 26880aatcgtgtga
cttcatggtc tcaaaggagg aacagaggct gatcttgact tagatatact
26940gaaccatgaa atcactgcat agaatgtggg gacttgaatg tgtctttggg
caagtcattt 27000aacctcttaa gacctcatct gtaaaatgga ttagatatgt
ttaattatag ccttagcatt 27060aaatattcat tgctgttatt attaagtgtc
tgataagtct ctgtgtacat ggatgtaatc 27120ttcctaactc ccattacctc
catttataga tgagggttat atggccaata aagcctgggt 27180ttgaatctag
gtctactgcc tccaaagcca gtcttctctc ctgcaacatc atgctctgtc
27240tagcaggaga tgagaacagg tctccatttg gagcctgtca gtggggtcag
agactaagat 27300tcaggctcag ggtctaaatt ccatatcctt tcttccatac
cctggtgttt cctatgaaca 27360gatagatact ttagggctgc aaggtttgga
ttgcatggca ctgctcagaa gataagttac 27420aggtctgggc taggctgtag
ctgcccctcc aggtggctag acctttcctt tctgtgtcac 27480cagttaacac
tggccaacag ttccttccat taactgttca ctgctttctc ctgtgtctaa
27540ctgatgcagt ttatgaccca taactaagag cagtaccagg tatggctctg
tttcctgttc 27600atgtcccctg tcctctgggc tgcatgcatt ccgttcttac
agaaagaata cctttaacct 27660agtacatcct gccacacatc tgcttctact
gtgaaattga tgagggggta ttaccgattc 27720ttccctcacc catcatttac
tgagatgctg gtgattgcat tataatcctc taaagcttac 27780attgtctttc
tgattcttgg tcttatctga gcaagtgatc tataaataac tcagtggctt
27840tctcatgact gttttaatta ttagatttta atcaagtgtc ttattaaata
tatctgcatg 27900cttccacagg catctgtctc ttcacatggc tgttcagtgt
gcctctcaca agttagccca 27960cgttttctgt tctcctgctt caaactcagt
tgagctgcct tgctttggct ttgatcccag 28020ctttccagcg ctgctcaatc
tgttgccatg gcaggccatt ggaaaggctc agtgcatccc 28080cgtgcctgaa
gccaagtgag cgctcactcc atgcatgcat ggaggctggg caggagcctg
28140cctaatcaac cagccatgtg aggagggagg gcctgttcct tcctgtaagc
tatgtcatga 28200ggcagcgtgg tcaagtcctc tgccagggag tggcctgggc
ccagcctggg catgttttca 28260tgccagggtg ctagagccta ctgccagatt
gtctccctcc acccccaatg aaaaaatcct 28320tccagaaggg aagagccaat
ttcccctgta ttggagggga agtggcagca cctcctgaag 28380cagttggact
ttcatcaccc tacctctgca tctgcctgaa ggacagattt agccaattaa
28440cctaaggtta ccttcctctc tgataaattc cccattctgt cttcccatgt
gttgtgtctc 28500gtttttttcc tcctccttcc ctcttccttg ccccctcttc
ccctaaacct tacagatagc 28560tcgtgaggct gaggcagcca tgttccaccg
caagctgttt gaagaacttg tgcgagcctc 28620aagtcactcc acagacctca
tggaagccat ggccatgggc agcgtggagg cttcttataa 28680gtgtttagca
gcagctttga tagttctgac ggagtctggc aggtagggcc ctaagggcag
28740gtaacactgt taggataacc agcctcttgc tccacctgct ctaggagaag
acagccaggc 28800ccaacctggc atctgggcac agagcctctt ctcgtctgta
ggaacaccgc cagggaggtc 28860atggcagggc aggaccaaag ggtcctgtgg
ctcagtaggc acagtagatg tcacaggcac 28920ttggtgaagg actggtttct
gtggagtctt gatcttggct cagctcagaa tctccagtga 28980ttgggctcct
cttggccttt gttcccagga acatgttcct caccagctgt ccggtgactc
29040ttcccctccc tctccttttg tgacaaagct ctgacaaagc tctgtccccc
tctcgtccct 29100ctggacggat gttgctcccc tagattgccc gtgaggcaga
ggctgccatc taccacttgc 29160aattatttga ggaactccgc cgcctggcgc
ccattaccag cgaccccaca gaagccaccg 29220ccgtgggtgc cgtggaggcc
tccttcaagt gctgcagtgg ggccataatc gtcctcacca 29280agtctggcag
gtaggaggcg gcagcggctc cctggaatgc cctgctcagt ggtacctcac
29340cttgggggtc ctgggagcag tccattgaac aatgctcagg tggcactgag
ccaaggtaag 29400acccctctgc ctgccacctt gggcctgcag ggaaggattg
agcagagccc cttccctggg 29460cccaaaggac tctaggtagc actcataagg
aatgtcagaa catttggatc aaaagcaaat 29520ttatgctgga gatttattac
ataacagtgc acaggctgac tacaaatggt tatttgatat 29580tgaaaattta
gtcctctaaa attgtaaaag ataaccactt ttgcttattc cagttactat
29640gtgctcttta aaaatttcag ttgggaaatg aatttattta aatgctgttt
actgtgcctc 29700catttggcac actagtccct gctgtttttg agccctaaag
acaaattggg ttccagctca 29760ggagaggttg ctgtgctatc ttggctgaca
ttctgtgggg cctggcagcc aggctgagga 29820ctgtgtggcc tatgctgggc
ctccaacttg ggatcccttc cttggcccag gacattgagt 29880taatgtcctt
cactctccta gttagggagt atgctccttg tccctgtcca cagggcagca
29940agggtttcct ggaagagggg agcaaacagg cagtgcccat gcactgagga
gcagcagatg 30000ggcgtgggca gcccagagaa ccaggacaca agctctgtgc
agatgccctc agcagagggc 30060tccagcctcc cactcttggc tgaacagctc
caacccgtag
ggttgacctt tcttaaaagg 30120tccagttctt gctgtttggc tattttaagc
tctagtcttc tggggtttca ctcagctggt 30180cctggcttca gcaattgctt
ccctctgaag gccttgcata gaggccaagc gtgaagtgca 30240gggacttctc
tgctgtgatg tggcttaagt ttccctgaca cctgttgagt gtcctcataa
30300cttcccttct ggtgcccctc cccagctcct gagacacagc tgcagctaca
agtgtgcagt 30360gtcagtgttc aagaaagtgc ctggcagagg ggctttagaa
gggtcccctg ccttccaaag 30420gagctttggc aggcagagct gctcctgcag
caacactccc atttcctgtt cttgcctgct 30480gagtagcacc tagatttcta
agcctcatct agatactcag atttgattct gggcctttat 30540agcccagttg
ctgggactgt ttcaggagct aggggccatg tggggcaggg agagggcaca
30600aaagtagaga agcctgatgt tgattcccag ggggctggtc agctctgcta
ctgctccttg 30660cagatgtcaa gagtcaggtg ctagtcacgt gctgcttggc
ttgtcactgt cattggcagc 30720gagaggaatg ggtgctggtg acattgggcc
agggctgcct ctctgtgtca gagttcaggg 30780tgtaggaggg gttctgccaa
ccatgggctg tgtggggtaa gtgggtgagg ctgatcttgc 30840tgggtcaagg
tgatcctgag cccttggcct gtggaatggg ggtagagggc aaatggtaac
30900ctagcatgct gtgggggata taggatgagg ggctgcccga gcctcgggag
gggtcctagg 30960gagcagatgt tgaagaggcc agagccctca gtgagctgga
tgagagggtg agctgtttga 31020acgccctgag ggtacttcct ggggcctcgt
gtaatggtct cttctgtatg tcccccatcc 31080catctcaggt ctgctcacca
ggtggccaga taccgcccac gtgcccccat cattgctgtg 31140acccggaatc
cccagacagc tcgtcaggcc cacctgtacc gtggcatctt ccctgtgctg
31200tgcaaggacc cagtccagga ggcctgggct gaggacgtgg acctccgggt
gaactttgcc 31260atgaatgttg gtacgtggct ggagcagggg ctagagccta
gaggagcttg gggatgcttg 31320agcattggct tctgtgggac cccgaaagtt
tggggaatag aaaggggaac acacagacct 31380tagtggggca aaaggcccag
cgactgttcc tctcccttat tgggaatgtt cattctgaat 31440ctctcattct
ccgaagtcct aagctgagcc aggagggaaa agggtccttt gagttgtagg
31500gctgagcaat tcagttcctc ttctcttcta gtctggggct caaagcaaaa
ttgtccattt 31560tttggcatct gctcattact gagagttttt tttgtttttt
gttttttttt taaataaaat 31620tggccacagc tcctgtgctg tggggtggca
tacacagatt acgtactgat gtggccattg 31680tccctgtata aggtagggta
tcatcagatg acaggaagca gctagctctg accctgggca 31740aggctttgca
ccctctccag gatagtgaat gatgtccaaa ggtccctgcc aaccctgcca
31800tctgagtgat aaggacattt cagggccttc ctcctgtttg cctgggctgt
gagtttggtg 31860ccaccttgtg gtgtgaggaa gtagtggtca gccagcctag
ttcagtactc aggctatggg 31920gcagctgccc aggtgcaaac ctgcctggct
tggcttttac tcaccaacct cccttctctt 31980cctccaggca aggcccgagg
cttcttcaag aagggagatg tggtcattgt gctgaccgga 32040tggcgccctg
gctccggctt caccaacacc atgcgtgttg ttcctgtgcc gtgatggacc
32100ccagagcccc tcctccagcc cctgtcccac ccccttcccc cagcccatcc
attaggccag 32160caacgcttgt agaactcact ctgggctgta acgtggcact
ggtaggttgg gacaccaggg 32220aagaagatca acgcctcact gaaacatggc
tgtgtttgca gcctgctcta gtgggacagc 32280ccagagcctg gctgcccatc
atgtggcccc acccaatcaa gggaagaagg aggaatgctg 32340gactggaggc
ccctggagcc agatggcaag agggtgacag cttcctttcc tgtgtgtact
32400ctgtccagtt cctttagaaa aaatggatgc ccagaggact cccaaccctg
gcttggggtc 32460aagaaacagc cagcaagagt taggggcctt agggcactgg
gctgttgttc cattgaagcc 32520gactctggcc ctggccctta cttgcttctc
tagctctcta ggcctctcca gtttgcacct 32580gtccccaccc tccactcagc
tgtcctgcag caaacactcc accctccacc ttccattttc 32640ccccactact
gcagcacctc caggcctgtt gctatagagc ctacctgtat gtcaataaac
32700aacagctgaa gcacctgttt cctctctttt ctgctgggga gggggaggtg
gttgaaccct 32760gccctctgag caggctggga atggctgcag cctcgtgccc
cgcagtggga gctatggtgg 32820tgtcacctgc catcctgccc acctcctggt
gcagaggcgc tgggaaagca gtagcttact 32880atcttagggt tacaggttgc
ccccttcagt gctgcgggga gactttaatg gcttacgtga 32940accgaagatg
ggaaagagca gggacaaggc ctccctccca ctctggtaga taaacccaaa
33000ttgcaaagtg gccttggcca tggttcttcc actttggtct tcctgcatta
gcgtatccct 33060tatgggggct gtaggaggag tcagctctgg gcgcctgaga
ctgggtttgg ctccc 33115220DNAArtificial SequencePrimer 2agaaacagcc
aaaggggact 20320DNAArtificial SequencePrimer 3cattcatggc aaagttcacc
20415DNAArtificial SequenceSynthetic oligonucleotide 4aataattgca
agtgg 15515DNAArtificial SequenceSynthetic oligonucleotide
5cctcaaataa ttgca 15615DNAArtificial SequenceSynthetic
oligonucleotide 6gagttcctca aataa 15715DNAArtificial
SequenceSynthetic oligonucleotide 7cggcggagtt cctca
15815DNAArtificial SequenceSynthetic oligonucleotide 8ccaggcggcg
gagtt 15915DNAArtificial SequenceSynthetic oligonucleotide
9gggcgccagg cggcg 151015DNAArtificial SequenceSynthetic
oligonucleotide 10gtaatgggcg ccagg 151115DNAArtificial
SequenceSynthetic oligonucleotide 11cgctggtaat gggcg
151215DNAArtificial SequenceSynthetic oligonucleotide 12ccccactgca
gcact 151315DNAArtificial SequenceSynthetic oligonucleotide
13tatggcccca ctgca 151415DNAArtificial SequenceSynthetic
oligonucleotide 14acgattatgg cccca 151515DNAArtificial
SequenceSynthetic oligonucleotide 15tgaggacgat tatgg
151615DNAArtificial SequenceSynthetic oligonucleotide 16cttggtgagg
acgat 151715DNAArtificial SequenceSynthetic oligonucleotide
17ccagacttgg tgagg 151815DNAArtificial SequenceSynthetic
oligonucleotide 18gttcctcaaa taatt 151915DNAArtificial
SequenceSynthetic oligonucleotide 19agttcctcaa ataat
152015DNAArtificial SequenceSynthetic oligonucleotide 20ggagttcctc
aaata 152115DNAArtificial SequenceSynthetic oligonucleotide
21cggagttcct caaat 152215DNAArtificial SequenceSynthetic
oligonucleotide 22gcggagttcc tcaaa 152315DNAArtificial
SequenceSynthetic oligonucleotide 23ggcggagttc ctcaa
152415DNAArtificial SequenceSynthetic oligonucleotide 24gcggcggagt
tcctc 152515DNAArtificial SequenceSynthetic oligonucleotide
25ggcggcggag ttcct 152615DNAArtificial SequenceSynthetic
oligonucleotide 26aggcggcgga gttcc 152715DNAArtificial
SequenceSynthetic oligonucleotide 27caggcggcgg agttc
152815DNAArtificial SequenceSynthetic oligonucleotide 28gccaggcggc
ggagt 152915DNAArtificial SequenceSynthetic oligonucleotide
29gacgattatg gcccc 153015DNAArtificial SequenceSynthetic
oligonucleotide 30ggacgattat ggccc 153115DNAArtificial
SequenceSynthetic oligonucleotide 31aggacgatta tggcc
153215DNAArtificial SequenceSynthetic oligonucleotide 32gaggacgatt
atggc 153315DNAArtificial SequenceSynthetic oligonucleotide
33gtgaggacga ttatg 153415DNAArtificial SequenceSynthetic
oligonucleotide 34ggtgaggacg attat 153515DNAArtificial
SequenceSynthetic oligonucleotide 35tggtgaggac gatta
153615DNAArtificial SequenceSynthetic oligonucleotide 36ttggtgagga
cgatt 153737DNAArtificial SequencePrimer 37ggggaagata tcaattcccc
attctgtctt cccatgt 373837DNAArtificial SequencePrimer 38ggggaactcg
agctagacat tcatggcaaa gttcacc 3739110DNAArtificial
SequenceSynthetic oligonucleotide 39ccctaaacct tacagatagc
tcgtgaggct gaggcagcca tgttccaccg caagctgttt 60gaggaactcc gccgagcctc
aagtcactcc acagacctca tggaagccat 11040110DNAArtificial
SequenceSynthetic oligonucleotide 40ccctaaacct tacagatagc
tcgtgaggct gaggcagcca tgttccaccg caagctgttt 60gaggaacttg tgcgagcctc
aagtcactcc acagacctca tggaagccat 11041110DNAArtificial
SequenceSynthetic oligonucleotide 41ccctaaacct tacagatagc
tcgtgaggct gaggcagcca tgttccaccg caagctgttt 60gaagaactcc gccgagcctc
aagtcactcc acagacctca tggaagccat 11042106DNAArtificial
SequenceSynthetic oligonucleotide 42cccttagggc cctacctgcc
agactccgtc agaactatca aagctgctgc taaacactta 60taagaagcct ccacgctgcc
catggccatg gcttccatga ggtctg 1064388DNAArtificial SequenceSynthetic
oligonucleotide 43ttccccattc tgtcttccca tgtgttgtgt ctcgtttttt
tcctcctcct tccctcttcc 60ttgccccctc ttcccctaaa ccttacag
884426DNAArtificial SequenceSynthetic oligonucleotide 44agtgttacct
gcccttaggg ccctac 264525DNAArtificial SequencePrimer 45gtagggccct
aagggcaggt aacac 254627DNAArtificial SequencePrimer 46ggggaaggta
ccactgagca gggcatt 274737DNAArtificial SequencePrimer 47ggggaagata
tcaattcccc attctgtctt cccatgt 374826DNAArtificial SequencePrimer
48ggggaggtac cactgagcag ggcatt 264918DNAArtificial
SequenceSynthetic oligonucleotide 49tcatttgctt catacagg
1850110DNAArtificial SequenceSynthetic oligonucleotide 50atgttgctcc
cctagattgc ccgtgaggca gaggctgcca tctaccactt gcaattattt 60gaagaacttg
tgcgcctggc gcccattacc agcgacccca cagaagccac 11051108DNAArtificial
SequenceSynthetic oligonucleotide 51cgctgccgcc tcctacctgc
cagacttggt gaggacgatt atggccccac tgcagcactt 60gaaggaggcc tccacggcac
ccacggcggt ggcttctgtg gggtcgct 1085222DNAArtificial
SequenceSynthetic oligonucleotide 52tggacggatg ttgctcccct ag
225346DNAArtificial SequenceSynthetic oligonucleotide 53ggtaccactg
agcagggcat tccagggagc cgctgccgcc tcctac 465425DNAArtificial
SequencePrimer 54gtagggccct aagggcaggt aacac 255544DNAArtificial
SequencePrimer 55tgccctgcca tgacctccca gacgagaaga ggctctgtgc ccag
445639DNAArtificial SequencePrimer 56acagagcctc ttctcgtctg
ggaggtcatg gcagggcag 395782DNAArtificial SequencePrimer
57ggggaactcg agatggcttc taggatggca tcgatgacag gtggccaaca gatgggcatg
60tcgaagcccc atagtgaagc cg 825837DNAArtificial SequencePrimer
58ggggaagaat tctcacggca caggaacaac acgcatg 375919RNAArtificial
SequenceSynthetic oligonucleotide 59ccauaaucgu ccgcaccaa
196019RNAArtificial SequenceSynthetic oligonucleotide 60caucuaccac
uugcaauua 196119RNAArtificial SequenceSynthetic oligonucleotide
61ccguggaggc cuccuucaa 196219RNAArtificial SequenceSynthetic
oligonucleotide 62cuugcaauua uuugaggaa 196326001DNAMus musculus
63gtacatgtta aattataggt atagtctata gggctagtga ttaaactaga acaaagataa
60gatacaacct aactatgtac tcctctatac catgccgatt tctcagcaga agcaagatag
120taggaagtta ctgtgacaca ttctgtcatc taatgagaac acttcccata
gaccccattt 180gtgtaactgt cagatcattg aagcctgcag atgaagagca
attcttggct agcaccaatt 240ctccagttta atggatattc atgtcagtct
gggtccatat ccagattggc ctggagttct 300gcctcagtcc ctaagtgtca
aggtcacaga cttaagatca ccaagctttg tatctagatt 360tgtggtgatg
gtagagttca ttaatgcatg tgtgcgtgca ttcctctgtg tgtgtgtaaa
420agaggagagg agagagaggg agggagaaaa agaatgaata tgaatctata
accgaaaccc 480tgacctgcgt gggcctagat ctgtgtggct cagactgact
ttggcctctt gagcgttgga 540attacaggtg tgagctactc tgcttgacgc
acagtatgca cagtggacct caacatgagt 600agatagataa ctgtcaccct
gttgaacact atggttcttt tgtgtgtgtg tgtccaaggc 660acaaagaggt
catttcttct acccccttct cttgcagaaa ggaatgattt cctccacaga
720tataacctcc ccctccccaa cttcatgttc tttccaccat aataaccaag
catttacttc 780cctaaactaa ggggaccaag gggacttata gaagaaacta
aaaaacttta tttcactaca 840aattgcattt atgttaccct tccctctaat
caaaactgac cgaaaatggg atgaaggcct 900gtgattcaac tacaaagaag
tgtctgcttg aaatggtcac acccatcttt taccaagaaa 960aacaaaagaa
caaaacaaaa ccaaaaaaaa tccaaaacct aaggtacagt cttcccattt
1020agaatgtggc aacattgtat ctgctttcaa aactctgcgg aatgaagact
agtgttaaca 1080gttgggaaat tagaaaatac tttgtaggga aaaaattgtt
aatgcctcca atactacaaa 1140tttaaataca tacacgcctg agtcaaaaac
cagtgttgac tcctgcatag ataatggcta 1200cacgtaggtc cagttctgca
ctaattacct tggattggtt tgctgcgtcc aggtccaggc 1260attttaaaag
tgcaggattc gagactcaaa gtattaacat gggtccaatc tagccctcct
1320tattaggagg tcgcgctcac gttccaaaga gagacttaag ttcttcctac
ccagcctcta 1380agtctggaac cctctaggag gcagcccaga ccttccacca
ctctcttgct cccatcaccc 1440cagcttcccg ttccgctcag cctcagaggg
tgtactgggg cgggcgccgg gagggtggag 1500agtctccggg cggggctgga
ggaatgtccg tggacctata aatctgggca ccgccctggt 1560aggccagggc
agatggggag acctgggcaa aaggccaaaa agggaacatt ttgtagccga
1620tctaaagcaa caggtggcgg tggcgcccgg gaacctaggg gtggtggtgg
cggcggcggc 1680gctggcccgg tgggcgggcc ttgctccctc accacttccc
cattggtcaa caggataacc 1740cttgagcaaa tttggtctac gatgtccttc
cgccacggaa ggtagtcctc ctcaaaaggg 1800caacctgctt gtcccgccta
ccctgagctt ctctcaggag gtgcgggcgc cccgttgaga 1860ggcggggcgc
cgccggccgc agcccggatt gggcgagggg cggggctgcg gagggattgc
1920ggcggcccgc agctgtgata accttgaggc ccagtcggcg cagccccgca
cagcagcgac 1980tcgtcttcac ttgactgacg tccgctctag gtatcgcagc
aggaaccgaa gtacgcccga 2040ggtgagcggg gagaacctaa gccatctgtc
cccagagccg atgcccactg gtgtgtaacg 2100caggcctgcc tgcccacgcg
ggactcaggc gccaggcatc gagcatccca ctccgggttg 2160gggaggagcc
acacttgagt ccaagtctta atcctccaaa ttgagggtgg ccggctagct
2220cctttcccac ggtctcattc tgctctctct tccatctcaa tctggttcca
gcctcttatc 2280ttactattgc tatcctcgcc accctgttct cgccctgctc
cgatgctcgt cctcctacat 2340ccactacgac ttacgacctt cctcttagct
ctgtgccctc ataattcggt gccctcctct 2400taatctctac ttgaaataat
tcccctactc accccacccc caccccccat tcagcctccg 2460cgttcatcct
cctttcaggt cagcgttctc ttcccgcgcc agtgttcgca gctcttcgtc
2520gcccctcccc cctccgatcc ggtcacgtcc gcgccgcagc atcctttcaa
cctccatatc 2580ctcgcccctc cccctcgcag cttttcccct ccccccgcat
tctagtcacg tccgcggact 2640cctcgtggtc cggtgcatgg aggtaggatg
cagtcactag cggtccttgg taatgcagct 2700acaagttacg taacttttgt
attcccggtg gcctggcaag aaaggttggc cgctattgct 2760gcctgttttg
tgtgcccgca gatttttggt ggtgggcacg ggccctcatt gctctcgcgc
2820tccatcctgc ggcggagggg cggcacgtac tgcgatgcgt ctgattaatc
ggtcatgctg 2880ctcccacgtg ctggcgaggg ggagggtggg cgatcaaccc
atacccgttc ccgacagaaa 2940ctggagcccg acgctaccag aacacacata
gcccacagag ctcggtctaa ttagggaagc 3000agattttgtc aagtcagtgc
tatgaggaag atggggctgc atgcacaagg tggccggcat 3060actggttttg
aaaaagccgg gcatcttcta gtctgaaggc tataaagacc cagtaaatac
3120ccagtcatag taagataaga gctcgaccac tttttccaaa tccaggacac
tggtagtttg 3180gaaaaagtga accttatagt gaaaatccag tcgtgcatgg
aggcagctag gttttggaat 3240ccggtgtgat ctattaatat tcttaggttt
ggcctctggt cctgtgtcac tccaggctgc 3300taaattactg gtctccttgt
aagtacgggc catcctcgat gtagtgacta acctcgggtg 3360aaatatccag
aagggcatgc attatatcct tttggtcaat gaatgaagta gttaccttga
3420aggctaccaa cttgattctg tctccttact atttttatgc acattagggg
taagcttggg 3480gaggcaggta ggctctgaat acccagtatg cccatggaaa
caaattctct ctggaatccc 3540gtcagtgttt acaaagtaat taatgttaca
ttgcagctct cctgagaaag agctatctaa 3600agggagaaat ctgtgcagcc
tttgtctttg gctgtgaggg tagaaacaaa gaaacaggta 3660cccagataga
agccttccgg tcctctttgt tcaagtaagc cttttatgcc ttctggcttg
3720taggaagttt ggtactgttg ccccaacagt ggggtggggg ggctcagatc
aagactcaag 3780gaagcattgt tagcaaataa tttgccctct gatggcctga
ttatgctgta ggaaaggcag 3840tgagggtgtt ctttgggaaa gtagtgtaaa
ccatcaccgg gtctgggcaa gatgactcaa 3900cctttcaact ttgcggcttt
tgagaaaatt ttcttccttg ggtgagtgag gggaccacac 3960ttgttctctg
aagtgttgta aggttccctc ttttttagtg agtcaaatag cgtgcatttt
4020ccctgaatta aacatgtctc actcagactg agtgtggtgg ttcagcttta
atcccagtac 4080ttgggaggaa ggcctgtgag cttgagaaca tggagcgggt
gataccctgt ttccagaggt 4140ggcgggtatc acctaaatga aggtgaccat
aagagtggaa atgtggagtg gctgcttcta 4200gacggcatat tttcattctt
gaatgattgg cacagcagct tttcatagaa caaccagtat 4260ccagattggc
agtttctctc gaggcatttc tgaattattg cttaagccaa actatatgaa
4320tactaatcac ttatttagta catagctatt ttcattttaa gcattatatt
ttaaattatt 4380taatttgtag ggaaatttgt taagaactgt ttgccagcac
tcaggaggca gaggcatgca 4440gatctgagtt tgaggccagc ctactctaca
aagtaccaag acatccagag ctacacagaa 4500accctatttt gggagtgggc
tttggtggaa atgtatctca accaggtata atggcccttg 4560atccctttat
tcccggtgtt ctggaggcaa actggcaaat gactttgagt ttagtccagc
4620cagtgagtga cttggcacat ttcatagctg actccaaaca gatttatggg
ggctgggtat 4680gccatctgtg ttatatgaac gtgttggtca caggaaacgc
tattttattt cttaaagctg 4740ttaattgctt aatattgagt ggaagggatg
aggaagcggc tatggacaga aaggtagaaa 4800aagcgtttct tgccttaaac
tcacattggg tttttagcat ctttagcttt tttgcagcaa 4860gtcgacacga
gttgggcaag aactaagctg gagattgagg tagaggaaaa tgactcattt
4920gtctttcagt ttctcaatca tctcaaatac ccacaggcaa gttaactggt
gagttttttt 4980tttttttttt ttttttactg cttctggtaa aggaccgagt
catctctgta aactgcactc 5040atggagacta taataggagt agatgactgt
atgacgaaga acattcttcc tgccctggaa 5100ctttcgtgcg tcttgaaatt
tttaaccaag agccagactt
actttggcta tgtagtaatc 5160aggagaggtg agccccacgt gcatcgtggc
ctgcaaaact gctggatctt aaggcctagt 5220gtagctactc aggtttggag
gtggtcccag ggcaccacca gctgtgctgt gaggccacac 5280ccctactgtg
gtttgtgcct gtctgcacgt aggagagagg tctgggctgc agtaccttaa
5340gtggcctcta gggagctctg agcatctcct gaggcctgcc tccaaaggaa
gctgtattcc 5400ttctaaatgt gtgaataacc tttaggccat attttggcct
taaagtactg gtgtctccag 5460tgtaaaagac tttacccttt gccatgccca
ctttggagga gtcaaaggtt tgatttgatg 5520tagagaaggg ctgggtgtgg
tggaatgtat ttttaatctc agagagacag gacagtcagg 5580atttgtagag
tccttgtctc aaaaaaacaa agtagggaag gggctggcaa tgtagatctg
5640atacaaagcc atggtccatc cctactacta cataaaatgc acatagtagc
acgtgtctgt 5700aatcatactg agcaaaggac agtgggattg gagaagttgt
gagttggaaa aaacaaaatg 5760gactatgaac tgaataaagt cagaatgcta
tttaattaag ttttggaaac tataaagata 5820aaaagtcagt gttgatgcta
agttctgggt gggagaaatg gagtctttag atcccactcc 5880ttggggaaaa
ggcggtcgtg caagcctgcg ggcagaagta gtaagtaggt cagtgctctt
5940ggacagctgg tgctgccttc cttccgactt taatcaccct gcccccaact
gtggctccgg 6000gctgagccgg tgcctcctgt tgctgagacc attgtgcatt
ctgcttacac ctggttctct 6060gggcttctga gccagggtcc agagcatggg
cagcattccc ggaaacactg gccttgctaa 6120ggaagaccgc atgtgccaac
cggacagaaa cttctgcaaa gtcacctcct tcctgctctg 6180gctagttctc
cgctctgcac agctgagcta gaagccagga aatcccttgc tttgaggaaa
6240gtaagacctt gtcttaaaaa tcaaataagc tgggccgtga ggcaggcaga
tctctcagtt 6300tgaggccagc ctggtctatt gagttccagg acagccaggg
ctacacagag aaaccctgtc 6360tggaatctga ctctcaaccc ccaaaatctc
tgctcaagtg atctgtaccc ttgataccgc 6420acatttaatt ttgttgtatg
ctgggtactg tgctccaggc cttaccactt tctggggata 6480gaactgtcac
ctgctttgac cctggtgttg gcttctcatt agggtcactg atagctggac
6540agcagccttt ctgatggatg aagtgagatg atcttgggta ctggggaaag
taggcttggg 6600gtgacatcag agaaaggttg ctacaaagcc ctgttcctag
gccaggctgc tttattaggg 6660cagcaatgat ttggacctac gtgacgatgt
cattggtggg gtgaggcatg accttccaag 6720agtgttggct ctaagaagca
gggtggcacc aggcattttt ggtttgggga tttttttttt 6780ttaatgacct
ttgttcctga cacgagggag atgaatgtga agggccgagg agaactgcct
6840gagacaggaa agggcagaac caggtaatca gagccaagct gggcctgtgc
atgctccaac 6900ctacagccca actgaggcct gggctggtgt ctcctttctc
acagaggggc aatggctctg 6960aagaacatcc tgcttcaggg gctcaggttc
aagagtaagg cttctgcccc agggcatggt 7020atctactgct gtcgtgggac
acaccgggtt tctgctgccg gctggaggtt ggctgtgcat 7080gtgggtgcct
cctgaggagg aggatgctgt agtgagttgg ctggcatggg tggggccgca
7140tgtcctggca gtcactgcta tctatacaag tatttggcca ataaggcaag
tcctgcccag 7200gggcccacct taccctaagg aacaaggctg gagctgctgt
cctgggccag aaaagacttc 7260taaaagggtg ttctatttat actatactat
agataggtgg ttggctggag ttgtggggct 7320ctggaggcca tgcaatgggc
agaagagctg tgggagggag ggaggggctc caggtcagag 7380ccttgggagt
gaaaatagct gggttctaag gatgaggttg gtaggggact tgaaacccct
7440gtaaggtttg ttagaagtct gtttaattgt gtccatccat tggaacacat
gtattttcat 7500ttgtcacttt gtatatggta gcaaggtaag tctactctgc
agactttagg tttaattcta 7560gatagagaaa tgggttgtgt gtgaaatttt
acctgctaaa ttgcatcctg agccctggag 7620ggcagcagtg cttgtctgtt
ggaacatcct tgttgcacaa caaagttctg tcaagcctga 7680gaccggtcaa
aacaggagaa gaaaattgca tggaactgat aggttgtggt catgaaattt
7740ttccatggat tagccacaca cttttgggaa ggtgactttt aaagtcagtg
gattaagttg 7800cccttcctgg gtcagtgaag ctgccctgct gagcactttt
gagggcatag agaacacaca 7860tctatcacta tattttagca gggtaattct
gaaggacacg gctgatgtca cagtgagctt 7920tatagggtgc atagagataa
atgtgtcatt ttcaaagact acttaattaa cagttttatt 7980aataaaggac
acgctgggca gacagaagtg tagtaagatg ctgtctcaga agagtagggc
8040agtaacgtga tacaggctat catccaaggt ggagcagcga gggtcagtga
gatagcttgg 8100aaacacacac aggagcttgc ttctgatggc tccagtgctt
ctgtccccag aacctgagtg 8160gtaggagggg agagcacagt tgtggtcctc
tgatccctgc aaggtgccca ccaggtaccc 8220cctaaaacta aatagtgaaa
tttgtgtatt gggggaataa agtacttcaa gggatccagt 8280aaagggtcac
ttttaccact gggttttttt atttatatct tctccactgt atatctgttt
8340taatgtagtt aacagcaact ttttgccttg ttattaaggt cgttaccaca
aagagcttag 8400tcatattcag ctttcacctt aatccttgta gctcttcagg
gcaaagcata ctccactctg 8460agcgatcttt ccaagtgagg ccaccaagcc
acactgagtc aacaaaacag caatatgcca 8520tcagaagccc agacccagag
aaccaaaggt atgacctgat cactgggcct cactcaggca 8580gggatttgcg
agggcacact cgtgtctcag atgggaagaa cggcctggtg gctggctttt
8640tcagtagttt tcagacactg tcctggtgtc tgtcccgctc acttgtccca
tctcggacac 8700agcaaggcct ttgtgtctca ttggcttggt gtaccatctg
tactgtccct tagcggccac 8760ttatcctaag cctggctggg agccgtgagt
ttgccagttg tgtttgtttc ggccatgagt 8820agaccaagga cctggctgcc
tagggacttc tcacatttgg ggagagggaa aaccaggcag 8880aattgatctt
ggcagagacc cggagctcat ttaacaaaca aggtgctggg aggcaaggag
8940ctaagactct ggagaagttg acatcttggt gtctgatgtg tcttgtagag
ttaggaatga 9000acaatgttgg ccactggttt cttccttcct ttaaaggttc
tcaattctgc aaagaatgta 9060gtggttgcac ccctgtaatc ccagcaccca
agagctggaa catgagactg tcatcagttc 9120aagaccagcc tgtgctacat
atgataactt tgtcttaaag tttttcatat ctgcatttga 9180agacttacag
gtgtctggta cttggtcact agtgggtggc tgaagtctca ggttgcagag
9240acagacttag gtacatactc tccaggcgtc cagaaaagcc agagttccgg
gaagagtggg 9300ggtcctcagc tgaggagaca ggggagagca aggatatgga
gatactgtgg agcacaggct 9360gaagacttta tgttcaggag tttgagagga
gccttgtggc ctgaaaactc agatgagaaa 9420gaatgtcagc ttcattcaag
tctcagatag tctgcgagct atagcccaga gctctcccga 9480gagttctgtc
ctctaatcag ctgactatcc agctcagtga gcacttagtt gtaatgaagt
9540aaaagcaaag gtcaggacag ctgttggaat tgtgacctgg gtggttaatt
acctggaaca 9600gatgttcaga ctactgggtg ctatacctat cagacagaga
aagaggctcc aaatagccag 9660acctcgggct ggggaagcta ggtctaatgt
cagcccttgg aaagattaaa gatggtaact 9720tcaaggtcag cctaggttgc
acagtggatt tcaggccagt gtagagtagc tgctgtgatt 9780ccatctccta
ggttacagaa gactccttgg tgaggttata atgactttgg ggccatttca
9840atgcccttgt gcaaaatttg ctttgtatgt cttgtaggtg gtactgtgtt
tttgtttttg 9900cttttgttta ttttttgcta aagaattatg gacttttgct
tcctgcccag aagaactgtt 9960ttgttccctg taatttggac cttactcttg
tgtctgataa aagctaaaga atacatttag 10020atagacctgg gactttggga
gtaaaagaaa ggctttggga cagggtttct cttgtttgca 10080ggaccacttt
aggtttgggt gaatgagaga gtgagaccat gctgagtgcc taccaaagcc
10140aatactggag attggacatc atgataggct tcccaagatg tttgtgtgct
gacatactag 10200ttagaacatg cgctgggggg tgtttcttac tgtaactttg
gaggtttcct tgtgtgggga 10260aagtgatgtt ctttctaggg ttgatgagaa
agctcttaag acaaggtgac agcccatgtg 10320agaagcctgc ttaaactggc
tcccagggtg tgtgcagtgg gtagggagtt actcttgttc 10380accaaggtct
ttgctgtttg ccaatagtca caagagccct ttgcccaatt tgagtagcac
10440ccacataacc agcacgtgcc aggcttttat gctgcttgtg cacaaagcaa
tcttattggg 10500ttaatgtgta agcaggagac agcttcctat gccaagtgcc
tcattaagca gtgcctaatc 10560taattgcact cttcaaatct ccgggaccca
ggacttcagg aaccatgccg aagccacaca 10620gtgaagcagg gactgccttc
attcagaccc agcagctcca tgcagccatg gctgacacct 10680tcctggaaca
catgtgccgc ctggacattg actctgcccc catcacggcc cgcaacactg
10740gcatcatttg taccattggt gagtgtggcc ctccttcctc taaatggagg
cttctacctg 10800atttgaaagg catagtaacc attgcagagc tagcctaggt
tctgagtgag gcacggtcca 10860catttctagg ggagtagagg tcttgggaat
tggccatcaa gaagaattag tgtgcttttt 10920ctgtagttgg tgaggttcag
gggtggtctt tttcatgtgc tgtcaccaac agcattcggt 10980agacagacat
cttgaaggca gagaaaactg ttgccctcca cttttctggc tgaatgaggc
11040cctgcagaat ttgtagagaa tgttagtgtt cccacataat taagaaagtg
actagtacaa 11100tagtcttttc tgtactttgg aaagaccttt ctcttaattt
gtgaaggtaa ttaaaagcaa 11160aggatgaaga gttgtttaaa tgttgagcaa
atttcagaca ttttcctacc tgagtcatga 11220ttttcttcct gtggatctaa
atgtttcttg atagggcctg cttcccgatc tgtggagatg 11280ctgaaggaga
tgattaagtc tggaatgaat gtggctcggc tgaatttctc tcatggaacc
11340catgaggtga gcgtcaacga gatccaggag actcagcgat tccttaacag
tcgtactgca 11400ggcaggtgtg agtccagggg tcccagtgaa cggaacattg
ccgtttctct cttctaactt 11460cactggaata gaaacctggc ctgctttgtc
acccaccgac cagggttagc cctaccgtca 11520acctttatga aagaaggcac
gtaagggttt agctggaaac cctaggccat cagatgtctt 11580ggcccccatg
cttcagggtt tttacagtgg ttcctgtgtg tgaaccaaaa ggttctgagc
11640agatggatag ctggagtcat tttaagatct accttttaaa tacttctctc
tccccctccc 11700tccctctcga cagggtttct ctgtatagcc ctggctgtcc
tggaactcac tttgtagacc 11760aggctggcct cgaattcaga aatctacctg
cctctgcctc ccgagtgctg ggattaaagg 11820cttgtgccac caccgcccag
ctttttaaat actttctaac ttgactgtgg atttcctact 11880ggtattggtg
aaggagggaa ggagactcct ctctgcctct tggtttctgt gtcctattta
11940gagtaaaagc attaaccctg tgctgttttg ccctctgacc tttggaagtt
gtttggacta 12000aaaatagatg gagaagaatg gtccaagaag tgaaccccag
aacatgagaa tcttcataga 12060ttccctaacc catattccat aaatagcttg
gaggctagtg cccaaatgtc atggaacctg 12120agatagttcc tcaggcacct
aagcaatatt tgacacattc ttgctgggtg tggtggtaca 12180agattgtggt
tttgaggcca gaatggggac tatcctcagt aacatagtaa gatcttattg
12240caaaccagga gaggtcctta ttttccaaac tctggctttc cacaggagct
cccaggaaga 12300aggtgagcct agttcagaga cagaactagg gccacttgcc
atggtccttg cgagtagtgt 12360gtttagtcag gcaaaaatag atttggaggt
gctgaccttt agggctcttg agtccagtaa 12420aataacacca tgcagcaggt
ctaagagggc aggggacagt gagactgtcc agaccactgg 12480gcaggccagc
tctgccttga tttcagacta aggcattaga gattggctgt actttgaacc
12540tttttatatc acaatataaa gcttcacaag tcagggctct tattccatgt
gcaccttcag 12600tgaggctctg ggtgatggtg gtgctggtct tggtgattcc
ctggagaccg tggaaaccaa 12660gctccttccc tctgacagga acatcagcca
cctagctgca cctgatcttg acagctttgg 12720ctgtgtctct aattcccatc
tcttgctttt cacatattca agatgtgtca ttcttgctga 12780acaggcagta
ctgtactccc acactggctt ttaaacagcc taaatttaga gcctctacaa
12840ggatagcact gatggctgcc agtcttcccc atttggttac atgccagaaa
aaccacagct 12900gtgataatgg atagcacgac ccagctccca gcagtgttac
catgcagaga aggctaattc 12960accaccagat actccaatca caatgcagct
ttatatatac gaagctgaag agtgtttatt 13020atgctcgtga atgtgctgag
gtgtgtaact cagtgtgtac agccataatt cttcagtgga 13080aattaaggga
gaaatccaaa cttctagagg atctctaaag caaatgaagg cagtcggtag
13140tcaatatttt gggatatctg gagctgggtt accgggtggt ggtcagcctt
tgggcagctt 13200cggtccttgt ggatgaatgg tggttccagc tctgccctaa
caaacaggct tgcaggtgtt 13260ttgctgtgct cagtggttca aggaccagac
tcataaagtg ctgaattgaa tggtccattg 13320tcaccagtgt cacaaggata
tgcactggca acaaactatt ttgctatctt ggctctgagt 13380cccagatagg
aaagggaaaa ggtttgggga aactttatta caagtgaaga aagcaatggc
13440ggttgcaccg gggcaggctc ctggtcggag gaagtggtta tgaaagcagg
gtctgcgtga 13500ctagagctgt ttagctcggc cattgctcac taagtcaaca
gctttgagtt tgaattgcag 13560ttgggatcga tagtgaaaac agatagaggc
tgccagggca gaaatcttca aacacaaatc 13620ctgggtcttt gcttgtcctg
attagcatcc cttggtgagt cctagggaca ctgggacaac 13680agaagggtcc
cacaggatgg gtttatagtc ttccctttaa ttgattttgg tggcagtatt
13740ctggaactgt atgagagttg gagttgatgc tgttgtgtag agggaagaat
ggatattgct 13800aaggttagga gatgggtgaa ggtcaggagt cagacatact
tttttttttt tatttgctaa 13860ttgatcatct ttagctccag ggtggggatt
ggaaactgga cagggacacc tcacctgcca 13920atctgccttt ctttctccag
taccatgcag agaccatcaa gaatgtccgt gaagccacag 13980aaagctttgc
atctgatccc attctctacc gtcctgttgc ggtggctctg gatacaaagg
14040gacctgagat ccggactgga ctcatcaagg gcgtgagtat ctagaatagc
ctggtagggg 14100gtcacacttt tgctatgtaa ataacctatt tagtctcact
ctgggaaacg ggtattttgt 14160ttgttttatt tcttcctcaa tatacaaatt
caggctttat agaaaggtga gaggtttctt 14220tggactttga gccagagttg
agcgccccca tcaggggcat tggcttcttc agttcacact 14280cccatttcct
gctttaatcc atagagcggc accgctgagg tggagctgaa gaagggagcc
14340actctgaaga tcaccctgga caacgcttac atggagaagt gtgacgagaa
catcctgtgg 14400ctggactaca agaacatctg caaggtggtg gaggtgggca
gcaagatcta cgtggacgat 14460gggctcatct cactgcaggt gaaggagaaa
ggtatgtctg gtacacagtc cgtggccaat 14520gccaactcca atccccagag
ctctggcaag cacagacctc gaatgtatga agatctgggt 14580ttaatctcca
gaggatcaaa agtctaaggt tattgttggt ctgcgtccct gacctgtctg
14640aaatactgtc tcagaaaaaa ggcagatggg gctggagaga tggctcagta
ctgactgatc 14700ttccgaagat cctgagttca aatatcccag taaccacatg
gttgctcaca accatctata 14760atggttgtga tgccctcttc tggtgtctaa
agagagctac agcgtgtata aaaggtcttt 14820gggccggagc aagtggggga
tcctaaattc aattcccagt agccacatga tggctcacaa 14880accatctcta
cagatacagt gtacagataa aacacattaa gtaaataaat aaataaataa
14940ataaatataa aaggtctttg ggccggagca agtgggggat cctaaattca
attcccagta 15000gccacatgat ggctcacaaa ccatctctac agatacagtg
tacagataaa atacattaag 15060taagtaaata aataaataaa taaataaata
aataaatttt tttaaaaaag aaaagggcaa 15120ataacccaca aaggtccagg
tacctttagt cctccgtcct agcgttcggg aatcaggaag 15180gtggagatgt
ctcggtgcag catatgttag actactatta tatgccttag aatgagagtt
15240aaagttactt attctaaata ctttgtgaca gtttgagagg gtttcctata
gctagccttg 15300aactcttgat tcttctgttt ccacctccca aatgctcaca
ttaagaatat acaccaccag 15360ctgggcatgg tggcgcacgc ctttagtccc
agtactcggg aggcagagac aggcagattt 15420ctgagttcga ggccagcctg
gtctacaaag tgagttacag gacagccagg gctatacaga 15480gaaaccctgt
ctcgaaaacc aaaaaagaat gtacaccacc tcgtgtggct atttatttgt
15540ttattcatta atttgaggca aggtttccct ttgtagccct gcctgacttg
gaattaactg 15600tgtgtgtaga ccaggctggt cttgaactca aaggtctgtt
tgcatttgcc tcttgtgcta 15660ccatacctaa aactcaaatt ttcttagcag
tttgtaagta agtatttata ggtgagaaaa 15720ctgacttggc tttcctgaag
tgttttgttt ggtttggttt ttgttttgtg tgtgttggag 15780tcttaattat
ggctttagag tcctcctccc tctgcttctt gtaaattgag gtggtcttct
15840gtgatccctt tcacacaggc gctgacttcc tggtgacgga ggtggagaat
ggtggctcct 15900tgggcagcaa gaagggcgtg aacctgccgg gcgctgctgt
ggatctcccc gctgtgtcgg 15960aaaaggacat ccaggacctg aagtttgggg
tggagcagga tgtggacatg gtgtttgcat 16020ctttcatccg caaggcagcc
gacgtgcatg aagtcaggaa ggtgctggga gagaagggca 16080agaacatcaa
gatcatcagc aaaatcgaga accatgaagg cgtccgcagg tgagtcctga
16140gacccttcca ttgcccagcc cttgagaggg gtgtggccat ggtgtgtcct
ggatacctgc 16200tcagcaaaat acagcctgct gggattggtc caggcggaca
tctgaatcag cattagggag 16260gccaagtatt tttagtcatc attttgggac
ccggctggat actcaagggc ctcagatgtc 16320catgctaaag cttgaagcct
tagaaatctt ctggtctgat aatggtgctg atgaggagtg 16380gcccattcag
cttcccatag agaagcatga tgcctacgta aatggaaatt aattaaggtg
16440gcattcataa ggatgagtgg tttattgaca aatgttcata cttggctttc
tccctactgc 16500ttcccctaga actgcttctg tgggttacag tgggcttggc
tctgtgtcct ttgtactggg 16560caactgggag tctctttcta tcttgataag
ccataggtgc tgatggcctt ggtatttggg 16620gctggggagt gggtcagctc
aaagggcagc agtcagtgcc cttagctaaa tgatgatcca 16680ctttgtagaa
gatccactgg cctcattctg tctttgaagt gtcgattagg gaagtacaaa
16740acggggtggg gggtgagatg cagaccaaaa cctccctgaa atatttatta
tggtgtttaa 16800gaagtccagc cagtaaaatt gttgtgctgt gagtattatc
atactgtgct gtggatgccc 16860cctcgcctgt gtgcccctgg gtgtgacctt
tgaaagcatc tctgtcggga tcccaggtac 16920tttggttgtg cttcctgtcc
tctattatct ttctcttctt taccaggttt gatgagatct 16980tggaggccag
tgatgggatc atggtggctc gtggtgacct gggcattgag attcctgcag
17040agaaggtctt cctggctcag aagatgatga tcgggcgatg caaccgagct
gggaagcctg 17100tcatctgtgc cacacaggca tgtgctattt cattccttct
gcattctcca cctaggagac 17160ctggccttgt cctgtccttt gggcacacat
agctgtgatc tgtgcacctg cacaatctta 17220agggaattat cttggcaatt
atcactgaag atggcctagg atctcattta gtgatggtct 17280tttaccgaga
gcccttgtct gtcccctcct agatgctgga gagcatgatc aagaagccac
17340gccccacccg tgctgaaggc agtgatgtgg ccaatgcagt cctggatgga
gcagactgca 17400tcatgctgtc tggagaaaca gccaaggggg actaccctct
ggaggctgtt cgcatgcagc 17460acctggtaag tcctccaagc ctaccaccaa
ggcctctgca tcacccagtc ttttacctcc 17520ctccgaccac ggccagaaga
gtgaggtgtg tggagcatgc tctgcttctt gattttcacg 17580ttgtgctctc
gctgcctgcg ccccaccacg ttgtcctgct ctggcgatta ccttttccat
17640tacgtaggcc acatctggct aaaatattaa agtcctagga cttagtcaag
ggataccttc 17700ctccctcctg aacacccaga cggcggggcg gcctctattc
taaaggagcc aagagtgtgt 17760attcttggct gttcgcctgg tttggcttct
aatttgatct cttgatggtc ccatgagcag 17820atgcttctct gcactgcagg
ctgtagccat actaagctgc tttgagctgg ccttgcatgg 17880tgcctgtcac
atgggacgtc tcttgctatg ccaaacccaa tgtagggcta gaaatagctc
17940tgggcgtggg gaatgggtgc tgaatttagc aggttctgga ctggagatta
taaagacttt 18000ctctgggcaa atctatgctc tttttgacta agtcttctgg
tttcagtaag atagggtctg 18060gaggtccagc attcagagcc tgaggcagga
agatagcttg aggctaggct gggctagaat 18120aaggcattat cttacagaaa
caacagactt ccagctgacc tgactcctgc tgactgtgat 18180gggtgaggac
ccagaacttc ctgagcagag cagttagcta gggcgccagt taggaccttt
18240ccttgcctca tgaaagcatt gttggctaac tttcttggag cttttctatt
cccttttcgg 18300ccagcaaaga accactgttc tttttgtgtc tccagtttcc
aataagcccc caaactgaaa 18360gaaaaaaaag cccccttcag gattagacat
cttaccttgc ttcatttgtg tacagctgtt 18420aagtagattc catgatctac
ccatggttta tctgaattgt agctgtagcc agatgtgtgc 18480ctatattgaa
acagaccagc cgttttgtag aagcttgaac tcagcttgtc tcagctggtc
18540acctcctgat ctgattggta ttgggagctg atcttcacag cttctcagta
gctagcatgc 18600agacattcct tctccagcag tctgtgtgcc ttcctgatct
acaccaaacc cccttctttt 18660ctagtcacct gcttagttgt cttatcacct
cagagtggtc aggaacaaga ccaggtagtc 18720taaaccatgc agtcacatac
atggatttat ctttgtatag ctctgggtga cttatatgac 18780cgcaagacct
tgcccaaggt ggcatttgat gagattaatt ataattaatt agtcataaca
18840ttaaacaatt tactgccata atgaaatgtt agataaccct ctgggctcat
tgatgtaatc 18900tttgcattct cattttcttt ttaaagggaa tcacatgtga
tagtgtgttt gagcacagat 18960ttgctatcct catagggcca gccagctgtc
tgtttgcacc ctgctgtagc aggtgtgggc 19020agagtaggag ttagttctca
tgtcctgccc tctctcatgc cctgcccttt cctatgaaca 19080gacaccttag
aacctcgagg ctgggattgc atggccctgc tcagaagatg agtcacagag
19140tccgggttag actgtggctg ccccttcagg gggtgcaagc ttctctctca
tcagttaaca 19200ctcaggatag cttctcccct tcatctgttc gctgcctcct
cctctgtcta actgatatag 19260ttcatgacct gtaattaaga gctagacatc
ccagctatgg tcgtttcctg ttcatgtcct 19320ttgggctgca tgcattccat
ttatttgtaa ctaaaagaat actttccact tgcaaatctg 19380ctaatactac
caataaatgt gagttattgg ttttacatct tctctatact aaaatacttg
19440ggattgcact ctctaaaact tagattttca ttctaatgcc tggttttact
tgaacagata 19500gtctatatat aacacatttg ctgttttgta acagttttaa
ttgctaagtt ttaattggtg 19560tcttaaggca tgcatgcttt ctcaggcatc
tgcctcttca cacggctgtc cactgtgttc 19620aagtgagcca gagttggcca
ctgttctgtt tagaactggc gcaccatgta actttggctc 19680ttttgacctt
tgaccccagc tttcagagct gcccagatgt ttctattata aaccaggtgc
19740aaggactcgc tcttgtatgt aggctaagct agatgtcttg taaccacaca
gccgtgtgtg 19800gaggggaggc ctagttcttc ctgtaagctg tgtcatgagg
cagtgtggtc aagtggaagt 19860gtggttggct ccaccttggc atctttccat
gccaaggtcc tagggcctaa caatatgtcc 19920ctgtcttagc ttcaatcaaa
aacaaaagaa attgatggtg cctgcctgtt atcctagcac 19980ttgggaggct
gaggcaaaga aaatagtgat ttttgaggat aactgtggca agttcaaggc
20040tgataggggc tatggtaaga tcccatctca aacacatggg ggtgagtccc
atctcataaa 20100cacatgggga tggggttttt tttaagaaac aaaggggaaa
gtcccaaaag gataatatct 20160ttctagaacg gaaggaactt tccttgtatt
tgaacagtaa
ggggaaaagg agcagcccaa 20220aatcccacgc aaccattcca ggagcatatg
ggctttgacc accctgcctc tgcatctgcc 20280tctgcatgaa gaaaagatta
aacctaaacc taagggtgcc ttccttcctc tctgatgtag 20340ttccctgtct
ttccatgtgt tgtctctctt gtttttgcct ttatccctct tccttatccc
20400tcctacccta aaccttacag atagctcggg aggctgaggc agccatgttc
caccgtctgc 20460tgtttgaaga gcttgtgcga gcctccagtc actccacaga
cctcatggag gccatggcca 20520tgggcagcgt ggaggcctct tataagtgtt
tagcagcagc tttgatagtt ctcacggagt 20580ctggcaggta gggccctaag
ggcaggtatc attataggat aaccagcttc tcgcgcaact 20640aggtccgcta
tgtgcctgag cctaggcaca gcctctctcc ttcaggaaga cagccaaggt
20700caccataggg caggaccaaa ggattccctt gggcacagtg gaagtcacag
cacctggtgc 20760aggatggttc ctgtggagtt tctaatcttg ctcagttcag
aacatggagt ggctcacctt 20820ctcctggcca tttttgtgcc cagggacatg
ttccttccca gttgtctgtg actcctttcc 20880tccctctcca tttgtgacaa
agctctgaca aagccctgtc ccccgtcctc gtccctctgg 20940acggatgttg
ctcccctaga ttgcccgaga ggcagaggct gccatctacc acttgcagct
21000attcgaggaa ctccgccgcc tggcgcccat taccagcgac cccacagaag
ctgccgccgt 21060gggtgccgtg gaggcctcct tcaagtgctg cagtggggcc
attatcgtgc tcaccaagtc 21120tggcaggtag gaggcggcag tggctccctg
gggatgccca cgctcagttg acacctctcc 21180ttgaggatgc caagagtgag
tggctctggg ccagtttaag gcccctggct gccactagag 21240gattccaggc
agcactcaca gatagaccaa accaactggc tggctccagt gcacgttcaa
21300agcctgcctc acagagagct ggaacaaaca cccagtttca ccgtgattag
tactgtgggg 21360ccttttgaca gaacactgcg tggcagctgg gcatggcgga
gcatgcctct aatctcagca 21420cttgggccaa agaggtaggc gaatgtctgg
atttgtagcc tgtctagtct acaaagtgag 21480ttccatccag gacagagccc
tactcacaaa atagctcagc tggtaaagtt gcttgctaca 21540caagcttgac
ccatatttgg tccccagaaa ccatggagga cggagaaggc tggccctggg
21600tatgcgcaag ggtacacact tggaggggtc ttggtggata aaggatttgc
acaatcatga 21660ctatctgaat ttgaatctgg caccttaaag gttttttatt
attacttttt atttttttaa 21720agtgcacaca gaggtcacca ggaaaggtgg
tctggccttt aggagcactg tcagttcttt 21780cagaggccca acacctgcct
atatatggca gctcacaact gtctgactcc agtcctgggg 21840aaatctaatg
catgtggtca gaatacccag gcagctgtag tgaatgtacg gtggagggag
21900agagtgaggt gcccagtgtc tatctatcta tatagcacaa tagatagata
aaaaataccc 21960aagtgtggtg gtgtgtgcct gtagccccag tgctcatggt
gcagaggaag aaagagcaag 22020ttgtatcaca gcctagctac agaaagccaa
acacatgtaa aatcagtgtg gaggactagg 22080cactggtctg tctccctaag
gcagtgttca tgaactaagt agcagaaagc tacttaggcc 22140tgggctgagg
atggtggcct ctgtgtaagc ttggccatga atgttggtat gtagctggaa
22200gccagggatg atggggtact gagaaatggg gacactaaaa ctatcatttt
tagtcctgga 22260gttttgaaag ctctaaaata caaggtctat gctaattctg
gggtttctct gaagagttcc 22320tggttccagc agctacctcc ttccttcaaa
gcctatgtat gcaggctagc atgaagctct 22380gctgtggaat tcctcagtcc
cccgtgccta gctaattgag taatctgata gagatagaca 22440ctatcatttg
ttacaggttg agaatagggg ttccctacat tcccagggga tcttgaatgg
22500ccagatattc ctcttaccac acctgatcac cacccagatt tctttttctt
tctttttttt 22560ttaaatttat ttatttatat gagtacacgt acttcagaca
taccagaaga ggacattggt 22620atcggatccc attacagatg gttgctggga
tcccatgtgg ttgctgggaa ttgaactcag 22680gccctctgga agagcaatca
gtgctcttaa ctgctgagct atctctccag cccccagatt 22740tctttttctt
tctttttttt tttaaagatt gatttattat tatatctaag tacactgtag
22800ctgtctgcag atgcaccaga agagggtgtc agatttcttt atggatagtt
gtgagccacc 22860atgtggttgc cgggacctga actcaggacc ttctgaagag
cagtcagtgc tcccaaccac 22920tgagctatct ctccagccct accacccaga
tttctaaaac catagaaatt ctgaggtttc 22980ttttaacatt agctgctagg
actcccatag gagaacagta tagtgttatg gtgaacattg 23040ttggcttcca
gggcctggta actctgctgc tgttctttgc agaagaagtc aggagctagg
23100cacatggtac ttggattgta aaagttgctg gcagctacag gagtgggttc
tgctgagatt 23160gggccaaagc tgcctcactg ccagatggaa gggttcattt
gtgggaagaa ttctaccagc 23220catgctccta taggactgcc catactgaga
gcaggataat catcttagaa aagacaggac 23280aggtctgagg ggcaggccag
accttgaaac agttgtcagt gggcaaagcc tgtggtccag 23340agttgaatta
gagggtatta cttttggctt aggcttactg aaagggtctt atgacatgtt
23400taacggtcag tctttccaac ctgtttccat ctcaggagtg ctcaccaagt
ggccaggtac 23460cgccctcggg ctcctatcat tgccgtgact cgaaatcccc
agactgctcg ccaggcccat 23520ctgtaccgtg gcatcttccc tgtgctgtgt
aaggatgccg tgctgaatgc ctgggctgag 23580gatgtcgacc ttcgtgtaaa
cttggccatg gatgttggta tgtagctgga aacaagggaa 23640tgatgaagtg
ctaataaatg gggaccctaa aactaccact tcctgaagtc atgggctggg
23700cctatctgtt ttatcaccca gttgtaagat tagctggagc tactgtcctg
agcagggtgg 23760ggttagaggg tggggaacac aagcttttgt ggccttattc
ctatatagag acaaggaggc 23820agctgaccct gactctctag agtataaact
gaatggtgtc caaaggtctc tgcattctga 23880gttcagcctc agcccttgtt
taggctagga ggcttgcacc atcttgtggt gagaagaagt 23940aactgtcaac
ctgctcccct acccagacga ggattattag ggcagttatc tgcacctgcc
24000ttgttggatt tgtgtctggg ttgggaaaag tgccactttg tgtgatcaat
taggactgtg 24060gggctttgca gttttcctca agtgtatacc tctactcacc
aacctccttt tccccccagg 24120caaggcccga ggcttcttca agaagggaga
tgtggtcatt gtgctgaccg ggtggcgccc 24180tggctctgga ttcaccaaca
ccatgcgtgt agtgcctgta ccttgatggc cctctggagc 24240ccctcttcta
gcccctgtcc cttcccctcc cctatccttt ccattaggcc agcaacgctt
24300gtagtgctca ctctgggcca tagtgtggcg ctggtgggct gggacaccag
ggaaaattaa 24360tgcctctaaa acatgcaata gagaccagct attattcagg
gccctacctg agccaggggt 24420ggaggaggaa tgcaggactg gaaaccctga
ctttatcaca gaagggcggc agcatctctg 24480ggctttgctt ctgtagaaag
ttgtcagaat tcccagccct agcctggagt caggagacag 24540caaaagagta
ggggctgagg gtgtggggcc cagggtccca gtgtagatga cgacttctgg
24600ccctggccct gacctgcttt cccaacagct ttggcctccc cacttcttgt
gcactccact 24660tctgtcactg cagacactcc actctccacc ttgtattctg
cagagtctcc aggcctgttg 24720ctatagtgcc cacctgaatg tcaataaaca
gcagctgaag cacctgtgtt gtgttttgtt 24780ttgttttttt ccgggggttg
gtagtggtgg tcgagccctg ccctttgagc aattgagaat 24840gacaacagcc
aggaggcctg gccttgggtg ctatggatcc accagataac cttcaagcac
24900gggaccactg gagacgccgg agactgaata ctttgggagt atataagttg
cctcctgcac 24960caaagtgcgg ctgtgtatcg ggaagctgat ccgttctatt
tcagggcaaa tactagaaaa 25020gtctgggaca ggttcagcta gcacctagaa
tggtcgaata gtgggctgat ccctgtggta 25080gaggcctgtt gagggcgctg
taggatgagt ccctgattgg atacttcaca aaaccctcag 25140cctccataac
agttaagcac aaagggtctc ttgttttcct gttgccctca ggaataaggt
25200acatagaaac aaggtgggac ccttgtccct ggcaactccc aacagccacc
tagtcagagg 25260ctaaggcctc tgaaattgag atgttgcagc accaagagct
caggttaggt aaggaggttg 25320gaaggcggag tagaatgaag agccctgagg
gaacattttg atatgaagtc ccataattga 25380ggacccaggc cctggtttcc
tcgacctcac aattttgaag acctacctgc agctgggacc 25440catcagggcg
gtctgggagc ggggaaggct ccaccaattg agccaggctc attctgcgcg
25500agcggccaat aggcgtgtgg gggcgggcct ttcccggggt gggcggtccc
cggagggcac 25560tgggtctggc gcacggcctc gggctcccgg agaaggcgct
gcgatgaccg ccctgagccg 25620tagcgagcct gtcgaggcgg gcaggtaagg
gaggcgtccc ggggctccag gtccaggagg 25680ctgcgacgaa gggcagggcg
actctgggaa tgccgcgcct aggcgccttc tgcctcccgg 25740ctgggcactt
ccaaccgcag aaatttaggc ttggaccctg cgcctccgcc cggctgtgag
25800gtgtgcgagt ctggtgcgat gtatccgatg tgtcttggtg gcttcaggcg
agcggaaggc 25860acgctccctt ctggaaatca cctcgtgtcg gccaccctcg
cggtccattc atttgtgttt 25920cattcatttc tcgccataac gaccccccag
tcccggttgt ctccacacac agcctggcgc 25980ttccctgtgg gcctctgcaa a
260016421DNAArtificial SequencePrimer 64tgtctggaga aacagccaag g
216522DNAArtificial SequencePrimer 65caagctcttc aaacagcaga cg
226622DNAArtificial SequenceProbe 66agcacctgat agctcgggag gc
226721DNAArtificial SequencePrimer 67aagatgccac ggtacagatg g
216820DNAArtificial SequencePrimer 68cagacctcat ggaggccatg
206921DNAArtificial SequenceProbe 69tggcaggagt gctcaccaag t
217023DNAArtificial SequencePrimer 70ggagttcctc gaatagctgc aag
237120DNAArtificial SequencePrimer 71agtcctggat ggagcagact
207220DNAArtificial SequenceProbe 72gctgttcgca tgcagcacct
207320DNAArtificial SequencePrimer 73gcgagcagtc tggggatttc
207417DNAArtificial SequencePrimer 74accccacaga agctgcc
177522DNAArtificial SequenceProbe 75accaagtctg gcaggagtgc tc
227618DNAArtificial SequenceSynthetic oligonucleotide 76gttcctcgaa
tagctgca 187718DNAArtificial SequenceSynthetic oligonucleotide
77agttcctcga atagctgc 187818DNAArtificial SequenceSynthetic
oligonucleotide 78ggagttcctc gaatagct 187918DNAArtificial
SequenceSynthetic oligonucleotide 79tgagcacgat aatggccc
188018DNAArtificial SequenceSynthetic oligonucleotide 80ggtgagcacg
ataatggc 188118DNAArtificial SequenceSynthetic oligonucleotide
81ccagacttgg tgagcacg 188216DNAArtificial SequenceSynthetic
oligonucleotide 82caagtggtag atggca 168316DNAArtificial
SequenceSynthetic oligonucleotide 83ccaggcggcg gagttc
168416DNAArtificial SequenceSynthetic oligonucleotide 84cggcggcagc
ttctgt 168516DNAArtificial SequenceSynthetic oligonucleotide
85ggcacccacg gcggca 168616DNAArtificial SequenceSynthetic
oligonucleotide 86acttggtgag cacgat 168718DNAArtificial
SequenceSynthetic oligonucleotide 87ggcggagttc ctcgaata
188818DNAArtificial SequenceSynthetic oligonucleotide 88cacggcggca
gcttctgt 188918DNAArtificial SequenceSynthetic oligonucleotide
89cacccacggc ggcagctt 189018DNAArtificial SequenceSynthetic
oligonucleotide 90ttggtgagca cgataatg 189118DNAArtificial
SequenceSynthetic oligonucleotide 91tgccagactt ggtgagca
189216DNAArtificial SequenceSynthetic oligonucleotide 92ggtgagcacg
ataatg 169318DNAArtificial SequenceSynthetic oligonucleotide
93ttggtgagca cgataatg 189418DNAArtificial SequenceSynthetic
oligonucleotide 94agacttggtg agcacgat 18
* * * * *